

EXHIBIT J

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

EDWARDS LIFESCIENCES AG and	)	
EDWARDS LIFESCIENCES LLC,	)	
	)	
Plaintiffs,	)	
	)	C.A. No. _____
v.	)	
	)	DEMAND FOR JURY TRIAL
MEDTRONIC, INC., MEDTRONIC	)	
COREVALVE, LLC, and MEDTRONIC	)	
VASCULAR, INC.	)	
	)	
Defendants.	)	

COMPLAINT

Plaintiffs Edwards Lifesciences AG (“Edwards AG”) and Edwards Lifesciences LLC (“Edwards LLC”) (collectively, “Plaintiffs”), for their Complaint against Defendants Medtronic, Inc. (“Medtronic”), Medtronic CoreValve, LLC (“Medtronic CoreValve”), and Medtronic Vascular, Inc. (“Medtronic Vascular”) (collectively, “Defendants”), allege as follows:

JURISDICTION AND VENUE

1. This action arises under the Patent Laws of the United States, 35 U.S.C. § 1 *et seq.* This Court has jurisdiction over the subject matter of this action based on 28 U.S.C. §§ 1338(a) and 1331. Venue is proper under 28 U.S.C. §§ 1391(b) and (c) and 1400(b).

THE PARTIES

Edwards

2. Plaintiff Edwards AG is a corporation organized and existing under the laws of Switzerland and having its principal executive offices in St.-Prex, Switzerland.

3. Plaintiff Edwards LLC is a limited liability company organized and existing under the laws of the State of Delaware and having its principal executive offices in Irvine, California.

4. Edwards AG is the assignee of the following United States Patent covering pioneering percutaneous heart valve products: U.S. Patent No. 7,618,446 (“the ‘446 Patent”). The ‘446 Patent discloses and claims, *inter alia*, collapsible and expandable tissue valve prostheses that replace human heart valves using minimally invasive catheterization procedures.

5. Edwards LLC is the exclusive licensee of the ‘446 Patent for the field of all cardiovascular applications.

Medtronic

6. Upon information and belief, Defendant Medtronic is a corporation organized and existing under the laws of the State of Minnesota and having its principal place of business in Minneapolis, Minnesota.

7. Upon information and belief, Medtronic is registered to do business in Delaware, and is doing business in Delaware.

8. Upon information and belief, Medtronic and/or its subsidiaries or affiliates have manufactured and currently manufacture in the United States heart valve prostheses, including the ReValving system, that infringe the ‘446 Patent.

9. Upon information and belief, Medtronic has offered and is currently offering for commercial sale and has commercially sold the ReValving system in Europe and elsewhere outside the United States.

10. Upon information and belief, Medtronic has knowingly and actively induced others to infringe the ‘446 Patent and continues to do so.

Medtronic CoreValve

11. Upon information and belief, Defendant Medtronic CoreValve is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business in Irvine, California.

12. Upon information and belief, Medtronic CoreValve is a wholly owned subsidiary of, and controlled by, Medtronic.

13. Upon information and belief, Medtronic CoreValve has manufactured and currently manufactures in the United States heart valve prostheses, including the ReValving system, that infringe the '446 Patent.

14. Upon information and belief, Medtronic CoreValve has offered and is currently offering for commercial sale and has commercially sold the ReValving system in Europe and elsewhere outside the United States.

15. Upon information and belief, Medtronic CoreValve has knowingly and actively induced others to infringe the '446 Patent and continues to do so.

Medtronic Vascular

16. Upon information and belief, Defendant Medtronic Vascular is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business in Santa Rosa, California.

17. Upon information and belief, Medtronic Vascular is a wholly owned subsidiary of, and controlled by, Medtronic.

18. Upon information and belief, Medtronic Vascular and/or its subsidiaries or affiliates have manufactured and currently manufacture in the United States heart valve prostheses, including the ReValving system, that infringe the '446 Patent.

19. Upon information and belief, Medtronic Vascular has knowingly and actively induced others to infringe the '446 Patent and continues to do so.

INFRINGEMENT OF THE '446 PATENT

20. Plaintiffs repeat and reallege the allegations of paragraphs 1 through 19 above.

21. On November 17, 2009, U.S. Patent No. 7,618,446 ("the '446 Patent") (a copy of which obtained from the U.S. Patent and Trademark Office on November 17, 2009 is attached hereto as Exh. 1), entitled "A Valve Prosthesis for Implantation in the Body and a Catheter for Implanting Such Valve Prosthesis," was duly and legally issued to Drs. Henning Rud Andersen, John Michael Hasenkam, and Lars Lyhne Knudsen. Edwards AG is the assignee, and Edwards LLC is the exclusive licensee of the '446 Patent for the field of all cardiovascular applications. Plaintiffs are the owners of all rights, title and interest in and to the '446 Patent, including all rights to recover for any and all past infringement thereof, in the field of all cardiovascular applications.

22. Upon information and belief, and in violation of 35 U.S.C. § 271, Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the '446 Patent by manufacturing, using, importing, selling, offering to sell and/or supplying heart valve prostheses covered by one or more claims of the '446 Patent, including products designated as the ReValving system.

23. Upon information and belief, and in violation of 35 U.S.C. § 271, Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the '446 Patent, including at least by their knowing and active inducement of the manufacturing,

using, importing, selling, offering to sell and/or supplying heart valve prostheses covered by one or more claims of the '446 Patent, including products designated as the ReValving system.

24. Defendants' foregoing infringement has been willful and deliberate, rendering this case exceptional within the meaning of 35 U.S.C. § 285.

25. Plaintiffs have been damaged and will be irreparably injured by Defendants' past and continuing infringement, for which Plaintiffs have no adequate remedy at law. Defendants' continued infringement will continue unless enjoined by this Court.

PRAYER FOR RELIEF

WHEREFORE Plaintiffs demand judgment as follows:

- (a) Finding that Defendants have infringed the '446 Patent;
- (b) Finding that Defendants' infringement of the '446 Patent has been willful and deliberate;
- (c) Preliminarily and permanently enjoining and restraining Defendants and their officers, agents, servants, employees and attorneys, all parent, subsidiary and affiliate corporations and other related business entities, and all other persons or entities acting in concert, participation or in privity with Defendants, and their successors and assigns, from infringing, contributing to the infringement of, or inducing others to infringe the '446 Patent;
- (d) Awarding Plaintiffs damages, in an amount to be determined at trial, together with interest and costs as fixed by the Court;
- (e) Awarding Plaintiffs enhanced damages under 35 U.S.C. § 284;
- (f) Awarding Plaintiffs their reasonable attorneys' fees and their costs and disbursements in this action, as provided by 35 U.S.C. § 285; and
- (g) Granting Plaintiffs such other and further relief as the Court deems just and proper.


JURY DEMAND

Plaintiffs demand a trial by jury on all issues so triable in this Complaint.

POTTER ANDERSON & CORROON LLP

OF COUNSEL:

John E. Nathan
Catherine Nyarady
Brian P. Egan
PAUL, WEISS, RIFKIND,
WHARTON & GARRISON LLP
1285 Avenue of the Americas
New York, NY 10019
(212) 373-3000

By: 
Richard L. Horwitz (#2246)
David E. Moore (#3983)
Hercules Plaza, 6th Floor
1313 N. Market Street
Wilmington, DE 19801
Tel: (302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com

Dated: November 17, 2009
937320 / 34927

*Attorneys for Plaintiffs Edwards Lifesciences
AG and Edwards Lifesciences LLC*

EXHIBIT 1



US007618446B2

(12) **United States Patent**
Andersen et al.

(10) **Patent No.:** **US 7,618,446 B2**(45) **Date of Patent:** ***Nov. 17, 2009**

(54) **VALVE PROSTHESIS FOR IMPLANTATION
IN THE BODY AND A CATHETER FOR
IMPLANTING SUCH VALVE PROSTHESIS**

(75) Inventors: **Henning Rud Andersen**, Højbjerg
(DK); **John Michael Hasenkam**, Aarhus
(DK); **Lars Lyhne Knudsen**, Aarhus
(DK)

(73) Assignee: **Edwards Lifesciences AG**, Nyon (CH)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **10/268,253**

(22) Filed: **Oct. 10, 2002**

(65) **Prior Publication Data**

US 2003/0036795 A1 Feb. 20, 2003

Related U.S. Application Data

(60) Continuation of application No. 09/514,426, filed on
Feb. 28, 2000, now Pat. No. 6,582,462, which is a
continuation of application No. 09/026,574, filed on
Feb. 20, 1998, now Pat. No. 6,168,614, which is a
continuation of application No. 08/955,228, filed on
Oct. 21, 1997, now abandoned, which is a division of
application No. 08/801,036, filed on Feb. 19, 1997,
now Pat. No. 5,840,081, which is a continuation of
application No. 08/569,314, filed on Dec. 8, 1995, now
abandoned, which is a continuation of application No.
08/352,127, filed on Dec. 1, 1994, now abandoned,
which is a division of application No. 08/261,235, filed
on Jun. 14, 1994, now Pat. No. 5,411,552, which is a
continuation of application No. 07/961,891, filed as
application No. PCT/DK91/00134 on May 16, 1991,
now abandoned.

(30) **Foreign Application Priority Data**

May 18, 1990 (DK) 1246/90

(51) **Int. Cl.**

A61F 2/24 (2006.01)

A61F 2/90 (2006.01)

A61F 2/88 (2006.01)

(52) **U.S. Cl.** **623/1.26; 623/2.14**

(58) **Field of Classification Search** **623/2.1-2.19,**
623/2.38-2.41, 900, 904, 1.24-1.26, FOR. 101,
623/23.68; 604/9

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,055,188 A 9/1936 Wappler et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 2246526 3/1973

(Continued)

OTHER PUBLICATIONS

Sugie et al., Clinical experience with supported homograft heart
valve for mitral and aortic valve replacement, *The Journal of Tho-*
racic and Cardiovascular Surgery, vol. 57, No. 4 (Apr. 1969), pp.
455-463.*

(Continued)



Primary Examiner—David H. Willse

(74) *Attorney, Agent, or Firm*—David L. Hauser

(57) **ABSTRACT**

A valve prosthesis for implantation in the body by use of a
catheter includes a stent made from an expandable cylinder-
shaped thread structure including several spaced apices. The
elastically collapsible valve is mounted on the stent as the
commissural points of the valve are secured to the projecting
apices. The valve prosthesis can be compressed around bal-
loons of the balloon catheter and inserted in a channel, for
instance, in the aorta. When the valve prosthesis is placed
correctly, the balloons are inflated to expand the stent and
wedge it against the wall of the aorta. The balloons are pro-
vided with beads to ensure a steady fastening of the valve
prosthesis on the balloons during insertion and expansion.
The valve prosthesis and the balloon catheter make it possible
to insert a cardiac valve prosthesis without a surgical opera-
tion involving opening the thoracic cavity.

49 Claims, 5 Drawing Sheets



US 7,618,446 B2

Page 2

U.S. PATENT DOCUMENTS

3,275,211 A 9/1966 Hirsch et al.
3,409,013 A 11/1968 Berry
3,472,230 A 10/1969 Fogarty
3,548,417 A 12/1970 Kischer
3,587,115 A 6/1971 Shiley
3,657,744 A 4/1972 Ersek
3,671,979 A 6/1972 Mouloupoulos
3,714,671 A 2/1973 Edwards et al.
3,755,823 A 9/1973 Hancock
3,799,150 A 3/1974 Bonnet
3,868,956 A 3/1975 Alfidi et al.
4,035,849 A 7/1977 Angell et al.
4,038,703 A 8/1977 Bokros
4,056,854 A 11/1977 Boretos et al.
4,106,129 A 8/1978 Carpentier et al.
4,222,126 A 9/1980 Boretos et al.
4,297,749 A 11/1981 Davis et al.
4,339,831 A 7/1982 Johnson
4,343,048 A * 8/1982 Ross et al. 623/2.14
4,345,340 A 8/1982 Rosen
4,391,282 A 7/1983 Amdo et al.
4,448,195 A 5/1984 LeVeen et al.
4,470,157 A 9/1984 Love
4,574,803 A 3/1986 Storz
4,580,568 A 4/1986 Gianturco
4,592,340 A 6/1986 Boyles
4,612,011 A 9/1986 Kautzky
4,655,771 A 4/1987 Wallsten
4,687,483 A * 8/1987 Fisher et al. 623/2.14
4,692,164 A 9/1987 Dzemeshevich et al.
4,725,274 A 2/1988 Lane et al.
4,731,074 A 3/1988 Rousseau et al.
4,733,665 A 3/1988 Palmaz
4,777,951 A 10/1988 Cribier et al.
4,778,461 A 10/1988 Pietsch et al.
4,787,899 A 11/1988 Lazarus
4,787,901 A 11/1988 Baykut
4,790,843 A 12/1988 Carpentier et al.
4,796,629 A 1/1989 Grayzel
4,830,003 A 5/1989 Wolff et al.
4,851,000 A 7/1989 Gupta
4,856,516 A 8/1989 Hillstead
4,878,495 A 11/1989 Grayzel
4,878,906 A 11/1989 Lindemann et al.
4,883,458 A 11/1989 Shiber
4,892,541 A 1/1990 Alonso
4,917,698 A 4/1990 Carpentier et al.
4,922,905 A 5/1990 Strecker
4,932,965 A 6/1990 Phillips
RE33,258 E 7/1990 Onik
4,966,604 A 10/1990 Reiss
4,979,939 A 12/1990 Shiber
4,986,830 A 1/1991 Owens et al.
4,994,077 A 2/1991 Dobben
5,007,896 A 4/1991 Shiber
5,019,102 A 5/1991 Hoene
5,026,366 A 6/1991 Leckrone
5,032,128 A 7/1991 Alonso
5,037,434 A 8/1991 Lane
5,041,130 A 8/1991 Cosgrove et al.
5,047,041 A 9/1991 Samuels
5,059,177 A 10/1991 Towne et al.
5,061,277 A 10/1991 Carpentier et al.
5,085,635 A 2/1992 Cragg
5,089,015 A 2/1992 Ross
5,104,407 A 4/1992 Lam et al.
5,123,919 A 6/1992 Sauter et al.
5,147,391 A 9/1992 Lane
5,152,771 A 10/1992 Sabbaghian et al.
5,163,953 A 11/1992 Vince
5,163,955 A 11/1992 Love et al.

5,167,628 A 12/1992 Boyles
5,201,880 A 4/1993 Wright et al.
5,258,021 A 11/1993 Duran
5,258,023 A 11/1993 Reger
5,295,958 A 3/1994 Shturman
5,306,296 A 4/1994 Wright et al.
5,332,402 A 7/1994 Teitelbaum
5,332,403 A 7/1994 Kolff
5,344,442 A 9/1994 Deac
5,350,420 A 9/1994 Cosgrove et al.
5,358,518 A 10/1994 Camilli
5,370,685 A 12/1994 Stevens
5,376,112 A 12/1994 Duran
5,376,113 A 12/1994 Jansen et al.
5,397,351 A 3/1995 Pavcnik et al.
5,411,552 A 5/1995 Andersen et al.
5,443,446 A 8/1995 Shturman
5,449,384 A 9/1995 Johnson
5,469,868 A 11/1995 Reger
5,480,424 A 1/1996 Cox
5,489,298 A 2/1996 Love et al.
5,500,014 A 3/1996 Quijano et al.
5,545,209 A 8/1996 Roberts et al.
5,554,185 A 9/1996 Block et al.
5,609,626 A 3/1997 Quijano et al.
5,755,782 A 5/1998 Love et al.
5,824,061 A 10/1998 Quijano et al.
5,840,081 A 11/1998 Andersen et al.
6,283,993 B1 9/2001 Cosgrove et al.

FOREIGN PATENT DOCUMENTS

DE 36 40 745 A1 6/1987
EP 0103546 A1 3/1984
EP 0350302 1/1990
EP 0357003 3/1990
EP 0592410 B1 10/1995
GB 1 268 484 * 3/1972
GB 2 056 023 A 3/1979
GB 2056023 3/1981
SU 158988 * 11/1963 623/FOR. 101
SU 1258406 9/1986
SU 1271508 11/1986
SU 1271508 A1 11/1986
SU 1371700 A1 * 2/1988
SU 1371701 2/1988
SU 1457921 A1 * 2/1989
WO WO 9117720 11/1991
WO WO 9217118 10/1992

OTHER PUBLICATIONS

Anderson, et al., "Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs", European Heart Journal, the journal of the European Society of Cardiology, vol. 13, Issue 5, pp. 704-708, (1992).

LexisNexis Search Results, U.S. District Court Civil Docket, U.S. District—Delaware (Wilmington), Civil Action No. 1:08-cv-00091-GMS, *Edwards Lifesciences AG et al v. Corevalve Inc.*, filed Feb. 12, 2008, Date of last filing Apr. 4, 2008, 7 sheets.

Morris, Nichols, Arsht & Tunnell LLP, Attorneys for Plaintiffs, Demand for Jury Trial filed Feb. 12, 2008 in the United States District Court for the District of Delaware, Case 1:08-cv-00091-UNA, Document 1, 41 sheets.

Richards, Layton & Finger, Attorneys for Defendant, CoreValve, Inc., Jury Trial Demanded filed Apr. 4, 2008 in the United States District Court for the District of Delaware, Case 1:08-cv-00091-GMS, Document 1, 41 sheets.

US 7,618,446 B2

Page 3

H.R. Andersen et al., Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs, *European Heart Journal* (1992) 13, 704-708.

Ernst-Peter Strecker, M.D., et al., Current Status of the Stecker Stent, *Contemporary Interventional Techniques*, Supplied by The British Library—"The world's knowledge", vol. 12, No. 1, Nov. 1994, pp. 673-687.

Steven R. Bailey, 75—Percutaneous Expandable Prosthetic Valves, *Textbook of Interventional Cardiology*, vol. 2, Second Edition, 1994, pp. 1268-1276.

Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243, Amended Product Description of Claimant, 7 pgs.

Dotter, Charles T., MD, Transluminally-placed Coilspring Endarterial Tube Grafts: Long-term Patency in Canine Popliteal Artery, *Investigate Radiology*, Sep.-Oct. 1969, pp. 329-332, vol. 4, Issue 5, Lippincott Williams & Wilkins, Inc. *Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc.*, United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Edwards' Opening Claim Construction Brief, Feb. 6, 2009 26 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Joint Markman Claim Construction Chart, Jan. 16, 2009, 32 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Joint Supplemental Markman Claim Construction Chart, 4 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Order Construing the Terms of U.S. Patent Nos. 5,411,552; 6,168,614; and 6,582,462, 5 pgs.

Request for Ex Parte Reexamination filed Jun. 12, 2009 for USPN 5,411,552, Issued May 2, 1995, Titled: Valve Prosthesis for Implantation in the Body and a Catheter for Implanting Such Valve Prosthesis.

Davies, Hywel, "Catheter-Mounted Valve for Temporary Relief of Aortic Insufficiency"; *The Lancet*, Preliminary Communications; Jan. 30, 1965, p. 250, Cardiac Department, Guy's Hospital, London, S.E.1.

Dotter, M.D., Charles T., "Transluminally-placed Coilspring Endarterial Tube Grafts"; *Investigative Radiology*, Sep.-Oct., 1969, vol. 4, pp. 329-332.

Magovern, George J., Replacement of Aortic and Mitral Valves with the Sutureless Prosthesis; Results in 100 Patients; *Chest Online*; American College of Chest Physicians; ISSN: 0096-0217; www.chestjournal.org; pp. 415-422, *Dis Chest* 1966; 50; 415-422.

Decision on Request for Reexamination in U.S. Appl. No. 09/009,484, filed Jun. 12, 2009; mailed Aug. 7, 2009.

Andersen, Henning Rud, History of Percutaneous Aortic Valve Prosthesis, *Herz* 34 2009 Nr.5 Urban & Vogel, pp. 343, 346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.

16th Edition of The Merck Manual of Diagnosis and Therapy (1992) "Valvular Heart Disease," pp. 546-553.

Yamaguchi, Case Description "A Case of a Reoperation Using a Balloon Catheter with Blocked Pars Ascendens Aortae" *Kyobu Geka*, Oct. 1989, 42:11, pp. 961-964.

World Medical Manufacturing Corp., Talent Endovascular Bifurcated Spring Graft System Composite Design brochure, c. 1989.

Derwent Abstract No. 87-1980867/27 (1987), SU 1271508 (Gorkii Kirov Medical Ins.).

UK proceedings in respect of EP 0592410, May 21, 2007.

* cited by examiner

U.S. Patent

Nov. 17, 2009

Sheet 1 of 5

US 7,618,446 B2




FIG. 1




FIG. 2

U.S. Patent

Nov. 17, 2009

Sheet 2 of 5

US 7,618,446 B2




FIG. 3




FIG. 4

U.S. Patent

Nov. 17, 2009

Sheet 3 of 5

US 7,618,446 B2




FIG. 7




FIG. 6




FIG. 5




FIG. 10




FIG. 9






FIG. 8

U.S. Patent

Nov. 17, 2009

Sheet 4 of 5

US 7,618,446 B2






FIG. 13




FIG. 14

US 7,618,446 B2

1

VALVE PROSTHESIS FOR IMPLANTATION IN THE BODY AND A CATHETER FOR IMPLANTING SUCH VALVE PROSTHESIS

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 09/514,426, filed Feb. 28, 2000, (now U.S. Pat. No. 6,582,462), which is a continuation of U.S. patent application Ser. No. 09/026,574, filed Feb. 20, 1998 (now U.S. Pat. No. 6,168,614), which is a continuation of U.S. patent application Ser. No. 08/955,228, filed Oct. 21, 1997 (abandoned), which is a divisional of U.S. patent application Ser. No. 08/801,036, filed Feb. 19, 1997 (issued as U.S. Pat. No. 5,840,081 on Nov. 24, 1998), which is a continuation of U.S. patent application Ser. No. 08/569,314, filed Dec. 8, 1995 (abandoned), which is a continuation of U.S. patent application Ser. No. 08/352,127, filed Dec. 1, 1994 (abandoned), which is a divisional of U.S. patent application Ser. No. 08/261,235, filed Jun. 14, 1994 (now U.S. Pat. No. 5,411,552), which is a continuation of U.S. patent application Ser. No. 07/961,891, filed Jan. 11, 1993 (abandoned), which is a national stage application of PCT/DK91/00134, filed May 16, 1991 (abandoned).

BACKGROUND OF THE INVENTION

The present invention relates to a valve prosthesis, preferably a cardiac valve prosthesis, for implantation in the body and comprising a collapsible elastic valve which is mounted on an elastic stent wherein the commissural points of the elastic collapsible valve are mounted on the cylinder surface of the elastic stent.

Valve prostheses of this type are usually implanted in one of the channels of the body to replace a natural valve. In the present description the invention will be explained in connection with a cardiac valve prosthesis for implantation in aorta. However, it will be possible to use a valve prosthesis according to the invention in connection with implantation in other channels in the body by using the same technique as the one used for implantation of cardiac valve prosthesis. Such an implantation may, e.g., comprise the implantation of:

1. a valve (for instance a cardiac valve) in the veins,
2. a valve in the esophagus and at the stomach,
3. a valve in the ureter and/or the vesica,
4. a valve in the biliary passages,
5. a valve in the lymphatic system, and
6. a valve in the intestines.

An existing natural valve in the body is traditionally replaced with a valve prosthesis by a surgical implantation. However, a surgical implantation is often an exacting operation. Thus, today the implantation of cardiac valves are solely made by surgical technique where the thoracic cavity is opened. The operation calls for the use of a heart and lung machine for external circulation of the blood as the heart is stopped and opened during the surgical intervention and the artificial cardiac valves are subsequently sewed in.

Due to its exacting character, it is impossible to offer such operation to certain people. For instance, this is due to the fact that the person is physically weak because of age or illness. Moreover, the number of heart and lung machines available at a hospital will be a substantially limiting factor.

Cardiac valve prostheses that need no surgical intervention are known as there are used for implantation by means of a technique of catheterization. Examples of such valve prostheses are described in U.S. Pat. Nos. 3,671,979 and 4,056,

2

854. However, both of these valve prostheses are connected to means which lead to the surface of the patient either for a subsequent activation of the valve or for a subsequent reposition or removal of the valve prosthesis. With these valve prostheses it is impossible to make an implantation which makes it possible for the patient to resume a substantially normal life in the same way as it is possible in connection with a surgical implantation of a cardiac valve.

From U.S. Pat. No. 3,755,823 an elastic stent for a cardiac valve prosthesis is known. However, this valve prostheses is not designed for implantation in the body by catheterization. Even though this patent contains no detailed explanation, the description indicates that this valve prosthesis is designed for implantation and sewing on by a surgical intervention.

Moreover, from U.S. Pat. Nos. 4,856,516 and 4,733,665 different shapes of expandable stents are known. These stents are made to be expanded by impression of a radially outward force coming from a balloon catheter or the like. These stents are made to reinforce the wall when there is a risk that the channel is closed and/or compressed.

The nearest prior art may be that the described in GB-A-2,056,023. This document discloses an elastic stent as described by way of introduction. Thus, the stent described comprises an elastic collapsible valve mounted on the cylinder surface of a cylindrical stent. However, the valve prosthesis including the stent is designated for mounting through a surgical intervention. Even though the stent is slightly collapsible, it will not be suited for implantation by a catheterization procedure.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a valve prosthesis of the type mentioned in the introductory part, which permits implantation without surgical intervention in the body and by using a catheter technique known per se and which makes it possible for the patient to resume a substantially normal life.

This is achieved according to the invention with a valve prosthesis of the type mentioned in the introductory part, which is characterized in that the stent is made from a radially collapsible and re-expandable cylindrical support means for folding and expanding together with the collapsible valve for implantation in the body by means of a technique of catheterization.

The collapsible elastic valve is mounted on the stent for instance by gluing, welding or by means of a number of suitable sutures.

If the support means are made from a thread structure, this can for instance be grate shaped, loop shaped or helical. This makes it possible to compress the stent and the collapsible valve mounted thereon for placing on the insertion catheter. The use of a non-self-expandable stent may, e.g., be effected by a compression of the stent around the expansion arrangement of the catheter which preferably consists of a balloon. When using a self-expandable stent, a catheter with an expansion arrangement is not used. In this case the stent is compressed and is inserted into an insertion or protection cap from which the stent is eliminated after implantation in order to obtain an expansion due to the stresses in the compressed support means, which for instance may be made from plastics or metal. After the compression the entire outer dimension is relatively small, which makes it possible to introduce the valve prostheses through a channel in the body.

When the valve prosthesis is introduced and placed correctly, the stent is expanded by self-expansion or by means of the expansion arrangement until the stent is given its normal shape.

US 7,618,446 B2

3

dimension which is slightly larger than the channel in which it is placed. As the stent is elastic, a contraction of the stent is prevented once it is expanded. The stiffness in the material of the support means contributes to maintain the expanded shape of the stent. After the expansion is made, the expansion arrangement of the catheter is contracted and the catheter can be removed from the channel. The inlet opening can subsequently be closed and the patient will then be able to resume a normal life.

The valve prosthesis according to the invention does not require an actual operation but merely a small intervention to optionally expose the body channel, e.g., a vein, through which the insertion takes place. Thus, patients for whom an operation would be associated with high risk can be offered implantation of, for instance, cardiac valves. After the implantation has taken place, the after-treatment will advantageously be shorter than normal, which means fewer hospital days for the patient. Moreover, it is assumed that it will be possible to implant the valve prosthesis under local anaesthetic.

The valve prosthesis can be used to replace a natural valve or to establish a new valve function in one of the channels in the body which do not naturally contain a valve. For instance this goes for veins (arteries and veins) on a place without natural valves. The function of the valve prosthesis is then to ensure that the blood flows in one direction only. The valve is meant to be used in veins in the legs of persons suffering from varicose veins (varices).

In persons having varicose veins the blood flows in a wrong direction, viz. from the central veins in the center of the leg towards the superficial veins. Among other things, this is due to the changed pressure in the legs, upright working position and other conditions. A valve prosthesis according to the invention may easily be placed in the veins and prevent the flow of the blood in a wrong direction.

Also, the valve prosthesis can be used in connection with diseases, for instance cancerous tumors, where too much humour is produced. If the humour is able to flow from the cancerous tumor through several channels, it is possible to drain the humour in one desired direction through the channels of the body by an appropriate placing of the valve prosthesis.

When the valve prosthesis is used as a cardiac valve prosthesis in the aorta, it is possible to mount it in three positions, viz., in the descending part of the aorta in a position between the coronary arteries and the left ventricle of the heart, or in the aorta in a position immediately after the mouth of the coronary arteries.

The cardiac valve prosthesis can also be used in other places than in the aorta. Thus, the valve prosthesis can be used in the pulmonary artery and/or the right ventricle of the heart for replacing the pulmonary valves. Likewise, the cardiac valve prosthesis can be used in the passage between the right auricle of the heart and the right ventricle of the heart (tricuspidalostium) and the passage between the left auricle of the heart and the left ventricle of the heart (mistolostium) for replacing the tricuspidal valve and the mitral valve, respectively.

Even though the cardiac valve preferably is meant to be used for patients suffering from aorta insufficiency and who cannot be offered an open heart surgery, the valve prosthesis can also be used for patents in connection with treatment of aorta stenosis. Several of the patients with aorta stenosis are elderly people who cannot be offered a surgical cardiac operation. The patients are offered balloon dilatation of the aorta stenosis which may result in an aorta insufficiency as a side effect of the treatment.

4

As to these patients it is possible to insert a valve prosthesis in the descending or ascending part of the aorta thoracalis a few days or weeks before the balloon dilatation. As a result thereof, the left ventricle is protected against weight if the subsequent balloon dilatation of the stenosis results in aorta insufficiency. In certain cases the weight (reflux) on the left ventricle is reduced by up to approximately 75%.

Furthermore, the stent may be made with a relatively great height and with a cylinder surface which is closed by a suitable material. Thus, a vascular prosthesis known per se is formed wherein the valve is mounted. This may facilitate the implantation of the valve prosthesis, for instance in the arcus aorta. Moreover, the great surface which abuts the inner wall of the channel contributes to ensure the securing of the valve prosthesis in the channel. This embodiment is also suitable as valve prosthesis which is inserted in veins. As veins have relatively thin and weaker walls than arteries, it is desirable that the valve prosthesis has a greater surface to distribute the outward pressure which is necessary to secure the valve prosthesis.

Moreover, the invention relates to a balloon catheter for implanting a valve prosthesis according to the invention and comprising a channel for injection of a fluid for the inflation of the balloon means of the catheter and an insertion cap wherein the balloon means of the catheter and a collapsible valve prosthesis mounted thereon are located during the injection, characterized in that the balloon means are provided with profiled surface which is made to ensure a steady fastening of the valve prosthesis during the withdrawal of the balloon means from the protection cap and the subsequent inflation for the expansion of the stent.

Different balloon catheters for implanting cores in the body are known. For instance, such balloon catheters are known from U.S. Pat. Nos. 4,856,516, 4,733,665 and 4,796,629 and from DE publication No. 2,246,526. However, the known balloon catheters have a smooth or a slightly wavy surface. The use of such balloon catheter is disadvantageous for mounting a valve prosthesis in a channel having a large flow as for instance the aorta. A large humour flow is able to displace the stent on the smooth surface of the balloon and makes an accurate positioning difficult. This drawback has been remedied with the balloon catheter according to the present invention as the profiled surface prevents a displacement of the valve prosthesis in relation to the balloon means during introduction and the subsequent inflation of the balloon means.

In connection with the implantation, any prior art technique may be used to supervise an accurate introduction and positioning of the valve prosthesis. Thus, guide wires for the catheter, X-ray supervision, injection of X-ray traceable liquids, ultrasonic measuring, etc. may be used.

DESCRIPTION OF THE DRAWINGS

The invention will now be explained in detail with reference to the accompanying schematical drawing, wherein

FIG. 1 shows a perspective view of a stent without a valve,

FIG. 2 is a perspective view of a valve prosthesis according to the invention made from the stent shown in FIG. 1 having a biological valve mounted thereon,

FIG. 3 is a partial view through the aorta illustrating a partially inflated balloon catheter,

FIG. 4 is a cross section through the embodiment shown in FIG. 9,

FIGS. 5-7 are views illustrating the introduction and implantation of a valve prosthesis of the invention.

US 7,618,446 B2

5

FIGS. 8-10 are views illustrating three possible positions of a cardiac valve prosthesis,

FIGS. 11-12 are perspective views illustrating two further embodiments of a valve prosthesis having a closed cylindrical wall, and

FIGS. 13-14 are perspective views illustrating two further embodiments of a stent without a valve.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 shows a stent 1 made by support means in the form of two 0.55 mm surgical stainless steel wires 2,3. The wires are folded in 15 loops. Three loops 4 are 14 mm in height and are intended to secure the commissural points 5 (see FIG. 2) from a biological cardiac valve 6 which is mounted in the stent 1. The remaining loops have a height of 8 mm. These loops form circumferentially expandable sections 25 between the commissural points 5 forming commissural supports. Each of the two folded wires 2,3 is bent to form rings 7,8 which are closed by welding the ends. The two rings are placed on top of each other as will appear from FIG. 1 and they are mutually secured by means of a number of sutures (not shown). The lower ring is circumferentially expandable at least along sections thereof which correspond to the circumferentially expandable sections 25. By using a substantially cylindrical thread structure with projecting apices, a reduction in weight is obtained as compared to a stent which is exclusively cylindrical with the same loop heights for all the loops.

The biological valve 6 was removed from a slaughtered pig of 100 kg. The valve was cleaned before mounting in the stent 1. The cleaned valve has an outer diameter of 25-27 mm and the height of the three commissural points 5 is 8 mm. The valve 6 is mounted in the stent by means of a suitable number of sutures to form the cardiac valve prosthesis 9 shown in FIG. 2. The valve prosthesis produced is used for performing tests in pigs by implantation of cardiac valve prosthesis. However, the cardiac valve prosthesis for use in human beings has a corresponding form.

FIG. 3 shows a partial view through the aorta 10. A balloon catheter 11 is introduced in the aorta according to the direction of an arrow 12. In the Figure shown the balloon means 13 of the balloon catheter is led out of the protection cap 11A and is partly inflated through a fluid channel 15, which is led to the surface of the patient. The balloon means 13 constitutes a tri-sectional balloon upon which the cardiac valve prosthesis is placed. In the form shown, the cardiac valve prosthesis is expanded exactly to be in contact with the aorta 10. The balloon means 13 is provided with three projecting beads 14 which are engaged with the one side of the cardiac valve prosthesis 9. The blood flowing through the aorta according to the direction of an arrow 16 will thus cause the cardiac valve prosthesis 9 to abut on the beads 14 and the valve cannot be displaced in relation to the balloon means 13. Moreover, the balloon catheter used comprises a central channel 17 to receive a guide wire 18 which is used in a way known per se for supervising the introduction of the catheter through fluoroscopy. In the shown embodiment beads 14 are only used at one side of the valve prosthesis, but, however, it will often be desirable to use the beads in pairs placed along lines parallel to the longitudinal axes 19 through the balloon means 13. In this case the spacing of the pair of beads 14 will correspond to the height of the loops of the stent. This makes it possible to make an effective fastening of a valve prosthesis on balloon

6

means. Moreover, the fastening on the balloon means may be provided by using balloon means with an indentation in the surface (not shown).

FIG. 4 shows a cross section through the embodiment shown in FIG. 3 illustrating the placing of the beads 14 on the tri-sectional balloon means 13.

A balloon catheter of the above-described type which was used in tests of implanting of cardiac valve prosthesis 9 in pigs had the following dimensions. Each of the three balloons was 60 mm in length and 15 mm in diameter. The total diameter for the three inflated balloons was 31 mm and in the balloon catheter used two beads 14 having a height of 3 mm were mounted on each side of the three balloons. The beads had a spacing of 15 mm. The protection cap 11A of the balloon catheter had an outer diameter of 13.6 mm and an inner diameter of 12.5 mm and a length of 75 cm. The balloon catheter was provided with a standard guide wire having a diameter of 0.9 mm and a length 300 cm.

FIGS. 5-7 show the valve prosthesis 9 at different steps in introducing and implanting in the aorta 10 by means of the catheter 11 having the inflatable balloon means 13. The cardiac valve prosthesis 9 is initially placed above the deflated balloon means 13 and compressed manually around the balloon means (FIG. 5), whereafter the outer diameter for the valve prosthesis is approximately 10 mm. After the introduction and positioning, the balloon means 13 is inflated (FIG. 6), thereby contributing an outer dimension of approximately 30 mm to the cardiac valve prosthesis. To obtain an effective fastening in the aorta, the outer dimension of the cardiac valve prosthesis is greater than the diameter of the aorta. This means that the prosthesis is tight against the inner wall of the aorta with a pressure which is sufficiently large to counteract a detachment due to the flow of the blood. The balloon catheter 11 may subsequently be removed from the aorta 10 (FIG. 7). Due to the stiffness of the metal the valve prosthesis will prevent a contraction. However, smaller contractions may occur (<10% diameter reduction) after the deflation and removal of the balloon catheter 13. When the valve prosthesis is mounted as shown in FIG. 7, the patient will be able to resume a substantially normal life after a few days.

FIGS. 8-10 show the positioning of the valve prosthesis 9 as cardiac valve prosthesis in the aorta 10 in three different positions, i.e., in a position between the coronary arteries 20 and the left ventricle of the heart 21 (FIG. 8), in a position immediately after the mouth of the coronary arteries in the ascending part of the aorta (FIG. 9), and in a position in the descending part of the aorta 10. The positioning of the valve prosthesis is chosen in accordance with the diagnosis of the illness of the patient. By placing the cardiac valve prosthesis as shown in FIG. 8, there is a risk of detachment and/or covering the mouth of the coronary arteries, and therefore it is preferred to use a higher stent which, for instance, comprises several ranges placed on top of each other. This allows a fixation of the prosthesis at a place after the mouth of coronary arteries even though the valve itself is in the position between the coronary arteries and the left ventricle. FIGS. 8 and 9 show how a contrast medium 23 is injected by means of a so-called pigtail catheter for registration of tightness of the implanted valve prosthesis 9.

A specific embodiment for a valve prosthesis and a balloon catheter for implanting the valve prosthesis has been explained above. However, it is obvious that it is possible to modify the valve prosthesis depending on the desired use, and moreover, it is possible to modify the catheter used in the implantation. Thus, the stent of the valve prosthesis may be made solely of one closed ring folded in a number of loops or with three or more mutually secured

US 7,618,446 B2

7

on top of each other. Moreover, it is possible to make the stent having a thread structure which instead of loops is grate shaped, helical or is formed otherwise if only it is ensured that the form of the stent permits the compression and expansion of the stent and fastening of the collapsible valve. Instead of a biological valve it might be possible to use other collapsible valves, such as valves made from synthetic materials, e.g., polyurethane. It is also possible to use valves with more or fewer flaps than three.

It is possible to make the valve prosthesis with a closed cylinder surface as illustrated in FIGS. 11 and 12. In both Figures the support means of the valve prosthesis is made of an elongated tubular means 24 having a closed cylinder surface. This valve prosthesis is intended to expand by self-expansion or by means of a catheter according to the invention. This prosthesis is especially suitable for placing in veins and other channels where only a small pressure is exerted against the wall of the channel. In FIG. 11 the valve 6 is mounted at the end of the tubular means 24. In FIG. 12 an embodiment is shown where the valve 6 is mounted in a central position in the tubular means 24.

An explanation of a method of implanting a valve prosthesis according to the invention is given below:

- a valve prosthesis 9 made of a stent 1 and a collapsible valve 6, as described above, is placed on a deflated balloon means and is manually compressed thereon,
- the balloon means 13 and the valve prosthesis are drawn into an insertion cover 11A,
- a guide wire 18 is inserted into the left ventricle of the heart through the central opening 17 of the balloon catheter under continuous fluoroscopy,
- the insertion cover 11A conveys the guide wire 18 to a point in the channel in the immediate vicinity of the desired position of the valve prosthesis,
- the balloon means 13 is pushed out of the protection cap 11A and the valve prosthesis is positioned in the desired position if necessary by use of further registration means to ensure an accurate positioning,
- the balloon means 13 is inflated with a certain overstretching of the channel,
- the balloon means 13 is deflated, and
- the balloon means 13, the guide wire 18 and the protection cap 11A are drawn out and the opening in the channel, if any, wherein the valve prosthesis is inserted can be closed.

FIGS. 13-14 are perspective view illustrating two further embodiments of a stent without a valve. In FIG. 13, the stent 100 is made by support means in the form of helical wires 102, 103, with loops 104 and circumferentially expandable sections 125. Each of the two helical wires 102, 103 is bent to form rings 107, 108. In FIG. 14, the stent 200 is made by support means in the form of gate-shaped wires 202, 203, with loops 204 and circumferentially expandable sections 225. Each of the two gate-shaped wires 202, 203 is bent to form rings 207, 208. The primary difference between prior described embodiments, such as in FIG. 2, versus those embodiments shown in FIGS. 13 and 14, for example, is the replacement of the series of loops 4 (FIG. 2) with the helical wires 102, 103 and loops 104 (FIG. 13) or the grate-shaped wires 202, 203 and loops 204 (FIG. 14). As the artisan will readily appreciate, the embodiments of FIGS. 13-14 otherwise include those features shown in prior described embodiments, such as in FIG. 2, including the commissural points 5 forming commissural supports.

8

What is claimed is:

1. A valve prosthesis for implantation in a body, comprising:
an elastical stent comprising a cylindrical support having circumferentially expandable sections comprised of a series of loops with commissural supports therebetween and integral therewith; and
an elastical valve, commissural points of which are mounted on a respective one of the commissural supports;
wherein the cylindrical support is radially collapsible for implantation in the body via a catheter.
2. The valve prosthesis according to claim 1 wherein: the elastical valve comprises a biologically trilobate valve.
3. The valve prosthesis according to claim 1, wherein: the elastical valve comprises a cardiac valve.
4. The valve prosthesis according to claim 1, wherein: the elastical valve comprises a venous valve.
5. The valve prosthesis according to claim 1, wherein: the cylindrical support comprises a metal having a stiffness sufficient to prevent a contraction of the cylindrical support of more than about 10% following expansion.
6. The valve prosthesis according to claim 1, wherein: the cylindrical support comprises a thread structure which forms a cylinder surface.
7. A valve prosthesis for implantation in a body, comprising:
an elastical stent comprising a support means having circumferentially expandable sections comprised of a series of loops with commissural supports therebetween and integral therewith; and
an elastical valve, commissural points of which are mounted on a respective one of the commissural supports;
wherein the support means is radially collapsible for implantation in the body via a catheter and the support means extends axially for supporting the elastical valve.
8. The valve prosthesis according to claim 7, wherein: the support means is cylindrical.
9. The valve prosthesis according to claim 7, wherein: a surface of the support means is cylindrical.
10. The valve prosthesis according to claim 7, wherein: the elastical valve is a biologically trilobate valve.
11. The valve prosthesis according to claim 7, wherein: the support means is expandable upon removal from the catheter.
12. The valve prosthesis according to claim 7, wherein: the elastical valve comprises a cardiac valve.
13. The valve prosthesis according to claim 7, wherein: the elastical valve comprises a venous valve.
14. The valve prosthesis according to claim 7, wherein: the support means comprises a metal having a stiffness sufficient to prevent a contraction of the support means of more than about 10% following expansion.
15. A valve prosthesis for implantation in a body, comprising:
an elastical stent comprising a cylindrical support having a thread structure cylinder surface; and
an elastical valve, commissural points of which are mounted on the cylinder surface; and
wherein the cylinder surface is radially collapsible for implantation in the body via a catheter,
the thread structure comprises stainless steel wire folded in a plurality of loops, bended according to a circle, and welded to provide at least two closed rings,
the at least two closed rings are mutually connected end to end to form the cylindrical support.

US 7,618,446 B2

9

three loops in an external one of the rings are folded with a greater height than remaining ones of loops to form apices.

16. The valve prosthesis according to claim 15, wherein: the cylindrical support is expandable upon removal from the catheter;

each of the closed rings comprises a wire having a diameter of 0.55 mm;

a height of the remaining ones of loops is approximately 8 mm;

a height of the three greater height loops is approximately 14 mm; and

the cylindrical support and the elastical valve mounted thereon, when collapsed, have an outer diameter of approximately 10 mm and, when expanded, an outer diameter of approximately 30 mm.

17. The valve prosthesis according to claim 15, wherein: the stent is made to be fixed, through expansion of the cylindrical support upon removal from the catheter, at one point in a channel in which the valve prosthesis is implanted, which point is different from a point where the elastical valve is mounted on the stent.

18. A valve prosthesis for implantation in a patient's body without requiring open heart surgery, comprising:

a self expandable stent constructed to be radially compressible and re-expandable, the stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and

a collapsible and re-expandable elastical valve comprising three flaps formed entirely of biological tissue, the elastical valve positioned within an interior portion of the stent for folding and expanding together with the stent, the elastical valve located between the top and bottom ends of the stent, the elastical valve having three commissural points sutured to the self expandable stent, the elastical valve configured to allow blood to flow in one direction such that blood is capable of flowing through the stent from the bottom end toward the top end;

wherein the valve prosthesis is radially compressible from an expanded condition to a compressed condition, the compressed condition having a first outer diameter of 10 mm or less for insertion inside a tubular wall of a cap along a distal end portion of a delivery catheter for advancement through a small inlet opening into the body channel and wherein the valve prosthesis is radially self-expandable upon ejection from the cap to a re-expanded condition comprising a second outer diameter of approximately 27 mm or more such that the second outer diameter of the valve prosthesis is greater than an inner diameter of the body channel for securing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and to establish valvular function in the body channel, thereby allowing implantation of the valve prosthesis in the body channel for replacing the function of a natural aortic valve in an adult human being without open heart surgery and wherein the valve prosthesis is detachable from the delivery catheter such that the delivery catheter can be removed from the body channel and the small inlet opening can be closed such that the patient can resume a substantially normal life.

19. The valve prosthesis according to claim 18, wherein: the self-expandable stent has a height comprising a first range configured to be positioned downstream of the coronary ostia and a second range configured to support the elastical valve between the coronary ostia and the left ventricle.

10

20. The valve prosthesis according to claim 19, wherein: the elastical valve is formed entirely of biological tissue from a pig heart.

21. The valve prosthesis according to claim 18, wherein: the elastical valve comprises a venous valve.

22. The valve prosthesis according to claim 18, wherein: the stent has a stiffness sufficient to prevent a contraction of more than about 10% following re-expansion.

23. The valve prosthesis according to claim 18, wherein: the stent comprises a grate shaped structure which forms a cylinder surface.

24. A valve prosthesis configured to be implanted in a body channel without open heart surgery for replacing the function of a natural aortic valve in an adult human being, comprising:

a radially compressible and re-expandable metallic stent having a top end, a bottom end and a metallic outer surface configured to directly contact surrounding native tissue in a body channel with a pressure sufficient to prevent detachment from the body channel; and

a radially collapsible and re-expandable valve positioned within an interior portion of the stent and sutured to the stent for folding and expanding together with the stent, the valve having three flaps formed of biological tissue from a pig, the three flaps positioned between the top and bottom ends of the stent for allowing blood to flow in one direction such that blood is capable of flowing through the stent from the bottom end toward the top end, the valve having three commissural points sutured to the stent;

wherein the valve prosthesis is radially compressible from an expanded condition to a compressed condition, the compressed condition having an outer diameter of less than 12.5 mm to be located inside a tubular wall of a cap along a distal end portion of a catheter for advancement through a small inlet opening into the body channel and wherein the valve prosthesis is radially re-expandable upon ejection from the cap to a re-expanded condition comprising an outer diameter of approximately 27 mm or larger for securing the valve prosthesis to the surrounding native tissue without suturing the valve prosthesis to the surrounding native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel and the small inlet opening can be closed and wherein the metallic stent has a sufficient height such that the top end of the stent is capable of being positioned downstream of the coronary ostia while the valve is positioned substantially between coronary ostia and a left ventricle of a heart for replacing the function of the natural aortic valve without open heart surgery.

25. The valve prosthesis according to claim 24, wherein: at least a portion of the metallic stent is substantially cylindrical.

26. The valve prosthesis according to claim 24, wherein: the metallic stent is self-expandable upon ejection from the cap and wherein the outer diameter in the re-expanded condition is slightly larger than an inner diameter of the body channel.

27. The valve prosthesis according to claim 24, wherein: the radially collapsible and re-expandable valve comprises a cardiac valve.

28. The valve prosthesis according to claim 24, wherein: the radially collapsible and re-expandable valve comprises a venous valve.

29. The valve prosthesis according to claim 24, wherein: the metallic stent comprises a grate shaped structure having a stiffness sufficient to prevent a contraction of the metallic stent of more than about 10% following re-expansion.

30. A valve prosthesis for replacing the function of a native valve in a patient's body by a technique of catheterization, comprising:

- a radially collapsible and re-expandable stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and
- a collapsible and re-expandable valve structure positioned within an interior portion of the stent and sutured to the stent, the valve structure having three flaps formed entirely of biological tissue, the three flaps positioned between the top and bottom ends of the stent, the valve structure having three commissural points sutured to the stent, the valve structure configured to allow blood to flow in one direction such that blood enters through a bottom opening at the bottom end of the stent and exits through a top opening at the top end of the stent;

wherein the valve prosthesis is radially collapsible to an outer diameter of less than 10 mm for introduction by way of a catheter through an inlet opening into the body channel and wherein the outer diameter of the stent is radially re-expandable to a re-expanded dimension sized to engage the native tissue in the body channel with a pressure sufficient for preventing detachment from the body channel and for fixing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the patient's body and the inlet opening can be closed while the valve prosthesis remains in the body channel;

wherein the valve structure has an expanded outer diameter in the range of about 25 to 27 mm.

31. A valve prosthesis for replacing the function of a native valve in a patient's body by a technique of catheterization, comprising:

- a radially collapsible and re-expandable stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and
- a collapsible and re-expandable valve structure positioned within an interior portion of the stent and sutured to the stent, the valve structure having three flaps formed entirely of biological tissue, the three flaps positioned between the top and bottom ends of the stent, the valve structure having three commissural points sutured to the stent, the valve structure configured to allow blood to flow in one direction such that blood enters through a bottom opening at the bottom end of the stent and exits through a top opening at the top end of the stent;

wherein the valve prosthesis is radially collapsible to an outer diameter of less than 10 mm for introduction by way of a catheter through an inlet opening into the body channel and wherein the outer diameter of the stent is radially re-expandable to a re-expanded dimension sized to engage the native tissue in the body channel with a pressure sufficient for preventing detachment from the body channel and for fixing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the patient's body and the inlet opening can be closed while the valve prosthesis remains in the body channel;

wherein the re-expanded dimension has a diameter of about 30 mm.

32. A valve prosthesis for replacing the function of a natural heart valve, comprising:

- a radially compressible and re-expandable stent, the stent being compressible from an expanded condition to a compressed condition having an outer diameter suitable for introduction through a small inlet opening into a body channel by way of a delivery catheter and the stent being re-expandable to a re-expanded condition, the stent having a metallic outer surface for contacting surrounding tissue in the body channel, wherein an outer diameter of the stent in the re-expanded condition is at least 2.7 times larger than the outer diameter of the stent in the compressed condition; and

a collapsible and re-expandable valve structure mounted to the stent for folding and expanding together with the stent, the valve structure having three commissural points coupled to the stent, the valve structure having three flaps formed entirely of biological tissue, the valve structure positioned within an interior portion of the stent for preventing blood flow in one direction;

wherein the valve prosthesis is detachable from the delivery catheter after deployment in the body channel such that the delivery catheter can be removed from the body channel and the small inlet opening can be closed and wherein the stent has a stiffness in the expanded condition, the stiffness being sufficient to maintain pressure along surrounding tissue in the body channel for securing the valve prosthesis and preventing detachment from the body channel, thereby allowing the valve prosthesis to be permanently implanted in the body channel by way of catheterization without requiring surgical intervention.

33. The valve prosthesis according to claim 32, wherein: the stent is balloon expandable.

34. The valve prosthesis according to claim 32, wherein: the stent is formed of a metallic self-expandable material.

35. The valve prosthesis according to claim 34, wherein: the self-expandable stent has a height comprising a first range configured for fixation in the ascending aorta downstream of the coronary ostia and a second range configured to position the valve structure substantially between the coronary ostia and the left ventricle after implantation.

36. The valve prosthesis of claim 32, wherein: the valve structure is formed entirely of biological tissue from a slaughtered pig.

37. The valve prosthesis of claim 32, wherein: the valve prosthesis is configured to be implanted in the body channel without opening the thoracic cavity.

38. A valve prosthesis configured for implantation without surgical intervention for replacing the function of a defective natural valve in an adult human heart, comprising:

- a compressible and re-expandable stent having an inlet end, an outlet end and a metallic outer surface, the stent being radially compressible from an expanded state to a compressed state for introduction through an inlet opening into a body channel by way of a catheter, the stent being re-expandable to a re-expanded state such that the metallic outer surface engages surrounding tissue in the body channel, wherein an outer diameter of the stent in the re-expanded state is at least 2.7 times larger than an outer diameter of the stent in the compressed state; and
- a collapsible and re-expandable valve structure mounted within an interior portion of the stent between the inlet and outlet ends of the stent for

US 7,618,446 B2

13

together with the stent and configured for preventing blood flow in one direction, the valve structure having movable flaps positioned between the inlet and outlet ends of the stent for allowing blood to flow only from the inlet end toward the outlet end of the stent;

wherein stent stiffness provides the sole means of fixation to surrounding tissue for securing the valve prosthesis to the body channel and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel after deploying the valve prosthesis in the body channel and the inlet opening can be closed such that the valve prosthesis is permanently implantable in the body channel for replacing the function of a native valve without suturing the valve prosthesis to surrounding native tissue.

39. The valve prosthesis of claim 38, wherein: the stent comprises a grate-shaped structure.

40. The valve prosthesis of claim 39, wherein: the stent is self expandable.

41. The valve prosthesis of claim 40, wherein: the stent further comprises an outlet end portion configured for fixation in the ascending aorta at a location downstream of the coronary ostia and an inlet end portion configured for positioning the valve structure substantially between the coronary ostia and the left ventricle.

42. The valve prosthesis of claim 41, wherein: at least the inlet end portion of the stent is substantially cylindrical.

43. The valve prosthesis of claim 38, wherein: the valve structure is formed of biological tissue before the valve prosthesis is introduced through the inlet opening into the body channel.

44. The valve prosthesis of claim 43, wherein the biological tissue forms two or more adjacent flaps, the flaps forming commissural points between adjacent flaps.

45. The valve prosthesis of claim 38, wherein: the outer diameter of the stent in the re-expanded state is at least three times larger than the outer diameter of the stent in the compressed state.

46. A valve prosthesis configured for implantation in an adult human being without requiring surgical intervention for replacing the function of a defective natural aortic valve, comprising:

14

a self expandable metallic stent having an inlet end, an outlet end and a metallic outer surface, the stent being radially compressible to a compressed condition having an outer diameter suitable for insertion into a protection cap and sized for introduction through an inlet opening into a body channel by way of a catheter, the stent configured to self-expand to an expanded condition upon ejection from the protection cap, the stent comprising an outer diameter in the expanded condition at least three times greater than the outer diameter in the compressed condition, the outer diameter being greater than an inner diameter of an ascending aorta such that at least a portion of the metallic outer surface of the stent engages an inner wall of the ascending aorta for counteracting detachment of the valve prosthesis;

a collapsible and expandable elastical valve comprising three flaps formed of biological tissue, the elastical valve positioned within an interior portion of the stent for folding and expanding together with the stent, the elastical valve located between the inlet and outlet ends of the stent, the elastical valve having three commissural points sutured to the self expandable stent, the elastical valve configured to allow blood to flow in one direction such that blood is capable of flowing through the stent from the inlet end toward the outlet end;

wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel after implanting the valve prosthesis and the inlet opening can be closed such that the valve prosthesis is permanently implantable for replacing the function of the defective natural aortic valve without suturing the valve prosthesis to surrounding native tissue.

47. The valve prosthesis according to claim 46, wherein: the self-expandable stent comprises an inlet end portion configured to position the elastical valve substantially between the coronary ostia and the left ventricle.

48. The valve prosthesis according to claim 46, wherein: the outer diameter of the stent in the compressed condition is 10 mm or less.

49. The valve prosthesis according to claim 48, wherein: the outer diameter of the stent in the expanded condition is 30 mm or greater.

* * * * *

JS 44 (Rev. 12/07)

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

I. (a) PLAINTIFFS

EDWARDS LIFESCIENCES AG and EDWARDS LIFESCIENCES LLC

(b) County of Residence of First Listed Plaintiff

(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorney's (Firm Name, Address, and Telephone Number)

Richard L. Horwitz (#2246)/David E. Moore (#3983) (302) 984-6000
Potter Anderson & Corroon LLP, 1313 N. Market Street Wilmington, Delaware 19801

DEFENDANTS

MEDTRONIC, INC., MEDTRONIC COREVALVE, LLC, and
MEDTRONIC VASCULAR, INC.

County of Residence of First Listed Defendant

(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE
LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION

(Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
☐ 2 U.S. Government Defendant
☒ 3 Federal Question (U.S. Government Not a Party)
☐ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES

(For Diversity Cases Only)

(Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | | | | | |
|---|---|---|---|---------|---|
| Citizen of This State | PTF DEF | ☐ 1 ☐ 1 | Incorporated or Principal Place of Business In This State | PTF DEF | ☐ 4 ☐ 4 |
| Citizen of Another State | ☐ 2 ☐ 2 | Incorporated and Principal Place of Business In Another State | ☐ 5 ☐ 5 | | |
| Citizen or Subject of a Foreign Country | ☐ 3 ☐ 3 | Foreign Nation | ☐ 6 ☐ 6 | | |

IV. NATURE OF SUIT

(Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
☐ 110 Insurance ☐ 120 Marine ☐ 130 Miller Act ☐ 140 Negotiable Instrument ☐ 150 Recovery of Overpayment & Enforcement of Judgment ☐ 151 Medicare Act ☐ 152 Recovery of Defaulted Student Loans (Excl. Veterans) ☐ 153 Recovery of Overpayment of Veteran's Benefits ☐ 160 Stockholders' Suits ☐ 190 Other Contract ☐ 195 Contract Product Liability ☐ 196 Franchise	PERSONAL INJURY ☐ 310 Airplane ☐ 315 Airplane Product Liability ☐ 320 Assault, Libel & Slander ☐ 330 Federal Employers' Liability ☐ 340 Marine ☐ 345 Marine Product Liability ☐ 350 Motor Vehicle ☐ 355 Motor Vehicle Product Liability ☐ 360 Other Personal Injury PERSONAL INJURY ☐ 362 Personal Injury - Med. Malpractice ☐ 365 Personal Injury - Product Liability ☐ 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY ☐ 370 Other Fraud ☐ 371 Truth in Lending ☐ 380 Other Personal Property Damage ☐ 385 Property Damage Product Liability	☐ 610 Agriculture ☐ 620 Other Food & Drug ☐ 625 Drug Related Seizure of Property 21 USC 881 ☐ 630 Liquor Laws ☐ 640 R.R. & Truck ☐ 650 Airline Regs. ☐ 660 Occupational Safety/Health ☐ 690 Other LABOR ☐ 710 Fair Labor Standards Act ☐ 720 Labor/Mgmt. Relations ☐ 730 Labor/Mgmt. Reporting & Disclosure Act ☐ 740 Railway Labor Act ☐ 790 Other Labor Litigation ☐ 791 Empl. Ret. Inc. Security Act IMMIGRATION ☐ 462 Naturalization Application ☐ 463 Habeas Corpus - Alien Detainee ☐ 465 Other Immigration Actions	☐ 422 Appeal 28 USC 158 ☐ 423 Withdrawal 28 USC 157 PROPERTY RIGHTS ☐ 820 Copyrights ☒ 830 Patent ☐ 840 Trademark SOCIAL SECURITY ☐ 861 HIA (1395ff) ☐ 862 Black Lung (923) ☐ 863 DIWC/DIWW (405(g)) ☐ 864 SSID Title XVI ☐ 865 RSI (405(a)) FEDERAL TAX SUITS ☐ 870 Taxes (U.S. Plaintiff or Defendant) ☐ 871 IRS—Third Party 26 USC 7609	☐ 400 State Reapportionment ☐ 410 Antitrust ☐ 430 Banks and Banking ☐ 450 Commerce ☐ 460 Deportation ☐ 470 Racketeer Influenced and Corrupt Organizations ☐ 480 Consumer Credit ☐ 490 Cable/Sat TV ☐ 810 Selective Service ☐ 850 Securities/Commodities/Exchange ☐ 875 Customer Challenge 12 USC 3410 ☐ 890 Other Statutory Actions ☐ 891 Agricultural Acts ☐ 892 Economic Stabilization Act ☐ 893 Environmental Matters ☐ 894 Energy Allocation Act ☐ 895 Freedom of Information Act ☐ 900 Appeal of Fee Determination Under Equal Access to Justice ☐ 950 Constitutionality of State Statutes
REAL PROPERTY	CIVIL RIGHTS	PRISONER PETITIONS		
☐ 210 Land Condemnation ☐ 220 Foreclosure ☐ 230 Rent Lease & Ejectment ☐ 240 Torts to Land ☐ 245 Tort Product Liability ☐ 290 All Other Real Property	☐ 441 Voting ☐ 442 Employment ☐ 443 Housing/Accommodations ☐ 444 Welfare ☐ 445 Amer. w/Disabilities - Employment ☐ 446 Amer. w/Disabilities - Other ☐ 440 Other Civil Rights	☐ 510 Motions to Vacate Sentence Habeas Corpus: ☐ 530 General ☐ 535 Death Penalty ☐ 540 Mandamus & Other ☐ 550 Civil Rights ☐ 555 Prison Condition		

V. ORIGIN

(Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
☐ 2 Removed from State Court
☐ 3 Remanded from Appellate Court
☐ 4 Reinstated or Reopened
☐ 5 Transferred from another district (specify)
☐ 6 Multidistrict Litigation
☐ 7 Appeal to District Judge from Magistrate Judgment

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
35 U.S.C. § 1 et seq., 35 U.S.C. §271

Brief description of cause:
Patent Infringement

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23

DEMAND \$

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED CASE(S) IF ANY

(See instructions): JUDGE Another case filed today against same
Gregory M. Sleet

DOCKET NUMBER 08-91 (GMS)

DATE

11/17/2009

SIGNATURE OF ATTORNEY OF RECORD

Richard L. Horwitz

FOR OFFICE USE ONLY

RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

I. (a) Plaintiffs-Defendants. Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.

(b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)

(c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".

II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.C.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.

United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.

United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; federal question actions take precedence over diversity cases.)

III. Residence (citizenship) of Principal Parties. This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.

IV. Nature of Suit. Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerks in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.

V. Origin. Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.

Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.

Appeal to District Judge from Magistrate Judgment. (7) Check this box for an appeal from a magistrate judge's decision.

VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553
Brief Description: Unauthorized reception of cable service

VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.

Demand. In this space enter the dollar amount (in thousands of dollars) being demanded or indicate other demand such as a preliminary injunction.

Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.

VIII. Related Cases. This section of the JS 44 is used to reference related pending cases if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.

EXHIBIT K

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

EDWARDS LIFESCIENCES AG and	)	
EDWARDS LIFESCIENCES LLC,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 09-873 (GMS)
	)	
MEDTRONIC, INC., MEDTRONIC	)	DEMAND FOR JURY TRIAL
COREVALVE, LLC, and MEDTRONIC	)	
VASCULAR, INC.	)	
	)	
Defendants.	)	

SECOND AMENDED COMPLAINT

Plaintiffs Edwards Lifesciences AG (“Edwards AG”) and Edwards Lifesciences LLC (“Edwards LLC”) (collectively, “Plaintiffs”), for their Second Amended Complaint (“Complaint”) against Defendants Medtronic, Inc. (“Medtronic”), Medtronic CoreValve, LLC (“Medtronic CoreValve”), and Medtronic Vascular, Inc. (“Medtronic Vascular”) (collectively, “Defendants”), allege as follows:

JURISDICTION AND VENUE

1. This action arises under the Patent Laws of the United States, 35 U.S.C. § 1 *et seq.* This Court has jurisdiction over the subject matter of this action based on 28 U.S.C. §§ 1338(a) and 1331. Venue is proper under 28 U.S.C. §§ 1391(b) and (c) and 1400(b).

THE PARTIES

Edwards

2. Plaintiff Edwards AG is a corporation organized and existing under the laws of Switzerland and having its principal executive offices in Nyon, Switzerland.

3. Plaintiff Edwards LLC is a limited liability company organized and existing under the laws of the State of Delaware and having its principal executive offices in Irvine, California.

4. Edwards AG is the assignee of the following United States Patents covering pioneering percutaneous heart valve products: U.S. Patent No. 7,618,446 (“the ‘446 Patent”), U.S. Patent No. 5,411,552 (“the ‘552 Patent”), and U.S. Patent No. 6,582,462 (“the ‘462 Patent”) (collectively, “the Patents”). The Patents disclose and claim, *inter alia*, collapsible and expandable tissue valve prostheses that replace human heart valves using minimally invasive catheterization procedures.

5. Edwards LLC is the exclusive licensee of the Patents for the field of all cardiovascular applications.

Medtronic

6. Upon information and belief, Defendant Medtronic is a corporation organized and existing under the laws of the State of Minnesota and having its principal place of business in Minneapolis, Minnesota.

7. Upon information and belief, Medtronic is registered to do business in Delaware, and is doing business in Delaware.

8. Upon information and belief, Medtronic has been and is now manufacturing, using, importing, selling and/or offering to sell in the United States heart valve prostheses, including heart valve prostheses known as “Medtronic CoreValve Percutaneous System,” “CoreValve transcatheter aortic valve system,” and/or the “ReValving” system (hereinafter collectively the “ReValving” system), and/or supplying or causing to be supplied in

or from the United States one or more components of such heart valve prostheses, which activities infringe the '446 Patent, the '552 Patent and the '462 Patent.

9. Upon information and belief, Medtronic has been and is now knowingly and actively inducing others to infringe the '446 Patent, the '552 Patent and the '462 Patent and continues to do so.

Medtronic CoreValve

10. Upon information and belief, Defendant Medtronic CoreValve is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business in Irvine, California.

11. Upon information and belief, Medtronic CoreValve is a wholly owned subsidiary of, and controlled by, Medtronic.

12. Upon information and belief, Medtronic CoreValve has been and is now manufacturing, using, importing, selling and/or offering to sell in the United States heart valve prostheses, including heart valve prostheses known as the ReValving system, and/or supplying or causing to be supplied in or from the United States one or more components of such heart valve prostheses, which activities infringe the '446 Patent and the '462 Patent.

13. On April 1, 2010, in *Edwards Lifesciences AG et al. v. Medtronic CoreValve, LLC et al.*, C.A. No. 08-91 (D. Del.) (GMS), a jury returned a verdict that Medtronic CoreValve literally and willfully infringed the '552 Patent by manufacturing the ReValving system in the United States.

14. Upon information and belief, Medtronic CoreValve is now supplying or causing to be supplied in or from the United States one or more components of heart valve prostheses, including the ReValving system, which activities infringe the '552 Patent.

15. Upon information and belief, Medtronic CoreValve has been and is now knowingly and actively inducing others to infringe the '446 Patent, the '552 Patent and/or the '462 Patent and continues to do so.

Medtronic Vascular

16. Upon information and belief, Defendant Medtronic Vascular is a corporation organized and existing under the laws of the State of Delaware and having its principal place of business in Santa Rosa, California.

17. Upon information and belief, Medtronic Vascular is a wholly owned subsidiary of, and controlled by, Medtronic.

18. Upon information and belief, Medtronic Vascular has been and is now manufacturing, using, importing, selling and/or offering to sell in the United States heart valve prostheses, including heart valve prostheses known the ReValving system, and/or supplying or causing to be supplied in or from the United States one or more components of such heart valve prostheses, which activities infringe the '446 Patent, the '552 Patent and the '462 Patent.

19. Upon information and belief, Medtronic Vascular has been and is now knowingly and actively inducing others to infringe the '446 Patent, the '552 Patent and the '462 Patent and continues to do so.

**FIRST CAUSE OF ACTION
(Infringement of the '446 Patent)**

20. Plaintiffs repeat and reallege the allegations of paragraphs 1 through 19 above.

21. On November 17, 2009, the '446 Patent (Exhibit 1), entitled "A Valve Prosthesis for Implantation in the Body and a Catheter for Implanting Such Valve Prosthesis," was duly and legally issued to Drs. Henning Rud Andersen, John Michael Hasenkam, and Lars

Lyhne Knudsen. Edwards AG is the assignee, and Edwards LLC is the exclusive licensee of the '446 Patent for the field of all cardiovascular applications. Plaintiffs are the owners of all rights, title and interest in and to the '446 Patent, including all rights to recover for any and all past infringement thereof, in the field of all cardiovascular applications.

22. Upon information and belief, and in violation of 35 U.S.C. § 271(a), Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the '446 Patent by manufacturing, using, importing, selling and/or offering to sell heart valve prostheses covered by one or more claims of the '446 Patent, including products designated as the ReValving system.

23. Upon information and belief, and in violation of 35 U.S.C. § 271(b), Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the '446 Patent, including at least by their knowing and active inducement of the manufacture, use, importation, sale and/or offer to sell of heart valve prostheses covered by one or more claims of the '446 Patent, including products designated as the ReValving system.

24. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(1), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the '446 Patent by supplying or causing to be supplied in or from the United States all or a substantial portion of the components of the invention claimed in the '446 Patent, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside the United States in a manner that would infringe the '446 Patent if such combination occurred within the United States.

25. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(2), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the '446 Patent by

supplying or causing to be supplied in or from the United States one or more components of the invention claimed in the '446 Patent, that is or are especially made or especially adapted for use in the invention claimed in the '446 Patent and not a staple article or commodity of commerce suitable for substantial noninfringing use, where such component or components is or are uncombined in whole or in part, knowing that such component or components is or are so made or adapted and intending that such component or components will be combined outside of the United States in a manner that would infringe the '446 Patent if such combination occurred within the United States.

26. Defendants' foregoing infringement has been willful and deliberate, rendering this case exceptional within the meaning of 35 U.S.C. § 285.

27. Plaintiffs have been damaged and will be irreparably injured by Defendants' past and continuing infringement, for which Plaintiffs have no adequate remedy at law. Defendants' infringement will continue unless enjoined by this Court.

SECOND CAUSE OF ACTION (Infringement of the '552 Patent)

28. Plaintiffs repeat and reallege the allegations of paragraphs 1 through 27 above.

29. On May 2, 1995, the '552 Patent (Exhibit 2 hereto), entitled "Valve Prothesis for Implantation in the Body and a Catheter for Implanting such Valve Prothesis," was duly and legally issued to Drs. Henning Rud Andersen, John Michael Hasenkam, and Lars Lyhne Knudsen. Edwards AG is the assignee, and Edwards LLC is the exclusive licensee of the '552 Patent for the field of all cardiovascular applications. Plaintiffs are the owners of all rights, title and interest in and to the '552 Patent, including all rights to recover for any and all past infringement thereof, in the field of all cardiovascular applications.

30. Upon information and belief, and in violation of 35 U.S.C. § 271(a), Medtronic and Medtronic Vascular have been and are now infringing the ‘552 Patent by manufacturing, using, importing, selling and/or offering to sell heart valve prostheses covered by one or more claims of the ‘552 Patent, including products designated as the ReValving system.

31. Upon information and belief, and in violation of 35 U.S.C. § 271(b), Medtronic, Medtronic CoreValve and Medtronic Vascular have been and/or are now infringing the ‘552 Patent, including at least by their knowing and active inducement of the manufacture, use, importation, sale and/or offer to sell of heart valve prostheses covered by one or more claims of the ‘552 Patent, including products designated as the ReValving system.

32. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(1), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the ‘552 Patent by supplying or causing to be supplied in or from the United States all or a substantial portion of the components of the invention claimed in the ‘552 Patent, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside the United States in a manner that would infringe the ‘552 Patent if such combination occurred within the United States.

33. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(2), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the ‘552 Patent by supplying or causing to be supplied in or from the United States one or more components of the invention claimed in the ‘552 Patent, that is or are especially made or especially adapted for use in the invention claimed in the ‘552 Patent and not a staple article or commodity of commerce suitable for substantial noninfringing use, where such component or components is or are uncombined in whole or in part, knowing that such component or components is or are so made

or adapted and intending that such component or components will be combined outside of the United States in a manner that would infringe the ‘552 Patent if such combination occurred within the United States.

34. Defendants’ foregoing infringement has been willful and deliberate, rendering this case exceptional within the meaning of 35 U.S.C. § 285.

35. Plaintiffs have been damaged and will be irreparably injured by Defendants’ past and continuing infringement, for which Plaintiffs have no adequate remedy at law. Defendants’ infringement will continue unless enjoined by this Court.

**THIRD CAUSE OF ACTION
(Infringement of the ‘462 Patent)**

36. Plaintiffs repeat and reallege the allegations of paragraphs 1 through 35 above.

37. On June 24, 2003, the ‘462 Patent (Exhibit 3 hereto), entitled “Valve Prosthesis for Implantation in the Body and a Catheter for Implanting such Valve Prosthesis,” was duly and legally issued to Drs. Henning Rud Andersen, John Michael Hasenkam, and Lars Lyhne Knudsen. Edwards AG is the assignee, and Edwards LLC is the exclusive licensee of the ‘462 Patent for the field of all cardiovascular applications. Plaintiffs are the owners of all rights, title and interest in and to the ‘462 Patent, including all rights to recover for any and all past infringement thereof, in the field of all cardiovascular applications.

38. Upon information and belief, and in violation of 35 U.S.C. § 271(a), Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the ‘462 Patent by manufacturing, using, importing, selling and/or offering to sell heart valve prostheses covered by one or more claims of the ‘462 Patent, including products designated as the ReValving system.

39. Upon information and belief, and in violation of 35 U.S.C. § 271(b), Medtronic, Medtronic CoreValve and Medtronic Vascular have been and are now infringing the ‘462 Patent, including at least by their knowing and active inducement of the manufacture, use, importation, sale and/or offer to sell of heart valve prostheses covered by one or more claims of the ‘462 Patent, including products designated as the ReValving system.

40. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(1), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the ‘462 Patent by supplying or causing to be supplied in or from the United States all or a substantial portion of the components of the invention claimed in the ‘462 Patent, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside the United States in a manner that would infringe the ‘462 Patent if such combination occurred within the United States.

41. Upon information and belief, and in violation of 35 U.S.C. § 271(f)(2), Medtronic, Medtronic CoreValve and Medtronic Vascular are now infringing the ‘462 Patent by supplying or causing to be supplied in or from the United States one or more components of the invention claimed in the ‘462 Patent, that is or are especially made or especially adapted for use in the invention claimed in the ‘462 Patent and not a staple article or commodity of commerce suitable for substantial noninfringing use, where such component or components is or are uncombined in whole or in part, knowing that such component or components is or are so made or adapted and intending that such component or components will be combined outside of the United States in a manner that would infringe the ‘462 Patent if such combination occurred within the United States.

42. Defendants' foregoing infringement has been willful and deliberate, rendering this case exceptional within the meaning of 35 U.S.C. § 285.

43. Plaintiffs have been damaged and will be irreparably injured by Defendants' past and continuing infringement, for which Plaintiffs have no adequate remedy at law. Defendants' infringement will continue unless enjoined by this Court.

PRAYER FOR RELIEF

WHEREFORE Plaintiffs demand judgment as follows:

- (a) Finding that Defendants have infringed the '446 Patent, the '552 Patent and the '462 Patent;
- (b) Finding that Defendants' infringement of the '446 Patent, the '552 Patent and the '462 Patent has been willful and deliberate;
- (c) Preliminarily and permanently enjoining and restraining Defendants and their officers, agents, servants, employees and attorneys, all parent, subsidiary and affiliate corporations and other related business entities, and all other persons or entities acting in concert, participation or in privity with Defendants, and their successors and assigns, from infringing, contributing to the infringement of, or inducing others to infringe the '446 Patent, the '552 Patent and the '462 Patent;
- (d) Awarding Plaintiffs damages, in an amount to be determined at trial, together with interest and costs as fixed by the Court;
- (e) Awarding Plaintiffs enhanced damages under 35 U.S.C. § 284;
- (f) Awarding Plaintiffs their reasonable attorneys' fees and their costs and disbursements in this action, as provided by 35 U.S.C. § 285; and
- (g) Granting Plaintiffs such other and further relief as the Court deems just and proper.

JURY DEMAND

Plaintiffs demand a trial by jury on all issues so triable in this Complaint.

MORRIS NICHOLS ARSHT & TUNNELL LLP

/s/ Jack B. Blumenfeld

Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com

Attorneys for Plaintiffs

OF COUNSEL:

John E. Nathan
Catherine Nyarady
Brian P. Egan
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
1285 Avenue of the Americas
New York, NY 10019
(212) 373-3000

April 23, 2010

CERTIFICATE OF SERVICE

I hereby certify that on April 23, 2010, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to:

John W. Shaw, Esquire
Karen E. Keller, Esquire
YOUNG CONAWAY STARGATT & TAYLOR, LLP

I further certify that I caused copies of the foregoing document to be served on April 23, 2010, upon the following in the manner indicated:

John W. Shaw, Esquire
Karen E. Keller, Esquire
YOUNG CONAWAY STARGATT & TAYLOR, LLP
The Brandywine Building – 17th Floor
1000 West Street
Wilmington, DE 19801

VIA ELECTRONIC MAIL

J. David Evered, Esquire
Joseph R. Re, Esquire
Joseph S. Cianfrani, Esquire
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street
Fourteenth Floor
Irvine, CA 92614

VIA ELECTRONIC MAIL

Karen Vogel Weil, Esquire
KNOBBE, MARTENS, OLSON & BEAR, LLP
1901 Avenue of the Stars
Suite 1500
Los Angeles, CA 90067

VIA ELECTRONIC MAIL

Robert A. Van Nest, Esquire
Brian Ferrall, Esquire
Ashok Ramani, Esquire
Nikki Vo, Esquire
Matan Shacham, Esquire
KEKER & VAN NEST LLP
710 Sansome Street
San Francisco, CA 94111

VIA ELECTRONIC MAIL

/s/ Jack B. Blumenfeld

Jack B. Blumenfeld (#1014)

EXHIBIT 1

(12) **United States Patent**
Andersen et al.

(10) **Patent No.:** **US 7,618,446 B2**
 (45) **Date of Patent:** ***Nov. 17, 2009**

(54) **VALVE PROSTHESIS FOR IMPLANTATION IN THE BODY AND A CATHETER FOR IMPLANTING SUCH VALVE PROSTHESIS**

(75) Inventors: **Henning Rud Andersen**, Højbjerg (DK); **John Michael Hasenkam**, Aarhus (DK); **Lars Lyhne Knudsen**, Aarhus (DK)

(73) Assignee: **Edwards Lifesciences AG**, Nyon (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/268,253**

(22) Filed: **Oct. 10, 2002**

(65) **Prior Publication Data**

US 2003/0036795 A1 Feb. 20, 2003

Related U.S. Application Data

(60) Continuation of application No. 09/514,426, filed on Feb. 28, 2000, now Pat. No. 6,582,462, which is a continuation of application No. 09/026,574, filed on Feb. 20, 1998, now Pat. No. 6,168,614, which is a continuation of application No. 08/955,228, filed on Oct. 21, 1997, now abandoned, which is a division of application No. 08/801,036, filed on Feb. 19, 1997, now Pat. No. 5,840,081, which is a continuation of application No. 08/569,314, filed on Dec. 8, 1995, now abandoned, which is a continuation of application No. 08/352,127, filed on Dec. 1, 1994, now abandoned, which is a division of application No. 08/261,235, filed on Jun. 14, 1994, now Pat. No. 5,411,552, which is a continuation of application No. 07/961,891, filed as application No. PCT/DK91/00134 on May 16, 1991, now abandoned.

(30) **Foreign Application Priority Data**

May 18, 1990 (DK) 1246/90

(51) **Int. Cl.**

A61F 2/24 (2006.01)

A61F 2/90 (2006.01)

A61F 2/88 (2006.01)

(52) **U.S. Cl.** **623/1.26; 623/2.14**

(58) **Field of Classification Search** 623/2.1–2.19, 623/2.38–2.41, 900, 904, 1.24–1.26, FOR. 101, 623/23.68; 604/9

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,055,188 A 9/1936 Wappler et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 2246526 3/1973

(Continued)

OTHER PUBLICATIONS

Sugie et al., Clinical experience with supported homograft heart valve for mitral and aortic valve replacement, The Journal of Thoracic and Cardiovascular Surgery, vol. 57, No. 4 (Apr. 1969), pp. 455-463.*

(Continued)



Primary Examiner—David H. Willse

(74) *Attorney, Agent, or Firm*—David L. Hauser

(57) **ABSTRACT**

A valve prosthesis for implantation in the body by use of a catheter includes a stent made from an expandable cylinder-shaped thread structure including several spaced apices. The elastically collapsible valve is mounted on the stent as the commissural points of the valve are secured to the projecting apices. The valve prosthesis can be compressed around balloons of the balloon catheter and inserted in a channel, for instance, in the aorta. When the valve prosthesis is placed correctly, the balloons are inflated to expand the stent and wedge it against the wall of the aorta. The balloons are provided with beads to ensure a steady fastening of the valve prosthesis on the balloons during insertion and expansion. The valve prosthesis and the balloon catheter make it possible to insert a cardiac valve prosthesis without a surgical operation involving opening the thoracic cavity.

49 Claims, 5 Drawing Sheets



US 7,618,446 B2

Page 2

U.S. PATENT DOCUMENTS

3,275,211 A 9/1966 Hirsch et al.
 3,409,013 A 11/1968 Berry
 3,472,230 A 10/1969 Fogarty
 3,548,417 A 12/1970 Kischer
 3,587,115 A 6/1971 Shiley
 3,657,744 A 4/1972 Ersek
 3,671,979 A 6/1972 Mouloupoulos
 3,714,671 A 2/1973 Edwards et al.
 3,755,823 A 9/1973 Hancodk
 3,799,150 A 3/1974 Bonnet
 3,868,956 A 3/1975 Alfidi et al.
 4,035,849 A 7/1977 Angell et al.
 4,038,703 A 8/1977 Bokros
 4,056,854 A 11/1977 Boretos et al.
 4,106,129 A 8/1978 Carpentier et al.
 4,222,126 A 9/1980 Boretos et al.
 4,297,749 A 11/1981 Davis et al.
 4,339,831 A 7/1982 Johnson
 4,343,048 A * 8/1982 Ross et al. 623/2.14
 4,345,340 A 8/1982 Rosen
 4,391,282 A 7/1983 Amdo et al.
 4,448,195 A 5/1984 LeVeen et al.
 4,470,157 A 9/1984 Love
 4,574,803 A 3/1986 Storz
 4,580,568 A 4/1986 Gianturco
 4,592,340 A 6/1986 Boyles
 4,612,011 A 9/1986 Kautzky
 4,655,771 A 4/1987 Wallsten
 4,687,483 A * 8/1987 Fisher et al. 623/2.14
 4,692,164 A 9/1987 Dzemeshekevich et al.
 4,725,274 A 2/1988 Lane et al.
 4,731,074 A 3/1988 Rousseau et al.
 4,733,665 A 3/1988 Palmaz
 4,777,951 A 10/1988 Cribier et al.
 4,778,461 A 10/1988 Pietsch et al.
 4,787,899 A 11/1988 Lazarus
 4,787,901 A 11/1988 Baykut
 4,790,843 A 12/1988 Carpentier et al.
 4,796,629 A 1/1989 Grayzel
 4,830,003 A 5/1989 Wolff et al.
 4,851,000 A 7/1989 Gupta
 4,856,516 A 8/1989 Hillstead
 4,878,495 A 11/1989 Grayzel
 4,878,906 A 11/1989 Lindemann et al.
 4,883,458 A 11/1989 Shiber
 4,892,541 A 1/1990 Alonso
 4,917,698 A 4/1990 Carpentier et al.
 4,922,905 A 5/1990 Strecker
 4,932,965 A 6/1990 Phillips
 RE33,258 E 7/1990 Onik
 4,966,604 A 10/1990 Reiss
 4,979,939 A 12/1990 Shiber
 4,986,830 A 1/1991 Owens et al.
 4,994,077 A 2/1991 Dobben
 5,007,896 A 4/1991 Shiber
 5,019,102 A 5/1991 Hoene
 5,026,366 A 6/1991 Leckrone
 5,032,128 A 7/1991 Alonso
 5,037,434 A 8/1991 Lane
 5,041,130 A 8/1991 Cosgrove et al.
 5,047,041 A 9/1991 Samuels
 5,059,177 A 10/1991 Towne et al.
 5,061,277 A 10/1991 Carpentier et al.
 5,085,635 A 2/1992 Cragg
 5,089,015 A 2/1992 Ross
 5,104,407 A 4/1992 Lam et al.
 5,123,919 A 6/1992 Sauter et al.
 5,147,391 A 9/1992 Lane
 5,152,771 A 10/1992 Sabbaghian et al.
 5,163,953 A 11/1992 Vince
 5,163,955 A 11/1992 Love et al.

5,167,628 A 12/1992 Boyles
 5,201,880 A 4/1993 Wright et al.
 5,258,021 A 11/1993 Duran
 5,258,023 A 11/1993 Reger
 5,295,958 A 3/1994 Shturman
 5,306,296 A 4/1994 Wright et al.
 5,332,402 A 7/1994 Teitelbaum
 5,332,403 A 7/1994 Kolff
 5,344,442 A 9/1994 Deac
 5,350,420 A 9/1994 Cosgrove et al.
 5,358,518 A 10/1994 Camilli
 5,370,685 A 12/1994 Stevens
 5,376,112 A 12/1994 Duran
 5,376,113 A 12/1994 Jansen et al.
 5,397,351 A 3/1995 Pavcnik et al.
 5,411,552 A 5/1995 Andersen et al.
 5,443,446 A 8/1995 Shturman
 5,449,384 A 9/1995 Johnson
 5,469,868 A 11/1995 Reger
 5,480,424 A 1/1996 Cox
 5,489,298 A 2/1996 Love et al.
 5,500,014 A 3/1996 Quijano et al.
 5,545,209 A 8/1996 Roberts et al.
 5,554,185 A 9/1996 Block et al.
 5,609,626 A 3/1997 Quijano et al.
 5,755,782 A 5/1998 Love et al.
 5,824,061 A 10/1998 Quijano et al.
 5,840,081 A 11/1998 Andersen et al.
 6,283,993 B1 9/2001 Cosgrove et al.

FOREIGN PATENT DOCUMENTS

DE 36 40 745 A1 6/1987
 EP 0103546 A1 3/1984
 EP 0350302 1/1990
 EP 0357003 3/1990
 EP 0592410 B1 10/1995
 GB 1 268 484 * 3/1972
 GB 2 056 023 A 3/1979
 GB 2056023 3/1981
 SU 158988 * 11/1963 623/FOR. 101
 SU 1258406 9/1986
 SU 1271508 11/1986
 SU 1271508 A1 11/1986
 SU 1371700 A1 * 2/1988
 SU 1371701 2/1988
 SU 1457921 A1 * 2/1989
 WO WO 9117720 11/1991
 WO WO 9217118 10/1992

OTHER PUBLICATIONS

Anderson, et al., "Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs", European Heart Journal, the journal of the European Society of Cardiology, vol. 13, Issue 5, pp. 704-708, (1992).
 LexisNexis Search Results, U.S. District Court Civil Docket, U.S. District—Delaware (Wilmington), Civil Action No. 1:08-cv-00091-GMS, *Edwards Lifesciences AG et al. v. Corevalve Inc.*, filed Feb. 12, 2008, Date of last filing Apr. 4, 2008, 7 sheets.
 Morris, Nichols, Arsht & Tunnell LLP, Attorneys for Plaintiffs, Demand for Jury Trial filed Feb. 12, 2008 in the United States District Court for the District of Delaware, Case 1:08-cv-00091-UNA, Document 1, 41 sheets.
 Richards, Layton & Finger, Attorneys for Defendant, CoreValve, Inc., Jury Trial Demanded filed Apr. 4, 2008 in the United States District Court for the District of Delaware, Case 1:08-cv-00091-GMS, Document 12, 13 pages.

US 7,618,446 B2

Page 3

H.R. Andersen et al., Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs, *European Heart Journal* (1992) 13, 704-708.

Ernst-Peter Strecker, M.D., et al., Current Status of the Stecker Stent, *Contemporary Interventional Techniques*, Supplied by The British Library—"The world's knowledge", vol. 12, No. 1, Nov. 1994, pp. 673-687.

Steven R. Bailey, 75—Percutaneous Expandable Prosthetic Valves, *Textbook of Interventional Cardiology*, vol. 2, Second Edition, 1994, pp. 1268-1276.

Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243, Amended Product Description of Claimant, 7 pgs.

Dotter, Charles T., MD, Transluminally-placed Coilspring Endarterial Tube Grafts: Long-term Patency in Canine Popliteal Artery, *Investigate Radiology*, Sep.-Oct. 1969, pp. 329-332, vol. 4, Issue 5, Lippincott Williams & Wilkins, Inc.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Edwards' Opening Claim Construction Brief, Feb. 6, 2009 26 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Joint Markman Claim Construction Chart, Jan. 16, 2009, 32 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Joint Supplemental Markman Claim Construction Chart, 4 pgs.

Edwards Lifesciences AG and Edwards Lifesciences LLC v. Corevalve, Inc., United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMS, Order Construing the Terms of U.S. Patent Nos. 5,411,552; 6,168,614; and 6,582,462, 5 pgs.

Request for Ex Parte Reexamination filed Jun. 12, 2009 for USPN 5,411,552, Issued May 2, 1995, Titled: Valve Prothesis for Implantation in the Body and a Catheter for Implanting Such Valve Prothesis.

Davies, Hywel, "Catheter-Mounted Valve for Temporary Relief of Aortic Insufficiency"; *The Lancet*, Preliminary Communications; Jan. 30, 1965, p. 250, Cardiac Department, Guy's Hospital, London, S.E.1.

Dotter, M.D., Charles T., "Transluminally-placed Coilspring Endarterial Tube Grafts"; *Investigative Radiology*, Sep.-Oct., 1969, vol. 4, pp. 329-332.

Magovern, George J., Replacement of Aortic and Mitral Valves with the Sutureless Prosthesis; Results in 100 Patients; *Chest Online*; American College of Chest Physicians; ISSN: 0096-0217; www.chestjournal.org; pp. 415-422, *Dis Chest* 1966; 50; 415-422.

Decision on Request for Reexamination in U.S. Appl. No. 09/009,484, filed Jun. 12, 2009; mailed Aug. 7, 2009.

Andersen, Henning Rud, History of Percutaneous Aortic Valve Prosthesis, *Herz* 34 2009 Nr.5 Urban & Vogel, pp. 343, 346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.

16th Edition of The Merck Manual of Diagnosis and Therapy (1992) "Valvular Heart Disease," pp. 546-553.

Yamaguchi, Case Description "A Case of a Reoperation Using a Balloon Catheter with Blocked Pars Ascendes Aortae" *Kyobu Geka*, Oct. 1989, 42:11, pp. 961-964.

World Medical Manufacturing Corp., Talent Endovascular Bifurcated Spring Graft System Composite Design brochure, c. 1989.

Derwent Abstract No. 87-1980867/27 (1987), SU 1271508 (Gorkii Kirov Medical Ins.).

UK proceedings in respect of EP 0592410, May 21, 2007.

* cited by examiner

U.S. Patent

Nov. 17, 2009

Sheet 1 of 5

US 7,618,446 B2




FIG. 1














FIG. 2










FIG. 13




FIG. 14

US 7,618,446 B2

1

VALVE PROSTHESIS FOR IMPLANTATION IN THE BODY AND A CATHETER FOR IMPLANTING SUCH VALVE PROSTHESIS

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent applica-
 tion Ser. No. 09/514,426, filed Feb. 28, 2000, (now U.S. Pat.
 No. 6,582,462), which is a continuation of U.S. patent applica-
 tion Ser. No. 09/026,574, filed Feb. 20, 1998 (now U.S. Pat.
 No. 6,168,614), which is a continuation of U.S. patent applica-
 tion Ser. No. 08/955,228, filed Oct. 21, 1997 (abandoned),
 which is a divisional of U.S. patent application Ser. No. 08/801,036,
 filed Feb. 19, 1997 (issued as U.S. Pat. No. 5,840, 081 on Nov. 24, 1998),
 which is a continuation of U.S. patent application Ser. No. 08/569,314,
 filed Dec. 8, 1995 (abandoned), which is a continuation of U.S. patent application Ser.
 No. 08/352,127, filed Dec. 1, 1994 (abandoned), which is a
 divisional of U.S. patent application Ser. No. 08/261,235,
 filed Jun. 14, 1994 (now U.S. Pat. No. 5,411,552), which is a
 continuation of U.S. patent application Ser. No. 07/961,891,
 filed Jan. 11, 1993 (abandoned), which is a national stage
 application of PCT/DK91/00134, filed May 16, 1991 (aban-
 doned).

BACKGROUND OF THE INVENTION

The present invention relates to a valve prosthesis, prefer-
 ably a cardiac valve prosthesis, for implantation in the body
 and comprising a collapsible elastic valve which is mounted
 on an elastic stent wherein the commissural points of the
 elastic collapsible valve are mounted on the cylinder surface
 of the elastic stent.

Valve prostheses of this type are usually implanted in one
 of the channels of the body to replace a natural valve. In the
 present description the invention will be explained in connec-
 tion with a cardiac valve prosthesis for implantation in aorta.
 However, it will be possible to use a valve prosthesis accord-
 ing to the invention in connection with implantation in other
 channels in the body by using the same technique as the one
 used for implantation of cardiac valve prosthesis. Such an
 implantation may, e.g., comprise the implantation of:

1. a valve (for instance a cardiac valve) in the veins,
2. a valve in the esophagus and at the stomach,
3. a valve in the ureter and/or the vesica,
4. a valve in the biliary passages,
5. a valve in the lymphatic system, and
6. a valve in the intestines.

An existing natural valve in the body is traditionally
 replaced with a valve prosthesis by a surgical implantation.
 However, a surgical implantation is often an exacting opera-
 tion. Thus, today the implantation of cardiac valves are solely
 made by surgical technique where the thoracic cavity is
 opened. The operation calls for the use of a heart and lung
 machine for external circulation of the blood as the heart is
 stopped and opened during the surgical intervention and the
 artificial cardiac valves are subsequently sewed in.

Due to its exacting character, it is impossible to offer such
 operation to certain people. For instance, this is due to the fact
 that the person is physically weak because of age or illness.
 Moreover, the number of heart and lung machines available at
 a hospital will be a substantially limiting factor.

Cardiac valve prostheses that need no surgical intervention
 are known as there are used for implantation by means of a
 technique of catheterization. Examples of such valve pros-
 theses are described in U.S. Pat. Nos. 3,671,979 and 4,056,

2

854. However, both of these valve prostheses are connected to
 means which lead to the surface of the patient either for a
 subsequent activation of the valve or for a subsequent repo-
 sition or removal of the valve prosthesis. With these valve
 prostheses it is impossible to make an implantation which
 makes it possible for the patient to resume a substantially
 normal life in the same way as it is possible in connection with
 a surgical implantation of a cardiac valve.

From U.S. Pat. No. 3,755,823 an elastic stent for a cardiac
 valve prosthesis is known. However, this valve prostheses is
 not designed for implantation in the body by catheterization.
 Even though this patent contains no detailed explanation, the
 description indicates that this valve prosthesis is designed for
 implantation and sewing on by a surgical intervention.

Moreover, from U.S. Pat. Nos. 4,856,516 and 4,733,665
 different shapes of expandable stents are known. These stents
 are made to be expanded by impression of a radially outward
 force coming from a balloon catheter or the like. These stents
 are made to reinforce the wall when there is a risk that the
 channel is closed and/or compressed.

The nearest prior art may be that the described in GB-A-
 2,056,023. This document discloses an elastic stent as
 described by way of introduction. Thus, the stent described
 comprises an elastic collapsible valve mounted on the cylin-
 der surface of a cylindrical stent. However, the valve prosthe-
 sis including the stent is designated for mounting through a
 surgical intervention. Even though the stent is slightly col-
 lapsible, it will not be suited for implantation by a catheter-
 ization procedure.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a valve
 prosthesis of the type mentioned in the introductory part,
 which permits implantation without surgical intervention in
 the body and by using a catheter technique known per se and
 which makes it possible for the patient to resume a substan-
 tially normal life.

This is achieved according to the invention with a valve
 prosthesis of the type mentioned in the introductory part,
 which is characterized in that the stent is made from a radially
 collapsible and re-expandable cylindrical support means for
 folding and expanding together with the collapsible valve for
 implantation in the body by means of a technique of catheter-
 ization.

The collapsible elastic valve is mounted on the stent for
 instance by gluing, welding or by means of a number of
 suitable sutures.

If the support means are made from a thread structure, this
 can for instance be grate shaped, loop shaped or helical. This
 makes it possible to compress the stent and the collapsible
 valve mounted thereon for placing on the insertion catheter.
 The use of a non-self-expandable stent may, e.g., be effected
 by a compression of the stent around the expansion arrange-
 ment of the catheter which preferably consists of a balloon.
 When using a self-expandable stent, a catheter with an expan-
 sion arrangement is not used. In this case the stent is com-
 pressed and is inserted into an insertion or protection cap from
 which the stent is eliminated after implantation in order to
 obtain an expansion due to the stresses in the compressed
 support means, which for instance may be made from plastics
 or metal. After the compression the entire outer dimension is
 relatively small, which makes it possible to introduce the
 valve prostheses through a channel in the body.

When the valve prosthesis is introduced and placed cor-
 rectly, the stent is expanded by self-expansion or by means of
 the expansion arrangement until the stent is given an outer

3

dimension which is slightly larger than the channel in which it is placed. As the stent is elastic, a contraction of the stent is prevented once it is expanded. The stiffness in the material of the support means contributes to maintain the expanded shape of the stent. After the expansion is made, the expansion arrangement of the catheter is contracted and the catheter can be removed from the channel. The inlet opening can subsequently be closed and the patient will then be able to resume a normal life.

The valve prosthesis according to the invention does not require an actual operation but merely a small intervention to optionally expose the body channel, e.g., a vein, through which the insertion takes place. Thus, patients for whom an operation would be associated with high risk can be offered implantation of, for instance, cardiac valves. After the implantation has taken place, the after-treatment will advantageously be shorter than normal, which means fewer hospital days for the patient. Moreover, it is assumed that it will be possible to implant the valve prosthesis under local anaesthetic.

The valve prosthesis can be used to replace a natural valve or to establish a new valve function in one of the channels in the body which do not naturally contain a valve. For instance this goes for veins (arteries and veins) on a place without natural valves. The function of the valve prosthesis is then to ensure that the blood flows in one direction only. The valve is meant to be used in veins in the legs of persons suffering from varicose veins (varices).

In persons having varicose veins the blood flows in a wrong direction, viz. from the central veins in the center of the leg towards the superficial veins. Among other things, this is due to the changed pressure in the legs, upright working position and other conditions. A valve prosthesis according to the invention may easily be placed in the veins and prevent the flow of the blood in a wrong direction.

Also, the valve prosthesis can be used in connection with diseases, for instance cancerous tumors, where too much humour is produced. If the humour is able to flow from the cancerous tumor through several channels, it is possible to drain the humour in one desired direction through the channels of the body by an appropriate placing of the valve prosthesis.

When the valve prosthesis is used as a cardiac valve prosthesis in the aorta, it is possible to mount it in three positions, viz., in the descending part of the aorta in a position between the coronary arteries and the left ventricle of the heart, or in the aorta in a position immediately after the mouth of the coronary arteries.

The cardiac valve prosthesis can also be used in other places than in the aorta. Thus, the valve prosthesis can be used in the pulmonary artery and/or the right ventricle of the heart for replacing the pulmonary valves. Likewise, the cardiac valve prosthesis can be used in the passage between the right auricle of the heart and the right ventricle of the heart (tricuspidalostium) and the passage between the left auricle of the heart and the left ventricle of the heart (mistolostium) for replacing the tricuspidal valve and the mitral valve, respectively.

Even though the cardiac valve preferably is meant to be used for patients suffering from aorta insufficiency and who cannot be offered an open heart surgery, the valve prosthesis can also be used for patents in connection with treatment of aorta stenosis. Several of the patients with aorta stenosis are elderly people who cannot be offered a surgical cardiac operation. The patients are offered balloon dilatation of the aorta stenosis which may result in an aorta insufficiency as a side effect of the treatment.

4

As to these patients it is possible to insert a valve prosthesis in the descending or ascending part of the aorta thoracalis a few days or weeks before the balloon dilatation. As a result thereof, the left ventricle is protected against weight if the subsequent balloon dilatation of the stenosis results in aorta insufficiency. In certain cases the weight (reflux) on the left ventricle is reduced by up to approximately 75%.

Furthermore, the stent may be made with a relatively great height and with a cylinder surface which is closed by a suitable material. Thus, a vascular prosthesis known per se is formed wherein the valve is mounted. This may facilitate the implantation of the valve prosthesis, for instance in the arcus aorta. Moreover, the great surface which abuts the inner wall of the channel contributes to ensure the securing of the valve prosthesis in the channel. This embodiment is also suitable as valve prosthesis which is inserted in veins. As veins have relatively thin and weaker walls than arteries, it is desirable that the valve prosthesis has a greater surface to distribute the outward pressure which is necessary to secure the valve prosthesis.

Moreover, the invention relates to a balloon catheter for implanting a valve prosthesis according to the invention and comprising a channel for injection of a fluid for the inflation of the balloon means of the catheter and an insertion cap wherein the balloon means of the catheter and a collapsible valve prosthesis mounted thereon are located during the injection, characterized in that the balloon means are provided with profiled surface which is made to ensure a steady fastening of the valve prosthesis during the withdrawal of the balloon means from the protection cap and the subsequent inflation for the expansion of the stent.

Different balloon catheters for implanting cores in the body are known. For instance, such balloon catheters are known from U.S. Pat. Nos. 4,856,516, 4,733,665 and 4,796,629 and from DE publication No. 2,246,526. However, the known balloon catheters have a smooth or a slightly wavy surface. The use of such balloon catheter is disadvantageous for mounting a valve prosthesis in a channel having a large flow as for instance the aorta. A large humour flow is able to displace the stent on the smooth surface of the balloon and makes an accurate positioning difficult. This drawback has been remedied with the balloon catheter according to the present invention as the profiled surface prevents a displacement of the valve prosthesis in relation to the balloon means during introduction and the subsequent inflation of the balloon means.

In connection with the implantation, any prior art technique may be used to supervise an accurate introduction and positioning of the valve prosthesis. Thus, guide wires for the catheter, X-ray supervision, injection of X-ray traceable liquids, ultrasonic measuring, etc. may be used.

DESCRIPTION OF THE DRAWINGS

The invention will now be explained in detail with reference to the accompanying schematical drawing, wherein

FIG. 1 shows a perspective view of a stent without a valve,

FIG. 2 is a perspective view of a valve prosthesis according to the invention made from the stent shown in FIG. 1 having a biological valve mounted thereon,

FIG. 3 is a partial view through the aorta illustrating a partially inflated balloon catheter,

FIG. 4 is a cross section through the embodiment shown in FIG. 9,

FIGS. 5-7 are views illustrating the introduction and implantation of a valve prosthesis of the invention in the aorta,

US 7,618,446 B2

5

FIGS. 8-10 are views illustrating three possible positions of a cardiac valve prosthesis,

FIGS. 11-12 are perspective views illustrating two further embodiments of a valve prosthesis having a closed cylindrical wall, and

FIGS. 13-14 are perspective views illustrating two further embodiments of a stent without a valve.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 shows a stent 1 made by support means in the form of two 0.55 mm surgical stainless steel wires 2,3. The wires are folded in 15 loops. Three loops 4 are 14 mm in height and are intended to secure the commissural points 5 (see FIG. 2) from a biological cardiac valve 6 which is mounted in the stent 1. The remaining loops have a height of 8 mm. These loops form circumferentially expandable sections 25 between the commissural points 5 forming commissural supports. Each of the two folded wires 2,3 is bent to form rings 7,8 which are closed by welding the ends. The two rings are placed on top of each other as will appear from FIG. 1 and they are mutually secured by means of a number of sutures (not shown). The lower ring is circumferentially expandable at least along sections thereof which correspond to the circumferentially expandable sections 25. By using a substantially cylindrical thread structure with projecting apices, a reduction in weight is obtained as compared to a stent which is exclusively cylindrical with the same loop heights for all the loops.

The biological valve 6 was removed from a slaughtered pig of 100 kg. The valve was cleaned before mounting in the stent 1. The cleaned valve has an outer diameter of 25-27 mm and the height of the three commissural points 5 is 8 mm. The valve 6 is mounted in the stent by means of a suitable number of sutures to form the cardiac valve prosthesis 9 shown in FIG. 2. The valve prosthesis produced is used for performing tests in pigs by implantation of cardiac valve prosthesis. However, the cardiac valve prosthesis for use in human beings has a corresponding form.

FIG. 3 shows a partial view through the aorta 10. A balloon catheter 11 is introduced in the aorta according to the direction of an arrow 12. In the Figure shown the balloon means 13 of the balloon catheter is led out of the protection cap 11A and is partly inflated through a fluid channel 15, which is led to the surface of the patient. The balloon means 13 constitutes a tri-sectional balloon upon which the cardiac valve prosthesis is placed. In the form shown, the cardiac valve prosthesis is expanded exactly to be in contact with the aorta 10. The balloon means 13 is provided with three projecting beads 14 which are engaged with the one side of the cardiac valve prosthesis 9. The blood flowing through the aorta according to the direction of an arrow 16 will thus cause the cardiac valve prosthesis 9 to abut on the beads 14 and the valve cannot be displaced in relation to the balloon means 13. Moreover, the balloon catheter used comprises a central channel 17 to receive a guide wire 18 which is used in a way known per se for supervising the introduction of the catheter through fluoroscopy. In the shown embodiment beads 14 are only used at one side of the valve prosthesis, but, however, it will often be desirable to use the beads in pairs placed along lines parallel to the longitudinal axes 19 through the balloon means 13. In this case the spacing of the pair of beads 14 will correspond to the height of the loops of the stent. This makes it possible to make an effective fastening of a valve prosthesis on balloon

6

means. Moreover, the fastening on the balloon means may be provided by using balloon means with an indentation in the surface (not shown).

FIG. 4 shows a cross section through the embodiment shown in FIG. 3 illustrating the placing of the beads 14 on the tri-sectional balloon means 13.

A balloon catheter of the above-described type which was used in tests of implanting of cardiac valve prosthesis 9 in pigs had the following dimensions. Each of the three balloons was 60 mm in length and 15 mm in diameter. The total diameter for the three inflated balloons was 31 mm and in the balloon catheter used two beads 14 having a height of 3 mm were mounted on each side of the three balloons. The beads had a spacing of 15 mm. The protection cap 11A of the balloon catheter had an outer diameter of 13.6 mm and an inner diameter of 12.5 mm and a length of 75 cm. The balloon catheter was provided with a standard guide wire having a diameter of 0.9 mm and a length 300 cm.

FIGS. 5-7 show the valve prosthesis 9 at different steps in introducing and implanting in the aorta 10 by means of the catheter 11 having the inflatable balloon means 13. The cardiac valve prosthesis 9 is initially placed above the deflated balloon means 13 and compressed manually around the balloon means (FIG. 5), whereafter the outer diameter for the valve prosthesis is approximately 10 mm. After the introduction and positioning, the balloon means 13 is inflated (FIG. 6), thereby contributing an outer dimension of approximately 30 mm to the cardiac valve prosthesis. To obtain an effective fastening in the aorta, the outer dimension of the cardiac valve prosthesis is greater than the diameter of the aorta. This means that the prosthesis is tight against the inner wall of the aorta with a pressure which is sufficiently large to counteract a detachment due to the flow of the blood. The balloon catheter 11 may subsequently be removed from the aorta 10 (FIG. 7). Due to the stiffness of the metal the valve prosthesis will prevent a contraction. However, smaller contractions may occur (<10% diameter reduction) after the deflation and removal of the balloon catheter 13. When the valve prosthesis is mounted as shown in FIG. 7, the patient will be able to resume a substantially normal life after a few days.

FIGS. 8-10 show the positioning of the valve prosthesis 9 as cardiac valve prosthesis in the aorta 10 in three different positions, i.e., in a position between the coronary arteries 20 and the left ventricle of the heart 21 (FIG. 8), in a position immediately after the mouth of the coronary arteries in the ascending part of the aorta (FIG. 9), and in a position in the descending part of the aorta 10. The positioning of the valve prosthesis is chosen in accordance with the diagnosis of the illness of the patient. By placing the cardiac valve prosthesis as shown in FIG. 8, there is a risk of detachment and/or covering the mouth of the coronary arteries, and therefore it is preferred to use a higher stent which, for instance, comprises several ranges placed on top of each other. This allows a fixation of the prosthesis at a place after the mouth of coronary arteries even though the valve itself is in the position between the coronary arteries and the left ventricle. FIGS. 8 and 9 show how a contrast medium 23 is injected by means of a so-called pigtail catheter for registration of tightness of the implanted valve prosthesis 9.

A specific embodiment for a valve prosthesis and a balloon catheter for implanting the valve prosthesis has been explained above. However, it is obvious that it is possible to modify the valve prosthesis depending on the desired use, and moreover, it is possible to modify the catheter used in the implantation. Thus, the stent of the valve prosthesis may be made solely of one closed ring folded in a number of loops or with three or more mutually secured loop-shaped rings placed

US 7,618,446 B2

7

on top of each other. Moreover, it is possible to make the stent having a thread structure which instead of loops is grate shaped, helical or is formed otherwise if only it is ensured that the form of the stent permits the compression and expansion of the stent and fastening of the collapsible valve. Instead of a biological valve it might be possible to use other collapsible valves, such as valves made from synthetic materials, e.g., polyurethane. It is also possible to use valves with more or fewer flaps than three.

It is possible to make the valve prosthesis with a closed cylinder surface as illustrated in FIGS. 11 and 12. In both Figures the support means of the valve prosthesis is made of an elongated tubular means 24 having a closed cylinder surface. This valve prosthesis is intended to expand by self-expansion or by means of a catheter according to the invention. This prosthesis is especially suitable for placing in veins and other channels where only a small pressure is exerted against the wall of the channel. In FIG. 11 the valve 6 is mounted at the end of the tubular means 24. In FIG. 12 an embodiment is shown where the valve 6 is mounted in a central position in the tubular means 24.

An explanation of a method of implanting a valve prosthesis according to the invention is given below:

a valve prosthesis 9 made of a stent 1 and a collapsible valve 6, as described above, is placed on a deflated balloon means and is manually compressed thereon,

the balloon means 13 and the valve prosthesis are drawn into an insertion cover 11A,

a guide wire 18 is inserted into the left ventricle of the heart through the central opening 17 of the balloon catheter under continuous fluoroscopy,

the insertion cover 11A conveys the guide wire 18 to a point in the channel in the immediate vicinity of the desired position of the valve prosthesis,

the balloon means 13 is pushed out of the protection cap 11A and the valve prosthesis is positioned in the desired position if necessary by use of further registration means to ensure an accurate positioning,

the balloon means 13 is inflated with a certain overstretching of the channel,

the balloon means 13 is deflated, and

the balloon means 13, the guide wire 18 and the protection cap 11A are drawn out and the opening in the channel, if any, wherein the valve prosthesis is inserted can be closed.

FIGS. 13-14 are perspective view illustrating two further embodiments of a stent without a valve. In FIG. 13, the stent 100 is made by support means in the form of helical wires 102, 103, with loops 104 and circumferentially expandable sections 125. Each of the two helical wires 102, 103 is bent to form rings 107, 108. In FIG. 14, the stent 200 is made by support means in the form of gate-shaped wires 202, 203, with loops 204 and circumferentially expandable sections 225. Each of the two gate-shaped wires 202, 203 is bent to form rings 207, 208. The primary difference between prior described embodiments, such as in FIG. 2, versus those embodiments shown in FIGS. 13 and 14, for example, is the replacement of the series of loops 4 (FIG. 2) with the helical wires 102, 103 and loops 104 (FIG. 13) or the grate-shaped wires 202, 203 and loops 204 (FIG. 14). As the artisan will readily appreciate, the embodiments of FIGS. 13-14 otherwise include those features shown in prior described embodiments, such as in FIG. 2, including the commissural points 5 forming commissural supports.

8

What is claimed is:

1. A valve prosthesis for implantation in a body, comprising:

an elastical stent comprising a cylindrical support having circumferentially expandable sections comprised of a series of loops with commissural supports therebetween and integral therewith; and

an elastical valve, commissural points of which are mounted on a respective one of the commissural supports;

wherein the cylindrical support is radially collapsible for implantation in the body via a catheter.

2. The valve prosthesis according to claim 1 wherein:

the elastical valve comprises a biologically tribolobe valve.

3. The valve prosthesis according to claim 1, wherein:

the elastical valve comprises a cardiac valve.

4. The valve prosthesis according to claim 1, wherein:

the elastical valve comprises a venous valve.

5. The valve prosthesis according to claim 1, wherein:

the cylindrical support comprises a metal having a stiffness sufficient to prevent a contraction of the cylindrical support of more than about 10% following expansion.

6. The valve prosthesis according to claim 1, wherein:

the cylindrical support comprises a thread structure which forms a cylinder surface.

7. A valve prosthesis for implantation in a body, comprising:

an elastical stent comprising a support means having circumferentially expandable sections comprised of a series of loops with commissural supports therebetween and integral therewith; and

an elastical valve, commissural points of which are mounted on a respective one of the commissural supports;

wherein the support means is radially collapsible for implantation in the body via a catheter and the support means extends axially for supporting the elastical valve.

8. The valve prosthesis according to claim 7, wherein:

the support means is cylindrical.

9. The valve prosthesis according to claim 7, wherein:

a surface of the support means is cylindrical.

10. The valve prosthesis according to claim 7, wherein:

the elastical valve is a biologically trilobate valve.

11. The valve prosthesis according to claim 7, wherein:

the support means is expandable upon removal from the catheter.

12. The valve prosthesis according to claim 7, wherein:

the elastical valve comprises a cardiac valve.

13. The valve prosthesis according to claim 7, wherein:

the elastical valve comprises a venous valve.

14. The valve prosthesis according to claim 7, wherein:

the support means comprises a metal having a stiffness sufficient to prevent a contraction of the support means of more than about 10% following expansion.

15. A valve prosthesis for implantation in a body, comprising:

an elastical stent comprising a cylindrical support having a thread structure cylinder surface; and

an elastical valve, commissural points of which are mounted on the cylinder surface; and

wherein the cylinder surface is radially collapsible for implantation in the body via a catheter,

the thread structure comprises stainless steel wire folded in a plurality of loops, bended according to a circle, and welded to provide at least two closed rings,

the at least two closed rings are mutually connected end to end to form the cylindrical support, and

US 7,618,446 B2

9

three loops in an external one of the rings are folded with a greater height than remaining ones of loops to form apices.

16. The valve prosthesis according to claim 15, wherein: the cylindrical support is expandable upon removal from the catheter;

each of the closed rings comprises a wire having a diameter of 0.55 mm;

a height of the remaining ones of loops is approximately 8 mm;

a height of the three greater height loops is approximately 14 mm; and

the cylindrical support and the elastical valve mounted thereon, when collapsed, have an outer diameter of approximately 10 mm and, when expanded, an outer diameter of approximately 30 mm.

17. The valve prosthesis according to claim 15, wherein: the stent is made to be fixed, through expansion of the cylindrical support upon removal from the catheter, at one point in a channel in which the valve prosthesis is implanted, which point is different from a point where the elastical valve is mounted on the stent.

18. A valve prosthesis for implantation in a patient's body without requiring open heart surgery, comprising:

a self expandable stent constructed to be radially compressible and re-expandable, the stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and

a collapsible and re-expandable elastical valve comprising three flaps formed entirely of biological tissue, the elastical valve positioned within an interior portion of the stent for folding and expanding together with the stent, the elastical valve located between the top and bottom ends of the stent, the elastical valve having three commissural points sutured to the self expandable stent, the elastical valve configured to allow blood to flow in one direction such that blood is capable of flowing through the stent from the bottom end toward the top end;

wherein the valve prosthesis is radially compressible from an expanded condition to a compressed condition, the compressed condition having a first outer diameter of 10 mm or less for insertion inside a tubular wall of a cap along a distal end portion of a delivery catheter for advancement through a small inlet opening into the body channel and wherein the valve prosthesis is radially self-expandable upon ejection from the cap to a re-expanded condition comprising a second outer diameter of approximately 27 mm or more such that the second outer diameter of the valve prosthesis is greater than an inner diameter of the body channel for securing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and to establish valvular function in the body channel, thereby allowing implantation of the valve prosthesis in the body channel for replacing the function of a natural aortic valve in an adult human being without open heart surgery and wherein the valve prosthesis is detachable from the delivery catheter such that the delivery catheter can be removed from the body channel and the small inlet opening can be closed such that the patient can resume a substantially normal life.

19. The valve prosthesis according to claim 18, wherein: the self-expandable stent has a height comprising a first range configured to be positioned downstream of the coronary ostia and a second range configured to support the elastical valve between the coronary ostia and the left ventricle.

10

20. The valve prosthesis according to claim 19, wherein: the elastical valve is formed entirely of biological tissue from a pig heart.

21. The valve prosthesis according to claim 18, wherein: the elastical valve comprises a venous valve.

22. The valve prosthesis according to claim 18, wherein: the stent has a stiffness sufficient to prevent a contraction of more than about 10% following re-expansion.

23. The valve prosthesis according to claim 18, wherein: the stent comprises a grate shaped structure which forms a cylinder surface.

24. A valve prosthesis configured to be implanted in a body channel without open heart surgery for replacing the function of a natural aortic valve in an adult human being, comprising:

a radially compressible and re-expandable metallic stent having a top end, a bottom end and a metallic outer surface configured to directly contact surrounding native tissue in a body channel with a pressure sufficient to prevent detachment from the body channel; and

a radially collapsible and re-expandable valve positioned within an interior portion of the stent and sutured to the stent for folding and expanding together with the stent, the valve having three flaps formed of biological tissue from a pig, the three flaps positioned between the top and bottom ends of the stent for allowing blood to flow in one direction such that blood is capable of flowing through the stent from the bottom end toward the top end, the valve having three commissural points sutured to the stent;

wherein the valve prosthesis is radially compressible from an expanded condition to a compressed condition, the compressed condition having an outer diameter of less than 12.5 mm to be located inside a tubular wall of a cap along a distal end portion of a catheter for advancement through a small inlet opening into the body channel and wherein the valve prosthesis is radially re-expandable upon ejection from the cap to a re-expanded condition comprising an outer diameter of approximately 27 mm or larger for securing the valve prosthesis to the surrounding native tissue without suturing the valve prosthesis to the surrounding native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel and the small inlet opening can be closed and wherein the metallic stent has a sufficient height such that the top end of the stent is capable of being positioned downstream of the coronary ostia while the valve is positioned substantially between coronary ostia and a left ventricle of a heart for replacing the function of the natural aortic valve without open heart surgery.

25. The valve prosthesis according to claim 24, wherein: at least a portion of the metallic stent is substantially cylindrical.

26. The valve prosthesis according to claim 24, wherein: the metallic stent is self-expandable upon ejection from the cap and wherein the outer diameter in the re-expanded condition is slightly larger than an inner diameter of the body channel.

27. The valve prosthesis according to claim 24, wherein: the radially collapsible and re-expandable valve comprises a cardiac valve.

28. The valve prosthesis according to claim 24, wherein: the radially collapsible and re-expandable valve comprises a venous valve.

11

29. The valve prosthesis according to claim 24, wherein: the metallic stent comprises a grate shaped structure having a stiffness sufficient to prevent a contraction of the metallic stent of more than about 10% following re-expansion.

30. A valve prosthesis for replacing the function of a native valve in a patient's body by a technique of catheterization, comprising:

- a radially collapsible and re-expandable stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and
- a collapsible and re-expandable valve structure positioned within an interior portion of the stent and sutured to the stent, the valve structure having three flaps formed entirely of biological tissue, the three flaps positioned between the top and bottom ends of the stent, the valve structure having three commissural points sutured to the stent, the valve structure configured to allow blood to flow in one direction such that blood enters through a bottom opening at the bottom end of the stent and exits through a top opening at the top end of the stent;

wherein the valve prosthesis is radially collapsible to an outer diameter of less than 10 mm for introduction by way of a catheter through an inlet opening into the body channel and wherein the outer diameter of the stent is radially re-expandable to a re-expanded dimension sized to engage the native tissue in the body channel with a pressure sufficient for preventing detachment from the body channel and for fixing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the patient's body and the inlet opening can be closed while the valve prosthesis remains in the body channel;

wherein the valve structure has an expanded outer diameter in the range of about 25 to 27 mm.

31. A valve prosthesis for replacing the function of a native valve in a patient's body by a technique of catheterization, comprising:

- a radially collapsible and re-expandable stent having a top end, a bottom end and a metallic outer surface configured to contact native tissue in a body channel; and
- a collapsible and re-expandable valve structure positioned within an interior portion of the stent and sutured to the stent, the valve structure having three flaps formed entirely of biological tissue, the three flaps positioned between the top and bottom ends of the stent, the valve structure having three commissural points sutured to the stent, the valve structure configured to allow blood to flow in one direction such that blood enters through a bottom opening at the bottom end of the stent and exits through a top opening at the top end of the stent;

wherein the valve prosthesis is radially collapsible to an outer diameter of less than 10 mm for introduction by way of a catheter through an inlet opening into the body channel and wherein the outer diameter of the stent is radially re-expandable to a re-expanded dimension sized to engage the native tissue in the body channel with a pressure sufficient for preventing detachment from the body channel and for fixing the valve prosthesis in the body channel without suturing the valve prosthesis to native tissue and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the patient's body and the inlet opening can be closed while the valve prosthesis remains in the body channel;

12

wherein the re-expanded dimension has a diameter of about 30 mm.

32. A valve prosthesis for replacing the function of a natural heart valve, comprising:

- a radially compressible and re-expandable stent, the stent being compressible from an expanded condition to a compressed condition having an outer diameter suitable for introduction through a small inlet opening into a body channel by way of a delivery catheter and the stent being re-expandable to a re-expanded condition, the stent having a metallic outer surface for contacting surrounding tissue in the body channel, wherein an outer diameter of the stent in the re-expanded condition is at least 2.7 times larger than the outer diameter of the stent in the compressed condition; and

a collapsible and re-expandable valve structure mounted to the stent for folding and expanding together with the stent, the valve structure having three commissural points coupled to the stent, the valve structure having three flaps formed entirely of biological tissue, the valve structure positioned within an interior portion of the stent for preventing blood flow in one direction;

wherein the valve prosthesis is detachable from the delivery catheter after deployment in the body channel such that the delivery catheter can be removed from the body channel and the small inlet opening can be closed and wherein the stent has a stiffness in the expanded condition, the stiffness being sufficient to maintain pressure along surrounding tissue in the body channel for securing the valve prosthesis and preventing detachment from the body channel, thereby allowing the valve prosthesis to be permanently implanted in the body channel by way of catheterization without requiring surgical intervention.

33. The valve prosthesis according to claim 32, wherein: the stent is balloon expandable.

34. The valve prosthesis according to claim 32, wherein: the stent is formed of a metallic self-expandable material.

35. The valve prosthesis according to claim 34, wherein: the self-expandable stent has a height comprising a first range configured for fixation in the ascending aorta downstream of the coronary ostia and a second range configured to position the valve structure substantially between the coronary ostia and the left ventricle after implantation.

36. The valve prosthesis of claim 32, wherein: the valve structure is formed entirely of biological tissue from a slaughtered pig.

37. The valve prosthesis of claim 32, wherein: the valve prosthesis is configured to be implanted in the body channel without opening the thoracic cavity.

38. A valve prosthesis configured for implantation without surgical intervention for replacing the function of a defective natural valve in an adult human heart, comprising:

- a compressible and re-expandable stent having an inlet end, an outlet end and a metallic outer surface, the stent being radially compressible from an expanded state to a compressed state for introduction through an inlet opening into a body channel by way of a catheter, the stent being re-expandable to a re-expanded state such that the metallic outer surface engages surrounding tissue in the body channel, wherein an outer diameter of the stent in the re-expanded state is at least 2.7 times larger than an outer diameter of the stent in the compressed state; and
- a collapsible and re-expandable valve structure mounted within an interior portion of the stent between the inlet and outlet ends of the stent for folding and expanding

US 7,618,446 B2

13

together with the stent and configured for preventing blood flow in one direction, the valve structure having movable flaps positioned between the inlet and outlet ends of the stent for allowing blood to flow only from the inlet end toward the outlet end of the stent;

wherein stent stiffness provides the sole means of fixation to surrounding tissue for securing the valve prosthesis to the body channel and wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel after deploying the valve prosthesis in the body channel and the inlet opening can be closed such that the valve prosthesis is permanently implantable in the body channel for replacing the function of a native valve without suturing the valve prosthesis to surrounding native tissue.

39. The valve prosthesis of claim 38, wherein: the stent comprises a grate-shaped structure.

40. The valve prosthesis of claim 39, wherein: the stent is self expandable.

41. The valve prosthesis of claim 40, wherein: the stent further comprises an outlet end portion configured for fixation in the ascending aorta at a location downstream of the coronary ostia and an inlet end portion configured for positioning the valve structure substantially between the coronary ostia and the left ventricle.

42. The valve prosthesis of claim 41, wherein: at least the inlet end portion of the stent is substantially cylindrical.

43. The valve prosthesis of claim 38, wherein: the valve structure is formed of biological tissue before the valve prosthesis is introduced through the inlet opening into the body channel.

44. The valve prosthesis of claim 43, wherein the biological tissue forms two or more adjacent flaps, the flaps forming commissural points between adjacent flaps.

45. The valve prosthesis of claim 38, wherein: the outer diameter of the stent in the re-expanded state is at least three times larger than the outer diameter of the stent in the compressed state.

46. A valve prosthesis configured for implantation in an adult human being without requiring surgical intervention for replacing the function of a defective natural aortic valve, comprising:

14

a self expandable metallic stent having an inlet end, an outlet end and a metallic outer surface, the stent being radially compressible to a compressed condition having an outer diameter suitable for insertion into a protection cap and sized for introduction through an inlet opening into a body channel by way of a catheter, the stent configured to self-expand to an expanded condition upon ejection from the protection cap, the stent comprising an outer diameter in the expanded condition at least three times greater than the outer diameter in the compressed condition, the outer diameter being greater than an inner diameter of an ascending aorta such that at least a portion of the metallic outer surface of the stent engages an inner wall of the ascending aorta for counteracting detachment of the valve prosthesis;

a collapsible and expandable elastical valve comprising three flaps formed of biological tissue, the elastical valve positioned within an interior portion of the stent for folding and expanding together with the stent, the elastical valve located between the inlet and outlet ends of the stent, the elastical valve having three commissural points sutured to the self expandable stent, the elastical valve configured to allow blood to flow in one direction such that blood is capable of flowing through the stent from the inlet end toward the outlet end;

wherein the valve prosthesis is detachable from the catheter such that the catheter can be removed from the body channel after implanting the valve prosthesis and the inlet opening can be closed such that the valve prosthesis is permanently implantable for replacing the function of the defective natural aortic valve without suturing the valve prosthesis to surrounding native tissue.

47. The valve prosthesis according to claim 46, wherein: the self-expandable stent comprises an inlet end portion configured to position the elastical valve substantially between the coronary ostia and the left ventricle.

48. The valve prosthesis according to claim 46, wherein: the outer diameter of the stent in the compressed condition is 10 mm or less.

49. The valve prosthesis according to claim 48, wherein: the outer diameter of the stent in the expanded condition is 30 mm or greater.

* * * * *

EXHIBIT 2



US005411552A

United States Patent [19]

[11] Patent Number: 5,411,552

Andersen et al.

[45] Date of Patent: May 2, 1995

[54] VALVE PROTHESIS FOR IMPLANTATION IN THE BODY AND A CATHETER FOR IMPLANTING SUCH VALVE PROTHESIS

[76] Inventors: Henning R. Andersen, Dalvangen 37A, DK-8270 Hoejbjerg; John M. Hasenkam, Aprilvej 8, DK-8210 Aarhus V; Lars L. Knudsen, Rudolf Wulffsgade 6,4.mf., DK-8000 Aarhus C, all of Denmark

[21] Appl. No.: 261,235

[22] Filed: Jun. 14, 1994

Related U.S. Application Data

[63] Continuation of Ser. No. 961,891, Jan. 11, 1993, abandoned.

Foreign Application Priority Data

May 18, 1990 [DK] Denmark 1246/90

[51] Int. Cl.⁶ A61F 2/24

[52] U.S. Cl. 623/2; 623/900; 137/343; 137/844; 251/358

[58] Field of Search 623/2, 900; 137/343, 137/844, 316; 251/358; 606/108

References Cited

U.S. PATENT DOCUMENTS

3,671,979	6/1972	Mouloupoulos .	
4,038,703	8/1977	Bokros	623/2
4,056,854	11/1977	Boretos et al.	623/2
4,106,129	8/1978	Carpentier et al.	623/2
4,297,749	11/1981	Davis et al.	623/2
4,343,048	8/1982	Ross .	
4,733,665	3/1988	Palmaz	606/108
4,856,516	8/1989	Hillstead	604/194
5,037,434	8/1991	Lane	623/2
5,163,953	11/1992	Vince	623/2

FOREIGN PATENT DOCUMENTS

0357003	3/1990	European Pat. Off.	623/900
1271508	11/1986	U.S.S.R.	623/2
1371701	2/1988	U.S.S.R.	623/2

OTHER PUBLICATIONS

Derwent Abstract No. 87-190867/27 (1987), SU 1271508 (Gorkii Kirov Medical Ins.).

Primary Examiner—David H. Willse
Attorney, Agent, or Firm—Watson, Cole, Grindle & Watson


[57] ABSTRACT

A valve prosthesis (9) for implantation in the body by use of catheter (11) comprises a stent made from an expandable cylinder-shaped thread structure (2,3) comprising several spaced apices (4). The elastically collapsible valve (6) is mounted on the stent as the commissural points (5) of the valve (6) are secured to the projecting apices (4).

The valve prosthesis (9) can be compressed around the balloon means (13) of the balloon catheter (11) and be inserted in a channel, for instance in the aorta (10). When the valve prosthesis is placed correctly the balloon means (13) is inflated thereby expanding the stent and wedging it against the wall of aorta. The balloon means is provided with beads (14) to ensure a steady fastening of the valve prosthesis on the balloon means during insertion and expansion.

The valve prosthesis (9) and the balloon catheter (11) make it possible to insert a cardiac valve prosthesis without a surgical operation comprising opening the thoracic cavity.

8 Claims, 4 Drawing Sheets



U.S. Patent

May 2, 1995

Sheet 1 of 4

5,411,552




FIG. 1






FIG. 2

U.S. Patent

May 2, 1995

Sheet 2 of 4

5,411,552



U.S. Patent

May 2, 1995

Sheet 3 of 4

5,411,552




FIG. 7




FIG. 6




FIG. 5




FIG. 10




FIG. 9






FIG. 8

U.S. Patent

May 2, 1995

Sheet 4 of 4

5,411,552



5,411,552

1

VALVE PROTHESIS FOR IMPLANTATION IN THE BODY AND A CATHETER FOR IMPLANTING SUCH VALVE PROTHESIS

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of application Ser. No. 961,891, filed Jan. 11, 1993, now abandoned.

BACKGROUND OF THE INVENTION

The present invention relates to a valve prosthesis, preferably a cardiac valve prosthesis, for implantation in the body and comprising a collapsible elastical valve which is mounted on an elastical stent wherein the commissural points of the elastical collapsible valve are mounted on the cylinder surface of the elastical stent.

Valve prostheses of this type are usually implanted in one of the channels of the body to replace a natural valve. In the present description the invention will be explained in connection with an cardiac valve prosthesis for implantation in aorta. However, it will be possible to use a valve prosthesis according to the invention in connection with implantation in other channels in the body by using the same technique as the one used for implantation of cardiac valve prosthesis. Such an implantation may, e.g., comprise the implantation of:

1. a valve (for instance a cardiac valve) in the veins,
2. a valve in the oesophagus and at the stomach,
3. a valve in the ureter and/or the vesica,
4. a valve in the biliary passages,
5. a valve in the lymphatic system, and
6. a valve in the intestines.

An existing natural valve in the body is traditionally replaced with a valve prosthesis by a surgical implantation. However, a surgical implantation is often an exacting operation. Thus, today the implantation of cardiac valves are solely made by surgical technique where the thoracic cavity is opened. The operation calls for the use of a heart and lung machine for external circulation of the blood as the heart is stopped and opened during the surgical intervention and the artificial cardiac valves are subsequently sewed in.

Due to its exacting character, it is impossible to offer such operation to certain people. For instance, this is due to the fact that the person is physically weak because of age or illness. Moreover, the number of heart and lung machines available at a hospital will be a substantially limiting factor.

Cardiac valve prostheses that need no surgical intervention are known as there are used for implantation by means of a technique of catheterization. Examples of such valve prostheses are described in U.S. Pat. Nos. 3,671,979 and 4,056,854. However, both of these valve prostheses are connected to means which lead to the surface of the patient either for a subsequent activation of the valve or for a subsequent reposition or removal of the valve prosthesis. With these valve prostheses it is impossible to make an implantation which makes it possible for the patient to resume a substantially normal life in the same way as it is possible in connection with a surgical implantation of a cardiac valve.

From U.S. Pat. No. 3,755,823 an elastic stent for a cardiac valve prosthesis is known. However, this valve prosthesis is not designed for implantation in the body by catheterization. Even though this patent contains no detailed explanation, the description indicates that this

2

valve prosthesis is designed for implantation and sewer-
ing on by a surgical intervention.

Moreover, from U.S. Pat. Nos. 4,856,516 and 4,733,665 different shapes of expandable stents are known. These stents are made to be expanded by im-
pression of a radially outward force coming from a
balloon catheter or the like. These stents are made to
reinforce the wall when there is a risk that the channel
is closed and/or compressed.

The nearest prior art may be that described in GB-A-
2,056,023. This document discloses an elastic stent as
described by way of introduction. Thus, the stent de-
scribed comprises an elastic collapsible valve mounted
on the cylinder surface of a cylindrical stent. However,
the valve prosthesis including the stent is designated for
mounting through a surgical intervention. Even though
the stent is slightly collapsible, it will not be suited for
implantation by a catheterization procedure.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a
valve prosthesis of the type mentioned in the introduc-
tory part, which permits implantation without surgical
intervention in the body and by using a catheter tech-
nique known per se and which makes it possible for the
patient to resume a substantially normal life.

This is achieved according to the invention with a
valve prosthesis of the type mentioned in the introduc-
tory part, which is characterized in that the stent is
made from a radially collapsible and re-expandable
cylindrical support means for folding and expanding
together with the collapsible valve for implantation in
the body by means of a technique of catheterization.

The collapsible elastic valve is mounted on the stent
for instance by gluing, welding or by means of a number
of suitable sutures.

If the support means are made from a thread struc-
ture, this can for instance be grate shaped, loop shaped
or helical. This makes it possible to compress the stent
and the collapsible valve mounted thereon for placing
on the insertion catheter. The use of a non-self-expand-
able stent may, e.g., be effected by a compression of the
stent around the expansion arrangement of the catheter
which preferably consists of a balloon. When using a
self-expandable stent, a catheter with an expansion ar-
rangement is not used. In this case the stent is com-
pressed and is inserted into an insertion or protection
cap from which the stent is eliminated after implanta-
tion in order to obtain an expansion due to the stresses
in the compressed support means, which for instance
may be made from plastics or metal. After the compres-
sion the entire outer dimension is relatively small,
which makes it possible to introduce the valve prosthe-
sis through a channel in the body.

When the valve prosthesis is introduced and placed
correctly, the stent is expanded by self-expansion or by
means of the expansion arrangement until the stent is
given an outer dimension which is slightly larger than
the channel in which it is placed. As the stent is elastic,
a contraction of the stent is prevented once it is ex-
panded. The stiffness in the material of the support
means contributes to maintain the expanded shape of
the stent. After the expansion is made, the expansion
arrangement of the catheter is contracted and the cath-
eter can be removed from the channel. The inlet opening
can subsequently be closed and the patient will then be
able to resume a normal life.

5,411,552

3

The valve prosthesis according to the invention does not require an actual operation but merely a small intervention to optionally expose the body channel, e.g., a vein, through which the insertion takes place. Thus, patients for whom an operation would be associated with high risk can be offered implantation of, for instance, cardiac valves. After the implantation has taken place, the after-treatment will advantageously be shorter than normally, which means fewer hospital days for the patient. Moreover, it is assumed that it will be possible to implantate the valve prosthesis under local anaesthetic.

The valve prosthesis can be used to replace a natural valve or to establish a new valve function in one of the channels in the body which do not naturally contain a valve. For instance this goes for veins (arteries and veins) on a place without natural valves. The function of the valve prosthesis is then to ensure that the blood flows in one direction only. The valve is meant to be used in veins in the legs of persons suffering from varicose veins (varices).

In persons having varicose veins the blood flows in a wrong direction, viz. from the central veins in the centre of the leg towards the superficial veins. Among other things, this is due to the changed pressure in the legs, upright working position and other conditions. A valve prosthesis according to the invention may easily be placed in the veins and prevent the flow of the blood in a wrong direction.

Also, the valve prosthesis can be used in connection with diseases, for instance cancerous tumors, where too much humour is produced. If the humour is able to flow from the cancerous tumor through several channels, it is possible to drain the humour in one desired direction through the channels of the body by an appropriate placing of the valve prosthesis.

When the valve prosthesis is used as a cardiac valve prosthesis in the aorta, it is possible to mount it in three positions, viz., in the descending part of the aorta, in a position between the coronary arteries and the left ventricle of the heart, or in the aorta in a position immediately after the mouth of the coronary arteries.

The cardiac valve prosthesis can also be used in other places than in the aorta. Thus, the valve prosthesis can be used in the pulmonary artery and/or the right ventricle of the heart for replacing the pulmonary valves. Likewise, the cardiac valve prosthesis can be used in the passage between the right auricle of the heart and the right ventricle of the heart (tricuspidalostium) and the passage between the left auricle of the heart and the left ventricle of the heart (mistralostium) for replacing the tricuspidal valve and the mitral valve, respectively.

Even though the cardiac valve preferably is meant to be used for patients suffering from aorta insufficiency and who cannot be offered an open heart surgery, the valve prosthesis can also be used for patients in connection with treatment of aorta stenosis. Several of the patients with aorta stenosis are elderly people who cannot be offered a surgical cardiac operation. The patients are offered balloon dilatation of the aorta stenosis which may result in an aorta insufficiency as a side effect of the treatment.

As to these patients it is possible to insert a valve prosthesis in the descending or ascending part of the aorta thoracalis a few days or weeks before the balloon dilatation. As a result thereof, the left ventricle is protected against weight if the subsequent balloon dilatation of the stenosis results in aorta insufficiency. In

4

certain cases the weight (reflux) on the left ventricle is reduced by up to approximately 75%.

Furthermore, the stent may be made with a relatively great height and with a cylinder surface which is closed by a suitable material. Thus, a vascular prosthesis known per se is formed wherein the valve is mounted. This may facilitate the implantation of the valve prosthesis, for instance in the arcus aorta. Moreover, the great surface which abuts the inner wall of the channel contributes to ensure the securing of the valve prosthesis in the channel. This embodiment is also suitable as valve prosthesis which is inserted in veins. As veins have relatively thin and weaker walls than arteries, it is desirable that the valve prosthesis has a greater surface to distribute the outward pressure which is necessary to secure the valve prosthesis.

Moreover, the invention relates to a balloon catheter for implantating a valve prosthesis according to the invention and comprising a channel for injection of a fluid for the inflation of the balloon means of the catheter and an insertion cap wherein the balloon means of the catheter and a collapsible valve prosthesis mounted thereon are located during the injection, characterized in that the balloon means are provided with a profiled surface which is made to ensure a steady fastening of the valve prosthesis during the withdrawal of the balloon means from the protection cap and the subsequent inflation for the expansion of the stent.

Different balloon catheters for implantating cores in the body are known. For instance, such balloon catheters are known from U.S. Pat. Nos. 4,856,516, 4,733,665 and 4,796,629 and from DE publication No. 2,246,526. However, the known balloon catheters have a smooth or a slightly wavy surface. The use of such balloon catheter is disadvantageous for mounting a valve prosthesis in a channel having a large flow as for instance the aorta. A large humour flow is able to displace the stent on the smooth surface of the balloon and makes an accurate positioning difficult. This drawback has been remedied with the balloon catheter according to the present invention as the profiled surface prevents a displacement of the valve prosthesis in relation to the balloon means during introduction and the subsequent inflation of the balloon means.

In connection with the implantation, any prior art technique may be used to supervise an accurate introduction and positioning of the valve prosthesis. Thus, guide wires for the catheter, X-ray supervision, injection of X-ray traceable liquids, ultrasonic measuring, etc., may be used.

DESCRIPTION OF THE DRAWINGS

The invention will now be explained in detail with reference to the accompanying schematical drawing, wherein

FIG. 1 shows a perspective view of a stent without a valve,

FIG. 2 is a perspective view of a valve prosthesis according to the invention made from the stent shown in FIG. 1 having a biological valve mounted thereon,

FIG. 3 is a partial view through the aorta illustrating a partially inflated balloon catheter,

FIG. 4 is a cross section through the embodiment shown in FIG. 9,

FIG. 5-7 are views illustrating the introduction and implantation of a valve prosthesis of the invention in the aorta,

5,411,552

5

FIG. 8-10 are views illustrating three possible positions of a cardiac valve prosthesis, and

FIG. 11-12 are perspective views illustrating two further embodiments of a valve prosthesis having a closed cylindrical wall.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 shows a stent 1 made by support means in the form of two 0.55 mm surgical stainless steel wires 2,3. The wires are folded in 15 loops. Three loops 4 are 14 mm in height and are intended to secure the commissural points 5 (see FIG. 2) from a biological cardiac valve 6 which is mounted in the stent 1. The remaining loops have a height of 8 mm. These loops form circumferentially expandable sections 25 between the commissural points 5 forming commissural supports. Each of the two folded wires 2,3 is bent to form rings 7,8 which are closed by welding the ends. The two rings are placed on top of each other as will appear from FIG. 1 and they are mutually secured by means of a number of sutures (not shown). The lower ring is circumferentially expandable at least along sections thereof which correspond to the circumferentially expandable sections 25. By using a substantially cylindrical thread structure with projecting apices, a reduction in weight is obtained as compared to a stent which is exclusively cylindrical with the same loop heights for all the loops.

The biological valve 6 was removed from a slaughtered pig of 100 kg. The valve was cleaned before mounting in the stent 1. The cleaned valve has an outer diameter of 25-27 mm and the height of the three commissural points 5 is 8 mm. The valve 6 is mounted in the stent by means of a suitable number of sutures to form the cardiac valve prosthesis 9 shown in FIG. 2. The valve prosthesis produced is used for performing tests in pigs by implantation of cardiac valve prosthesis. However, the cardiac valve prosthesis for use in human beings has a corresponding form.

FIG. 3 shows a partial view through the aorta 10. A balloon catheter 11 is introduced in the aorta according to the direction of an arrow 12. In the Figure shown the balloon means 13 of the balloon catheter is led out of the protection cap 11A and is partly inflated through a fluid channel 15, which is led to the surface of the patient. The balloon means 13 constitutes a tri-sectional balloon upon which the cardiac valve prosthesis is placed. In the form shown, the cardiac valve prosthesis is expanded exactly to be in contact with the aorta 10. The balloon means 13 is provided with three projecting beads 14 which are engaged with the one side of the cardiac valve prosthesis 9. The blood flowing through the aorta according to the direction of an arrow 16 will thus cause the cardiac valve prosthesis 9 to abut on the beads 14 and the valve cannot be displaced in relation to the balloon means 13. Moreover, the balloon catheter used comprises a central channel 17 to receive a guide wire 18 which is used in a way known per se for supervising the introduction of the catheter through fluoroscopy. In the shown embodiment beads 14 are only used at one side of the valve prosthesis, but, however, it will often be desirable to use the beads in pairs placed along lines parallel to the longitudinal axes 19 through the balloon means 13. In this case the spacing of the pair of beads 14 will correspond to the height of the loops of the stent. This makes it possible to make an effective fastening of a valve prosthesis on balloon means. Moreover, the fastening on the balloon means may be pro-

6

vided by using balloon means with an indentation in the surface (not shown).

FIG. 4 shows a cross section through the embodiment shown in FIG. 3 illustrating the placing of the beads 14 on the tri-sectional balloon means 13.

A balloon catheter of the above-described type which was used in tests of implanting the cardiac valve prosthesis 9 in pigs had the following dimensions. Each of the three balloons was 60 mm in length and 15 mm in diameter. The total diameter for the three inflated balloons was 31 mm and in the balloon catheter used two beads 14 having a height of 3 mm were mounted on each side of the three balloons. The beads had a spacing of 15 mm. The protection cap 11A of the balloon catheter had an outer diameter of 13.6 mm and an inner diameter of 12.5 mm and a length of 75 cm. The balloon catheter was provided with a standard guide wire having a diameter of 0.9 mm and a length of 300 cm.

FIGS. 5-7 show the valve prosthesis 9 at different steps in introducing and implanting in the aorta 10 by means of the catheter 11 having the inflatable balloon means 13. The cardiac valve prosthesis 9 is initially placed above the deflated balloon means 13 and compressed manually around the balloon means (FIG. 5), whereafter the outer diameter for the valve prosthesis is approximately 10 mm. After the introduction and positioning, the balloon means 13 is inflated (FIG. 6), thereby contributing an outer dimension of approximately 30 mm to the cardiac valve prosthesis. To obtain an effective fastening in the aorta, the outer dimension of the cardiac valve prosthesis is greater than the diameter of the aorta. This means that the prosthesis is tight against the inner wall of the aorta with a pressure which is sufficiently large to counteract a detachment due to the flow of the blood. The balloon catheter 11 may subsequently be removed from the aorta 10 (FIG. 7). Due to the stiffness of the metal the valve prosthesis will prevent a contraction. However, smaller contractions may occur (<10% diameter reduction) after the deflation and removal of the balloon catheter 13. When the valve prosthesis is mounted as shown in FIG. 7, the patient will be able to resume a substantially normal life after a few days.

FIGS. 8-10 show the positioning of the valve prosthesis 9 as cardiac valve prosthesis in the aorta 10 in three different positions, i.e., in a position between the coronary arteries 20 and the left ventricle of the heart 21 (FIG. 8), in a position immediately after the mouth of the coronary arteries in the ascending part of the aorta (FIG. 9), and in a position in the descending part of the aorta 10. The positioning of the valve prosthesis is chosen in accordance with the diagnosis of the illness of the patient. By placing the cardiac valve prosthesis as shown in FIG. 8, there is a risk of detachment and/or covering the mouth of the coronary arteries, and therefore it is preferred to use a higher stent which, for instance, comprises several rings 7,8 placed on top of each other. This allows a fixation of the prosthesis at a place after the mouth of coronary arteries even though the valve itself is in the position between the coronary arteries and the left ventricle. FIGS. 8 and 9 show how a contrast medium 23 is injected by means of a so-called pigtail catheter for registration of the tightness of the implanted valve prosthesis 9.

A specific embodiment for a valve prosthesis and a balloon catheter for implanting the valve prosthesis has been explained above. However, it is obvious that it

5,411,552

7

is possible to modify the valve prosthesis depending on the desired use, and moreover, it is possible to modify the catheter used in the implantation. Thus, the stent of the valve prosthesis may be made solely of one closed ring folded in a number of loops or with three or more mutually secured loop-shaped rings placed on top of each other. Moreover, it is possible to make the stent having a thread structure which instead of loops is grate shaped, helical or is formed otherwise if only it is ensured that the form of the stent permits the compression and expansion of the stent and fastening of the collapsible valve. Instead of a biological valve it might be possible to use other collapsible valves, such as valves made from synthetic materials, e.g., polyurethane. It is also possible to use valves with more or fewer flaps than three.

It is possible to make the valve prosthesis with a closed cylinder surface as illustrated in FIGS. 11 and 12. In both Figures the support means of the valve prosthesis is made of an elongated tubular means having a closed cylinder surface. This valve prosthesis is intended to expand by self-expansion or by means of a catheter according to the invention. This prosthesis is especially suitable for placing in veins and other channels where only a small pressure is exerted against the wall of the channel. In FIG. 11 the valve 6 is mounted at the end of the tubular means 24. In FIG. 12 an embodiment is shown where the valve 6 is mounted in a central position in the tubular means 24.

An explanation of a method of implanting a valve prosthesis according to the invention is given below:

a valve prosthesis 9 made of a stent 1 and a collapsible valve 6, as described above, is placed on a deflated balloon means and is manually compressed thereon,

the balloon means 13 and the valve prosthesis are drawn into an insertion cover 11A,

a guide wire 18 is inserted into the left ventricle of the heart through the central opening 17 of the balloon catheter under continuous fluoroscopy,

the insertion cover 11A conveys the guide wire 18 to a point in the channel in the immediate vicinity of the desired position of the valve prosthesis,

the balloon means 13 is pushed out of the protection cap 11A and the valve prosthesis is positioned in the desired position if necessary by use of further registration means to ensure an accurate positioning,

the balloon means 13 is inflated with a certain overstretching of the channel,

the balloon means 13 is deflated, and

the balloon means 13, the guide wire 18 and the protection cap 11A are drawn out and the opening in the channel, if any, wherein the valve prosthesis is inserted can be closed.

We claim:

1. A valve prosthesis for implantation in a body channel, the valve prosthesis comprising a collapsible elastical valve which is mounted on an elastical stent, the

8

elastical valve having a plurality of commissural points, wherein the stent comprises:

a cylindrical support means which is radially collapsible for introduction within the body channel and which has a plurality of circumferentially-expandable sections such that the cylindrical support means is radially expandable for being secured within the body channel; and

a plurality of commissural supports projecting from one side of the cylindrical support means in a direction generally parallel to the longitudinal axis thereof for supporting the commissural points of the collapsible valve, at least one circumferentially-expandable section of the cylindrical support means lying between each of the commissural supports, such that the collapsible valve may be collapsed and expanded together with the cylindrical support means for implantation in the body channel by means of a technique of catheterization.

2. A valve prosthesis according to claim 1, wherein the cylindrical support means is made of a thread structure.

3. A valve prosthesis according to claim 2, wherein the thread structure comprises several spaced apices projecting from the one side of the cylindrical structure and in a direction along the longitudinal axis of the cylinder and that the commissural points of the valve are attached to the projecting apices.

4. A valve prosthesis according to claim 3, wherein the elastically collapsible valve is a biological trilobate valve.

5. A valve prosthesis to claim 4, wherein the stent is made from a stainless steel wire folded in a number of loops and bent into a circle and welded to form a closed ring, wherein the stent comprises two or more such closed rings which are mutually connected end to end to form the cylindrical thread structure, and wherein three of the loops in a ring at an end of said stent are folded with a greater height than the remaining loops to form the apices to which the commissural points of the biological valve are attached.

6. A valve prosthesis according to claim 5, wherein each of the rings of the stent is made from a wire having a diameter of 0.55 mm and a loop height of approximately 8 mm and approximately 14 mm for the three greater loops, and wherein the cylindrical thread structure produced and the collapsible valve mounted thereon in a folded state have an outer diameter of approximately 10 mm and in expanded state an outer diameter of approximately 30 mm.

7. A valve prosthesis according to claim 5, wherein the stent is made to be fixed through the expansion at one point in the channel wherein the valve prosthesis is inserted, which point is different from the point where the valve is mounted in the stent.

8. A valve prosthesis according to claim 1, wherein the cylinder surface of the support means is closed to form a tubular element.

* * * * *

60

65

EXHIBIT 3



US006582462B1

(12) **United States Patent**
Andersen et al.

(10) **Patent No.:** **US 6,582,462 B1**
(45) **Date of Patent:** ***Jun. 24, 2003**

(54) **VALVE PROSTHESIS FOR IMPLANTATION
IN THE BODY AND A CATHETER FOR
IMPLANTING SUCH VALVE PROSTHESIS**

3,409,013 A 11/1968 Berry
3,587,115 A 6/1971 Shiley

(List continued on next page.)

(75) Inventors: **Henning Rud Andersen**, Hoejbjerg
(DK); **John Michael Hasenkam**,
Aarhus V (DK); **Lars Lyhne Knudsen**,
Aarhus C (DK)

(73) Assignee: **Heartport, Inc.**, Redwood City, CA
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

FOREIGN PATENT DOCUMENTS

DE	2246526	3/1973	
EP	0103546 A1	3/1984	
EP	0350302	1/1990	
EP	0357003	3/1990	
EP	0592410 B1	10/1995	
GB	2056023	3/1981	
RU	1258406	9/1986	
RU	1271508	11/1986	
RU	1371701	2/1988	
SU	1271508 A *	11/1986	 623/FOR 101
WO	WO9117720	11/1991	
WO	WO9217118	10/1992	

OTHER PUBLICATIONS

Fishman et al., "Prevention of Prothetic Cardiac Valve
Detachment", Surgery, vol. 67, No. 5, pp. 867-873, May
1970.*

16th Edition of The Merck Manual of Diagnosis and
Therapy (1992) "Valvular Heart Disease," pp. 546-553.

Yamaguchi, Case Description "A Case of a Reoperation
Using a Balloon Catheter with Blocked Pars Ascendes
Aortae" Kyobu Geka, Oct. 1989, 42:11, pp. 961-964.

World Medical Manufacturing Corp., Talent Endovascular
Bifurcated Spring Graft System Composite Design bro-
chure, no date.

Derwent Abstract No. 87-1980867/27 (1987), SU 1271508
(Gorkii Kirov Medical Ins.).

Primary Examiner—David H. Willse

(21) Appl. No.: **09/514,426**

(22) Filed: **Feb. 28, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/026,574, filed on Feb.
20, 1998, now Pat. No. 6,168,614, which is a continuation
of application No. 08/955,228, filed on Oct. 21, 1997, now
abandoned, which is a division of application No. 08/801,
036, filed on Feb. 19, 1997, now Pat. No. 5,840,081, which
is a continuation of application No. 08/569,314, filed on
Dec. 8, 1995, now abandoned, which is a continuation of
application No. 08/352,127, filed on Dec. 1, 1994, now
abandoned, which is a division of application No. 08/261,
235, filed on Jun. 14, 1994, now Pat. No. 5,411,552, which
is a continuation of application No. 07/961,891, filed as
application No. PCT/DK91/00134 on Mar. 16, 1991, now
abandoned.

(30) Foreign Application Priority Data

May 18, 1990 (DK) 1246/90

(51) **Int. Cl.**⁷ **A61F 2/24**

(52) **U.S. Cl.** **623/1.26; 623/2.14**

(58) **Field of Search** 623/FOR 101,
623/2.1-2.19, 2.38-2.41, 900, 904, 1.24-1.26

(56) References Cited


U.S. PATENT DOCUMENTS

2,055,188 A 4/1934 Wapler et al.

(57) ABSTRACT

A valve prosthesis for implantation in the body by use of a
catheter includes a stent made from an expandable cylinder-
shaped thread structure having several spaced apices. The
elastically collapsible valve is mounted on the stent as the
commissural points of the valve are secured to the projecting
apices.

8 Claims, 4 Drawing Sheets



US 6,582,462 B1

Page 2

U.S. PATENT DOCUMENTS			
3,657,744 A	*	4/1972 Ersek	623/902 X
3,671,979 A		6/1972 Mouloupoulos	
3,714,671 A		2/1973 Edwards et al.	
3,755,823 A		9/1973 Handcodk	
3,799,150 A		3/1974 Bonnet	
4,035,849 A		7/1977 Angell et al.	
4,038,703 A		8/1977 Bokros	
4,056,854 A	*	11/1977 Boretos et al.	623/2.18
4,106,129 A		8/1978 Carpentier et al.	
4,222,126 A		9/1980 Boretos et al.	
4,297,749 A		11/1981 Davis et al.	
4,339,831 A		7/1982 Johnson	
4,343,048 A		8/1982 Ross	
4,391,282 A		7/1983 Ando et al.	
4,470,157 A		9/1984 Love	
4,574,803 A		3/1986 Storz	
4,580,568 A		4/1986 Gianturco	
4,592,340 A		6/1986 Boyles	
4,612,011 A		9/1986 Kautzky	
4,655,771 A		4/1987 Wallsten	
4,692,164 A		9/1987 Dzemeshevich et al.	
4,725,274 A		2/1988 Lane et al.	
4,731,074 A		3/1988 Rousseau et al.	
4,733,665 A		3/1988 Palmaz	
4,777,951 A		10/1988 Cribier et al.	
4,778,461 A		10/1988 Pietsch et al.	
4,787,899 A		11/1988 Lazarus	
4,787,901 A		11/1988 Baykut	
4,790,843 A		12/1988 Carpentier et al.	
4,796,629 A		1/1989 Grayzel	
4,830,003 A		5/1989 Wolff et al.	
4,851,000 A		7/1989 Gupta	
4,856,516 A		8/1989 Hillstead	
4,878,495 A		11/1989 Grayzel	
4,878,906 A		11/1989 Lindemann et al.	
4,883,458 A		11/1989 Shiber	
4,892,541 A		1/1990 Alonso	
4,917,698 A		4/1990 Carpentier et al.	
4,932,965 A		6/1990 Phillips	
RE33,258 E		7/1990 Onik	
4,966,604 A		10/1990 Reiss	
4,979,939 A		12/1990 Shiber	
4,986,830 A		1/1991 Owens et al.	
4,994,077 A	*	2/1991 Dobben	623/2.2
5,007,896 A		4/1991 Shiber	
5,019,102 A		5/1991 Hoene	
5,026,366 A		6/1991 Leckrone	
5,032,128 A		7/1991 Alonso	
5,037,434 A		8/1991 Lane	
5,041,130 A		8/1991 Cosgrove et al.	
5,047,041 A		9/1991 Samuels	
5,059,177 A		10/1991 Towne et al.	
5,061,277 A		10/1991 Carpentier et al.	
5,085,635 A		2/1992 Cragg	
5,089,015 A		2/1992 Ross	
5,104,407 A		4/1992 Lam et al.	
5,123,919 A		6/1992 Sauter et al.	
5,147,391 A		9/1992 Lane	
5,152,771 A		10/1992 Sabbaghian et al.	
5,163,953 A		11/1992 Vince	
5,163,955 A		11/1992 Love et al.	
5,167,628 A		12/1992 Boyles	
5,201,880 A		4/1993 Wright et al.	
5,258,021 A		11/1993 Duran	
5,258,023 A		11/1993 Reger	
5,295,958 A		3/1994 Shturman	
5,306,296 A		4/1994 Wright et al.	
5,332,402 A		7/1994 Teitelbaum	
5,332,403 A		7/1994 Kolff	
5,344,442 A		9/1994 Deac	
5,350,420 A		9/1994 Cosgrove et al.	
5,376,112 A		12/1994 Duran	
5,376,113 A		12/1994 Jansen et al.	
5,397,351 A		3/1995 Pavcnik et al.	
5,411,552 A		5/1995 Andersen et al.	
5,443,446 A		8/1995 Shturman	
5,449,384 A		9/1995 Johnson	
5,469,868 A		11/1995 Reger	
5,480,424 A		1/1996 Cox	
5,489,298 A		2/1996 Love et al.	
5,545,209 A		8/1996 Roberts et al.	
5,609,626 A		3/1997 Quijano et al.	
5,755,782 A		5/1998 Love et al.	
5,824,061 A		10/1998 Quijano et al.	
5,840,081 A		11/1998 Andersen et al.	
6,283,993 B1		9/2001 Cosgrove et al.	

* cited by examiner

U.S. Patent

Jun. 24, 2003

Sheet 1 of 4

US 6,582,462 B1




FIG. 1






FIG. 2

U.S. Patent

Jun. 24, 2003

Sheet 2 of 4

US 6,582,462 B1



U.S. Patent

Jun. 24, 2003

Sheet 3 of 4

US 6,582,462 B1




FIG. 5




FIG. 6

FIG. 7




FIG. 8




FIG. 9






FIG. 10

U.S. Patent

Jun. 24, 2003

Sheet 4 of 4

US 6,582,462 B1



US 6,582,462 B1

1

**VALVE PROSTHESIS FOR IMPLANTATION
IN THE BODY AND A CATHETER FOR
IMPLANTING SUCH VALVE PROSTHESIS**

**CROSS REFERENCE TO RELATED
APPLICATION**

This application is a continuation of application Ser. No. 09/026,574, filed Feb. 20, 1998, now U.S. Pat. No. 6,168,614, which is a continuation of application Ser. No. 08/955,228, filed Oct. 21, 1997, now abandoned, which is a division of application Ser. No. 08/801,036, filed Feb. 19, 1997, now U.S. Pat. No. 5,840,081, which is a continuation of application Ser. No. 08/569,314, filed Dec. 8, 1995, now abandoned, which is a continuation of application Ser. No. 08/352,127, filed Dec. 1, 1994, now abandoned, which is a division of application Ser. No. 08/261,235, filed Jun. 14, 1994, now U.S. Pat. No. 5,411,552, which is a continuation of application Ser. No. 07/961,891, filed Jan. 11, 1993, now abandoned which is based on PCT/DK91/00134, filed Mar. 16, 1991.

BACKGROUND OF THE INVENTION

The present invention relates to a valve prosthesis, preferably a cardiac valve prosthesis, for implantation in the body and comprising a collapsible elastic valve which is mounted on an elastic stent wherein the commissural points of the elastic collapsible valve are mounted on the cylinder surface of the elastic stent.

Valve prostheses of this type are usually implanted in one of the channels of the body to replace a natural valve. In the present description the invention will be explained in connection with a cardiac valve prosthesis for implantation in aorta. However, it will be possible to use a valve prosthesis according to the invention in connection with implantation in other channels in the body by using the same technique as the one used for implantation of cardiac valve prosthesis. Such an implantation may, e.g., comprise the implantation of:

1. a valve (for instance a cardiac valve) in the veins,
2. a valve in the esophagus and at the stomach,
3. a valve in the ureter and/or the vesica,
4. a valve in the biliary passages,
5. a valve in the lymphatic system, and
6. a valve in the intestines.

An existing natural valve in the body is traditionally replaced with a valve prosthesis by a surgical implantation. However, a surgical implantation is often an exacting operation. Thus, today the implantation of cardiac valves are solely made by surgical technique where the thoracic cavity is opened. The operation calls for the use of a heart and lung machine for external circulation of the blood as the heart is stopped and opened during the surgical intervention and the artificial cardiac valves are subsequently sewed in.

Due to its exacting character, it is impossible to offer such operation to certain people. For instance, this is due to the fact that the person is physically weak because of age or illness. Moreover, the number of heart and lung machines available at a hospital will be a substantially limiting factor.

Cardiac valve prostheses that need no surgical intervention are known as there are used for implantation by means of a technique of catheterization. Examples of such valve prostheses are described in U.S. Pat. Nos. 3,671,979 and 4,056,854. However, both of these valve prostheses are connected to means which lead to the surface of the patient either for a subsequent activation of the valve or for a

2

subsequent reposition or removal of the valve prosthesis. With these valve prostheses it is impossible to make an implantation which makes it possible for the patient to resume a substantially normal life in the same way as it is possible in connection with a surgical implantation of a cardiac valve.

From U.S. Pat. No. 3,755,823 an elastic stent for a cardiac valve prosthesis is known. However, this valve prostheses is not designed for implantation in the body by catheterization. Even though this patent contains no detailed explanation, the description indicates that this valve prosthesis is designed for implantation and sewing on by a surgical intervention.

Moreover, from U.S. Pat. Nos. 4,856,516 and 4,733,665 different shapes of expandable stents are known. These stents are made to be expanded by impression of a radially outward force coming from a balloon catheter or the like. These stents are made to reinforce the wall when there is a risk that the channel is closed and/or compressed.

The nearest prior art may be that the described in GB-A-2,056,023. This document discloses an elastic stent as described by way of introduction. Thus, the stent described comprises an elastic collapsible valve mounted on the cylinder surface of a cylindrical stent. However, the valve prosthesis including the stent is designated for mounting through a surgical intervention. Even though the stent is slightly collapsible, it will not be suited for implantation by a catheterization procedure.

SUMMARY OF THE INVENTION

It is the object of the present invention to provide a valve prosthesis of the type mentioned in the introductory part, which permits implantation without surgical intervention in the body and by using a catheter technique known per se and which makes it possible for the patient to resume a substantially normal life.

This is achieved according to the invention with a valve prosthesis of the type mentioned in the introductory part, which is characterized in that the stent is made from a radially collapsible and re-expandable cylindrical support means for folding and expanding together with the collapsible valve for implantation in the body by means of a technique of catheterization.

The collapsible elastic valve is mounted on the stent for instance by gluing, welding or by means of a number of suitable sutures.

If the support means are made from a thread structure, this can for instance be grate shaped, loop shaped or helical. This makes it possible to compress the stent and the collapsible valve mounted thereon for placing on the insertion catheter. The use of a non-self-expandable stent may, e.g., be effected by a compression of the stent around the expansion arrangement of the catheter which preferably consists of a balloon. When using a self-expandable stent, a catheter with an expansion arrangement is not used. In this case the stent is compressed and is inserted into an insertion or protection cap from which the stent is eliminated after implantation in order to obtain an expansion due to the stresses in the compressed support means, which for instance may be made from plastics or metal. After the compression the entire outer dimension is relatively small, which makes it possible to introduce the valve prostheses through a channel in the body.

When the valve prosthesis is introduced and placed correctly, the stent is expanded by self-expansion or by means of the expansion arrangement until the stent is given an outer dimension which is slightly larger than the channel in which it is placed. As the stent is elastic, a contraction of

US 6,582,462 B1

3

the stent is prevented once it is expanded. The stiffness in the material of the support means contributes to maintain the expanded shape of the stent. After the expansion is made, the expansion arrangement of the catheter is contracted and the catheter can be removed from the channel. The inlet opening can subsequently be closed and the patient will then be able to resume a normal life.

The valve prosthesis according to the invention does not require an actual operation but merely a small intervention to optionally expose the body channel, e.g., a vein, through which the insertion takes place. Thus, patients for whom an operation would be associated with high risk can be offered implantation of, for instance, cardiac valves. After the implantation has taken place, the after-treatment will advantageously be shorter than normal, which means fewer hospital days for the patient. Moreover, it is assumed that it will be possible to implant the valve prosthesis under local anaesthetic.

The valve prosthesis can be used to replace a natural valve or to establish a new valve function in one of the channels in the body which do not naturally contain a valve. For instance this goes for veins (arteries and veins) on a place without natural valves. The function of the valve prosthesis is then to ensure that the blood flows in one direction only. The valve is meant to be used in veins in the legs of persons suffering from varicose veins (varices).

In persons having varicose veins the blood flows in a wrong direction, viz. from the central veins in the center of the leg towards the superficial veins. Among other things, this is due to the changed pressure in the legs, upright working position and other conditions. A valve prosthesis according to the invention may easily be placed in the veins and prevent the flow of the blood in a wrong direction.

Also, the valve prosthesis can be used in connection with diseases, for instance cancerous tumors, where too much humour is produced. If the humour is able to flow from the cancerous tumor through several channels, it is possible to drain the humour in one desired direction through the channels of the body by an appropriate placing of the valve prosthesis.

When the valve prosthesis is used as a cardiac valve prosthesis in the aorta, it is possible to mount it in three positions, viz., in the descending part of the aorta in a position between the coronary arteries and the left ventricle of the heart, or in the aorta in a position immediately after the mouth of the coronary arteries.

The cardiac valve prosthesis can also be used in other places than in the aorta. Thus, the valve prosthesis can be used in the pulmonary artery and/or the right ventricle of the heart for replacing the pulmonary valves. Likewise, the cardiac valve prosthesis can be used in the passage between the right auricle of the heart and the right ventricle of the heart (tricuspidalostium) and the passage between the left auricle of the heart and the left ventricle of the heart (mistralostium) for replacing the tricuspidal valve and the mitral valve, respectively.

Even though the cardiac valve preferably is meant to be used for patients suffering from aorta insufficiency and who cannot be offered an open heart surgery, the valve prosthesis can also be used for patents in connection with treatment of aorta stenosis. Several of the patients with aorta stenosis are elderly people who cannot be offered a surgical cardiac operation. The patients are offered balloon dilatation of the aorta stenosis which may result in an aorta insufficiency as a side effect of the treatment.

As to these patients it is possible to insert a valve prosthesis in the descending or ascending part of the aorta

4

thoracalis a few days or weeks before the balloon dilatation. As a result thereof, the left ventricle is protected against weight if the subsequent balloon dilatation of the stenosis results in aorta insufficiency. In certain cases the weight (reflux) on the left ventricle is reduced by up to approximately 75%.

Furthermore, the stent may be made with a relatively great height and with a cylinder surface which is closed by a suitable material. Thus, a vascular prosthesis known per se is formed wherein the valve is mounted. This may facilitate the implantation of the valve prosthesis, for instance in the arcus aorta. Moreover, the great surface which abuts the inner wall of the channel contributes to ensure the securing of the valve prosthesis in the channel. This embodiment is also suitable as valve prosthesis which is inserted in veins. As veins have relatively thin and weaker walls than arteries, it is desirable that the valve prosthesis has a greater surface to distribute the outward pressure which is necessary to secure the valve prosthesis.

Moreover, the invention relates to a balloon catheter for implanting a valve prosthesis according to the invention and comprising a channel for injection of a fluid for the inflation of the balloon means of the catheter and an insertion cap wherein the balloon means of the catheter and a collapsible valve prosthesis mounted thereon are located during the injection, characterized in that the balloon means are provided with profiled surface which is made to ensure a steady fastening of the valve prosthesis during the withdrawal of the balloon means from the protection cap and the subsequent inflation for the expansion of the stent.

Different balloon catheters for implanting cores in the body are known. For instance, such balloon catheters are known from U.S. Pat. Nos. 4,856,516, 4,733,665 and 4,796,629 and from DE publication No. 2,246,526. However, the known balloon catheters have a smooth or a slightly wavy surface. The use of such balloon catheter is disadvantageous for mounting a valve prosthesis in a channel having a large flow as for instance the aorta. A large humour flow is able to displace the stent on the smooth surface of the balloon and makes an accurate positioning difficult. This drawback has been remedied with the balloon catheter according to the present invention as the profiled surface prevents a displacement of the valve prosthesis in relation to the balloon means during introduction and the subsequent inflation of the balloon means.

In connection with the implantation, any prior art technique may be used to supervise an accurate introduction and positioning of the valve prosthesis. Thus, guide wires for the catheter, X-ray supervision, injection of X-ray traceable liquids, ultrasonic measuring, etc. may be used.

DESCRIPTION OF THE DRAWINGS

The invention will now be explained in detail with reference to the accompanying schematical drawing, wherein

FIG. 1 shows a perspective view of a stent without a valve,

FIG. 2 is a perspective view of a valve prosthesis according to the invention made from the stent shown in FIG. 1 having a biological valve mounted thereon,

FIG. 3 is a partial view through the aorta illustrating a partially inflated balloon catheter,

FIG. 4 is a cross section through the embodiment shown in FIG. 9,

FIGS. 5-7 are views illustrating the introduction and implantation of a valve prosthesis of the invention in the aorta,

US 6,582,462 B1

5

FIGS. 8–10 are views illustrating three possible positions of a cardiac valve prosthesis, and

FIGS. 11–12 are perspective views illustrating two further embodiments of a valve prosthesis having a closed cylindrical wall.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 shows a stent 1 made by support means in the form of two 0.55 mm surgical stainless steel wires 2,3. The wires are folded in 15 loops. Three loops 4 are 14 mm in height and are intended to secure the commissural points 5 (see FIG. 2) from a biological cardiac valve 6 which is mounted in the stent 1. The remaining loops have a height of 8 mm. These loops form circumferentially expandable sections 25 between the commissural points 5 forming commissural supports. Each of the two folded wires 2,3 is bent to form rings 7,8 which are closed by welding the ends. The two rings are placed on top of each other as will appear from FIG. 1 and they are mutually secured by means of a number of sutures (not shown). The lower ring is circumferentially expandable at least along sections thereof which correspond to the circumferentially expandable sections 25. By using a substantially cylindrical thread structure with projecting apices, a reduction in weight is obtained as compared to a stent which is exclusively cylindrical with the same loop heights for all the loops.

The biological valve 6 was removed from a slaughtered pig of 100 kg. The valve was cleaned before mounting in the stent 1. The cleaned valve has an outer diameter of 25–27 mm and the height of the three commissural points 5 is 8 mm. The valve 6 is mounted in the stent by means of a suitable number of sutures to form the cardiac valve prosthesis 9 shown in FIG. 2. The valve prosthesis produced is used for performing tests in pigs by implantation of cardiac valve prosthesis. However, the cardiac valve prosthesis for use in human beings has a corresponding form.

FIG. 3 shows a partial view through the aorta 10. A balloon catheter 11 is introduced in the aorta according to the direction of an arrow 12. In the Figure shown the balloon means 13 of the balloon catheter is led out of the protection cap 11A and is partly inflated through a fluid channel 15, which is led to the surface of the patient. The balloon means 13 constitutes a tri-sectional balloon upon which the cardiac valve prosthesis is placed. In the form shown, the cardiac valve prosthesis is expanded exactly to be in contact with the aorta 10. The balloon means 13 is provided with three projecting beads 14 which are engaged with the one side of the cardiac valve prosthesis 9. The blood flowing through the aorta according to the direction of an arrow 16 will thus cause the cardiac valve prosthesis 9 to abut on the beads 14 and the valve cannot be displaced in relation to the balloon means 13. Moreover, the balloon catheter used comprises a central channel 17 to receive a guide wire 18 which is used in a way known per se for supervising the introduction of the catheter through fluoroscopy. In the shown embodiment beads 14 are only used at one side of the valve prosthesis, but, however, it will often be desirable to use the beads in pairs placed along lines parallel to the longitudinal axes 19 through the balloon means 13. In this case the spacing of the pair of beads 14 will correspond to the height of the loops of the stent. This makes it possible to make an effective fastening of a valve prosthesis on balloon means. Moreover, the fastening on the balloon means may be provided by using balloon means with an indentation in the surface (not shown).

6

FIG. 4 shows a cross section through the embodiment shown in FIG. 3 illustrating the placing of the beads 14 on the tri-sectional balloon means 13.

A balloon catheter of the above-described type which was used in tests of implanting of cardiac valve prosthesis 9 in pigs had the following dimensions. Each of the three balloons was 60 mm in length and 15 mm in diameter. The total diameter for the three inflated balloons was 31 mm and in the balloon catheter used two beads 14 having a height of 3 mm were mounted on each side of the three balloons. The beads had a spacing of 15 mm. The protection cap 11A of the balloon catheter had an outer diameter of 13.6 mm and an inner diameter of 12.5 mm and a length of 75 cm. The balloon catheter was provided with a standard guide wire having a diameter of 0.9 mm and a length 300 cm.

FIGS. 5–7 show the valve prosthesis 9 at different steps in introducing and implanting in the aorta 10 by means of the catheter 11 having the inflatable balloon means 13. The cardiac valve prosthesis 9 is initially placed above the deflated balloon means 13 and compressed manually around the balloon means (FIG. 5), whereafter the outer diameter for the valve prosthesis is approximately 10 mm. After the introduction and positioning, the balloon means 13 is inflated (FIG. 6), thereby contributing an outer dimension of approximately 30 mm to the cardiac valve prosthesis. To obtain an effective fastening in the aorta, the outer dimension of the cardiac valve prosthesis is greater than the diameter of the aorta. This means that the prosthesis is tight against the inner wall of the aorta with a pressure which is sufficiently large to counteract a detachment due to the flow of the blood. The balloon catheter 11 may subsequently be removed from the aorta 10 (FIG. 7). Due to the stiffness of the metal the valve prosthesis will prevent a contraction. However, smaller contractions may occur (<10% diameter reduction) after the deflation and removal of the balloon catheter 13. When the valve prosthesis is mounted as shown in FIG. 7, the patient will be able to resume a substantially normal life after a few days.

FIGS. 8–10 show the positioning of the valve prosthesis 9 as cardiac valve prosthesis in the aorta 10 in three different positions, i.e., in a position between the coronary arteries 20 and the left ventricle of the heart 21 (FIG. 8), in a position immediately after the mouth of the coronary arteries in the ascending part of the aorta (FIG. 9), and in a position in the descending part of the aorta 10. The positioning of the valve prosthesis is chosen in accordance with the diagnosis of the illness of the patient. By placing the cardiac valve prosthesis as shown in FIG. 8, there is a risk of detachment and/or covering the mouth of the coronary arteries, and therefore it is preferred to use a higher stent which, for instance, comprises several ranges placed on top of each other. This allows a fixation of the prosthesis at a place after the mouth of coronary arteries even though the valve itself is in the position between the coronary arteries and the left ventricle. FIGS. 8 and 9 show how a contrast medium 23 is injected by means of a so-called pigtail catheter for registration of tightness of the implanted valve prosthesis 9.

A specific embodiment for a valve prosthesis and a balloon catheter for implanting the valve prosthesis has been explained above. However, it is obvious that it is possible to modify the valve prosthesis depending on the desired use, and moreover, it is possible to modify the catheter used in the implantation. Thus, the stent of the valve prosthesis may be made solely of one closed ring folded in a number of loops or with three or more mutually secured loop-shaped rings placed on top of each other. Moreover, it is possible to make the stent having a thread structure which instead of

US 6,582,462 B1

7

loops is grate shaped, helical or is formed otherwise if only it is ensured that the form of the stent permits the compression and expansion of the stent and fastening of the collapsible valve. Instead of a biological valve it might be possible to use other collapsible valves, such as valves made from synthetic materials, e.g., polyurethane. It is also possible to use valves with more or fewer flaps than three.

It is possible to make the valve prosthesis with a closed cylinder surface as illustrated in FIGS. 11 and 12. In both Figures the support means of the valve prosthesis is made of an elongated tubular means 24 having a closed cylinder surface. This valve prosthesis is intended to expand by self-expansion or by means of a catheter according to the invention. This prosthesis is especially suitable for placing in veins and other channels where only a small pressure is exerted against the wall of the channel. In FIG. 11 the valve 6 is mounted at the end of the tubular means 24. In FIG. 12 an embodiment is shown where the valve 6 is mounted in a central position in the tubular means 24.

An explanation of a method of implanting a valve prosthesis according to the invention is given below:

- a valve prosthesis 9 made of a stent 1 and a collapsible valve 6, as described above, is placed on a deflated balloon means and is manually compressed thereon, the balloon means 13 and the valve prosthesis are drawn into an insertion cover 11A,
- a guide wire 18 is inserted into the left ventricle of the heart through the central opening 17 of the balloon catheter under continuous fluoroscopy,
- the insertion cover 11A conveys the guide wire 18 to a point in the channel in the immediate vicinity of the desired position of the valve prosthesis,
- the balloon means 13 is pushed out of the protection cap 11A and the valve prosthesis is positioned in the desired position if necessary by use of further registration means to ensure an accurate positioning,
- the balloon means 13 is inflated with a certain overstretching of the channel,
- the balloon means 13 is deflated, and
- the balloon means 13, the guide wire 18 and the protection cap 11A are drawn out and the opening in the channel, if any, wherein the valve prosthesis is inserted can be closed.

8


What is claimed is:

1. A valve prosthesis for implantation in a body channel having an inner wall, the prosthesis comprising:
 - a radially collapsible and expandable cylindrical stent, the stent including a cylindrical support means having a cylinder surface; and
 - a collapsible and expandable valve having commissural points, the valve mounted to the stent at the commissural points, wherein the stent and valve are configured to be implanted in the body by way of catheterization.
2. The valve prosthesis according to claim 1, wherein the support means is made of thread structure.
3. The valve prosthesis according to claim 2, wherein the thread structure comprises several spaced apices that extend from one end of the cylindrical support means in a direction along a longitudinal axis of the cylindrical support means, the commissural points of the valve being attached to the apices.
4. The valve prosthesis according to claim 3, wherein the collapsible valve is a biologically trilobate valve.
5. The valve prosthesis according to claim 1, wherein the stent comprises at least two closed rings, each formed from more than three loops, the rings connected one to another, and wherein three of the loops in at least one of the rings has a greater height than the remaining loops.
6. The valve prosthesis according to claim 5, wherein each of the rings of the stent is made from a wire having a diameter of 0.05 mm and a loop height of approximately 8 mm and approximately 14 mm for the three greater height loops, and that the cylindrical wire structure produced and the collapsible valve mounted thereon in a folded state have an outer diameter of approximately 10 mm and in an expanded state an outer diameter of approximately 30 mm.
7. The valve prosthesis according to claim 5, wherein three or more mutually attached rings placed on top of each other are used in that the stent is made to be fixed through the expansion at one point in the channel where the valve prosthesis is inserted, which point is different from the point where the valve is mounted in the stent.
8. The valve prosthesis according to claim 1, wherein the cylinder surface of the support means is closed to form a tubular element.

* * * * *

EXHIBIT L

David Martinez, Bar No. 193183
DMartinez@rkmc.com
ROBINS, KAPLAN, MILLER & CIRESI L.L.P.
2049 Century Park East, Suite 3400
Los Angeles, CA 90067-3208
Telephone: (310) 552-0130
Facsimile: (310) 229-5800



Jan M. Conlin (*pro hac vice* pending)
Minn. Bar No. 192697
JMConlin@rkmc.com
Stacie E. Oberts (*pro hac vice* pending)
Minn. Bar No. 278361
SEOberts@rkmc.com

Lauren E. Wood (*pro hac vice* pending)
Minn. Bar No. 389128
LEWood@rkmc.com

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.
2800 LaSalle Plaza
800 LaSalle Avenue
Minneapolis, MN 55402-2015
Telephone: (612) 349-8500
Facsimile: (612) 339-4181

Attorneys for Plaintiffs
**MEDTRONIC COREVALVE LLC, MEDTRONIC CV
LUXEMBOURG S.A.R.L., and MEDTRONIC
VASCULAR GALWAY LTD.**

**UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA**

**MEDTRONIC COREVALVE LLC,
MEDTRONIC CV LUXEMBOURG
S A R L, AND MEDTRONIC
VASCULAR GALWAY LTD.,**

Case **CV11-00961-JVS/MLG**
**COMPLAINT FOR PATENT
INFRINGEMENT**

Plaintiffs,

v.

**EDWARDS LIFESCIENCES
CORPORATION, EDWARDS
LIFESCIENCES LLC, AND
EDWARDS LIFESCIENCES (U.S.)
INC.,**

Defendants.

1 Plaintiffs Medtronic CoreValve LLC, Medtronic CV Luxembourg S.a.r.l.,
2 and Medtronic Vascular Galway, Ltd. (collectively "Medtronic") for their
3 Complaint against Defendants Edwards Lifesciences Corporation, Edwards
4 Lifesciences LLC, and Edwards Lifesciences (U.S.) Inc., hereby states and alleges
5 as follows:

6 I.

7 INTRODUCTION

8 1. This is an action for willful infringement by Defendants of a United
9 States patent owned by Medtronic CoreValve LLC.

10 2. Plaintiff Medtronic CoreValve LLC is a limited liability company
11 organized and existing under the laws of Delaware, with its principal place of
12 business in Irvine, California.

13 3. Plaintiff Medtronic CV Luxembourg S.a.r.l. is a limited liability
14 company organized and existing under the laws of Luxembourg, with its principal
15 place of business in Luxembourg.

16 4. Plaintiff Medtronic Vascular Galway Ltd. is a company organized and
17 existing under the laws of Ireland, with its principal place of business in Galway,
18 Ireland.

19 5. Upon information and belief, Defendant Lifesciences Corporation is a
20 corporation organized and existing under the laws of Delaware with its principal
21 place of business in Irvine, California.

22 6. Upon information and belief, Defendant Edward Lifesciences LLC is a
23 wholly-owned subsidiary of Edwards Lifesciences Corporation that is organized
24 under the laws of Delaware with its principal place of business in Irvine, California.

25 7. Upon information and belief, Defendant Edwards Lifesciences (U.S.)
26 Inc. is a wholly-owned subsidiary of Edwards Lifesciences Corporation that is
27 organized under the laws of Delaware with its principal place of business in Irvine,
28 California. Edwards Lifesciences Corporation, Edwards Lifesciences LLC and

1 Edwards Lifesciences (U.S.) Inc. are collectively hereinafter referred to as
2 “Edwards.”

3 **II.**

4 **JURISDICTION AND VENUE**

5 8. This Court has jurisdiction over the subject matter of this action
6 pursuant to 28 U.S.C. § 1331 and § 1338(a) in that this action arises under the
7 patent laws of the United States.

8 9. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391(b),
9 1391(c) and 1400(b).

10 10. This Court has personal jurisdiction over the Defendants because,
11 upon information and belief, Defendants conduct business within this judicial
12 district, and have their principal places of business within this judicial district.
13 Upon information and belief, Defendants have committed and continue to commit
14 acts of patent infringement within this judicial district.

15 **III.**

16 **FACTUAL BACKGROUND**

17 11. Plaintiff Medtronic CoreValve LLC is the lawful owner of United
18 States Patent No. 7,892,281 (“the ‘281 Patent”), which was duly and legally issued
19 by the United States Patent and Trademark Office on February 22, 2011. The ‘281
20 Patent is entitled “Prosthetic Valve for Transluminal Delivery.” A copy of the ‘281
21 Patent is attached hereto as Exhibit 1.

22 12. Plaintiff Medtronic CV Luxembourg S.a.r.l. is the exclusive licensee
23 of the ‘281 Patent.

24 13. Plaintiff Medtronic Vascular Galway Ltd. holds world wide
25 manufacturing and distribution rights to the ‘281 Patent.

26 14. Collectively, the Medtronic Plaintiffs own all rights, title and interests
27 in the ‘281 Patent.
28

15. Medtronic has the exclusive right under the patent laws of the United States to exclude others from making, using, offering for sale, selling, or importing its patented invention, including the right to bring this action for injunctive relief, and accounting and damages.

IV.

COUNT I

(Claim for Patent Infringement of U.S. Patent No. 7,892,281)

16. Medtronic hereby restates and re-alleges the allegations set forth in Paragraphs 1 through 15 and incorporates them into this count by reference.

17. Upon information and belief Defendant Edwards manufactures in the Central District of California and elsewhere within the United States devices that infringe, either literally or under the Doctrine of Equivalents, one or more claims of the '281 Patent. Such devices include, but are not limited to, the Sapien Transcatheter Aortic Valve.

18. Upon information and belief, and in violation of 35 U.S.C. § 271, Edwards has been and is now infringing the '281 patent by manufacturing, using, importing, selling, offering to sell and/or supplying heart valve devices covered by one or more claims of the '281 patent, including without limitation the Sapien Transcatheter Aortic Valve.

19. Edwards' foregoing infringement has been willful, warranting a finding that this case is an exceptional case pursuant to 35 U.S.C. § 285.

20. The unlawful infringing activities by Defendant Edwards are continuing and will continue unless enjoined by this Court.

21. As a result of the infringing acts herein described, Medtronic has sustained damages and will continue to sustain damages in the future, including irreparable harm, unless Defendant Edwards is enjoined from infringing said patent.

V.

PRAYER FOR RELIEF


WHEREFORE, Plaintiff Medtronic prays for judgment against Defendants as follows:

1. That Defendants have infringed, either literally or under the Doctrine of Equivalents, one or more claims of the '281 Patent;
2. That Defendants' infringement has been willful and trebling the award of damages;
3. That Defendants, and their respective agents, servants, officers, directors, employees and all persons acting in concert with them, directly or indirectly, be permanently enjoined from infringing the '281 Patent;
4. That Defendants account for and pay to Plaintiff damages adequate to compensate them for Defendants' infringement, in an amount to be proven at trial, together with interest and costs as fixed by the Court;
5. Declaring that this case is exceptional and awarding Plaintiff its costs and attorneys' fees in accordance with 35 U.S.C. § 285; and
6. That Plaintiff be awarded such other and further relief as the Court may deem just and equitable.

Dated: June 24, 2011

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.

By:


David Martinez
Jan Conlin
Stacie Oberts
Lauren Wood

**Attorneys for Plaintiffs
MEDTRONIC COREVALVE LLC,
MEDTRONIC CV LUXEMBOURG S.A.R.L.,
and MEDTRONIC VASCULAR GALWAY
LTD.**


DEMAND FOR JURY TRIAL

Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Plaintiff
demands a jury trial as to all matters so triable.

Dated: June 24, 2011

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.

By:


David Martinez

Jan Conlin

Stacie Oberts

Lauren Wood

Attorney for Plaintiffs

**MEDTRONIC COREVALVE LLC,
MEDTRONIC CV LUXEMBOURG S.A.R.L.,
and MEDTRONIC VASCULAR GALWAY
LTD.**

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.
ATTORNEYS AT LAW
LOS ANGELES

EXHIBIT 1

(12) **United States Patent**
Seguin et al.

(10) **Patent No.:** **US 7,892,281 B2**
 (45) **Date of Patent:** ***Feb. 22, 2011**

(54) **PROSTHETIC VALVE FOR TRANSLUMINAL DELIVERY**

(75) Inventors: **Jacques Seguin**, Old Windsor (GB);
Georg Börtlein, Meudon (FR)

(73) Assignee: **Medtronic CoreValve LLC**,
 Minneapolis, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
 This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/348,892**

(22) Filed: **Jan. 5, 2009**

(65) **Prior Publication Data**
 US 2009/0164006 A1 Jun. 25, 2009

Related U.S. Application Data

(63) Continuation of application No. 12/029,031, filed on Feb. 11, 2008, which is a continuation of application No. 11/352,614, filed on Feb. 13, 2006, now Pat. No. 7,329,278, which is a continuation of application No. 10/412,634, filed on Apr. 10, 2003, now Pat. No. 7,018,406, which is a continuation-in-part of application No. 10/130,355, filed as application No. PCT/FR00/03176 on Nov. 15, 2000, now Pat. No. 6,830,584, and a continuation-in-part of application No. PCT/FR01/03258, filed on Oct. 19, 2001, application No. 12/348,892, which is a continuation of application No. 11/434,506, filed on May 15, 2006, which is a continuation-in-part of application No. 10/772,101, filed on Feb. 4, 2004, which is a continuation-in-part of application No. 10/412,634.

(30) **Foreign Application Priority Data**

Nov. 17, 1999 (FR) 99/14462
 Nov. 17, 1999 (FR) 99/14462

(51) **Int. Cl.**
A61F 2/24 (2006.01)

(52) **U.S. Cl.** **623/2.1**

(58) **Field of Classification Search** 623/2.1-2.24
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,832,078 A * 4/1958 Williams 623/2.19

(Continued)

FOREIGN PATENT DOCUMENTS

DE 195 32 846 3/1997

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 12/250,163, filed Oct. 13, 2008.

(Continued)


Primary Examiner—Suzette J Gherbi

(74) *Attorney, Agent, or Firm*—Jeffrey J. Hohenshell; Mike Jaro

(57) **ABSTRACT**

A prosthetic valve assembly for use in replacing a deficient native valve comprises a replacement valve supported on an expandable valve support. If desired, one or more anchor may be used. The valve support, which entirely supports the valve annulus, valve leaflets, and valve commissure points, is configured to be collapsible for transluminal delivery and expandable to contact the anatomical annulus of the native valve when the assembly is properly positioned. The anchor engages the lumen wall when expanded and prevents substantial migration of the valve assembly when positioned in place. The prosthetic valve assembly is compressible about a catheter, and restrained from expanding by an outer sheath. The catheter may be inserted inside a lumen within the body, such as the femoral artery, and delivered to a desired location, such as the heart. When the outer sheath is retracted, the prosthetic valve assembly expands to an expanded position such that the valve and valve support expand within the deficient native valve, and the anchor engages the lumen wall.

15 Claims, 25 Drawing Sheets



US 7,892,281 B2

Page 2

U.S. PATENT DOCUMENTS

3,334,629	A	8/1967	Cohn	5,152,771	A	10/1992	Sabbaghian et al.
3,409,013	A	11/1968	Berry	5,161,547	A	11/1992	Tower
3,540,431	A	11/1970	Mobin-Uddin	5,163,953	A	11/1992	Vince
3,587,115	A	6/1971	Shiley	5,167,628	A	12/1992	Boyles
3,628,535	A	12/1971	Ostrowsky et al	5,217,483	A	6/1993	Tower
3,642,004	A	2/1972	Osthagen et al	5,232,445	A	8/1993	Bonzel
3,657,744	A *	4/1972	Ersek 128/898	5,272,909	A	12/1993	Nguyen et al.
3,671,979	A	6/1972	Moulopoulos	5,295,958	A	3/1994	Shturman
3,714,671	A	2/1973	Edwards et al.	5,327,774	A	7/1994	Nguyen et al.
3,755,823	A	9/1973	Hancock	5,332,402	A	7/1994	Teitelbaum et al.
3,795,246	A	3/1974	Sturgeon	5,350,398	A	9/1994	Pavcnik et al.
3,839,741	A	10/1974	Haller	5,370,685	A	12/1994	Stevens
3,868,956	A	3/1975	Alfidi et al	5,389,106	A	2/1995	Tower
3,874,388	A	4/1975	King et al	5,397,351	A	3/1995	Pavcnik et al.
4,035,849	A	7/1977	Angell et al.	5,411,552	A	5/1995	Andersen et al.
4,056,854	A	11/1977	Boretos et al.	5,415,633	A	5/1995	Lazarus et al.
4,106,129	A	8/1978	Carpentier et al.	5,431,676	A	7/1995	Dubrul et al.
4,222,126	A	9/1980	Boretos et al.	5,443,446	A	8/1995	Shturman
4,233,690	A	11/1980	Akins	5,480,424	A	1/1996	Cox
4,265,694	A	5/1981	Boretos	5,489,294	A	2/1996	McVenes et al.
4,291,420	A	9/1981	Reul	5,489,297	A	2/1996	Duran
4,297,749	A	11/1981	Davis et al.	5,496,346	A	3/1996	Horzewski et al.
4,339,831	A	7/1982	Johnson	5,500,014	A	3/1996	Quijano et al.
4,343,048	A	8/1982	Ross et al.	5,507,767	A	4/1996	Maeda et al.
4,345,340	A	8/1982	Rosen	5,545,209	A	8/1996	Roberts et al.
4,425,908	A	1/1984	Simon	5,545,211	A	8/1996	An et al.
4,470,157	A	9/1984	Love	5,545,214	A	8/1996	Stevens
4,501,030	A	2/1985	Lane	5,554,185	A	9/1996	Block et al.
4,574,803	A	3/1986	Storz	5,575,818	A	11/1996	Pinchuk
4,580,568	A	4/1986	Gianturco	5,580,922	A	12/1996	Park et al.
4,592,340	A	6/1986	Boyles	5,591,195	A	1/1997	Taheri et al.
4,610,688	A	9/1986	Silvestrini et al.	5,609,626	A	3/1997	Quijano et al.
4,612,011	A	9/1986	Kautzky	5,645,559	A	7/1997	Hachtman et al.
4,647,283	A	3/1987	Carpentier et al.	5,665,115	A	9/1997	Cragg
4,648,881	A	3/1987	Carpentier et al.	5,667,523	A	9/1997	Bynon et al.
4,655,771	A	4/1987	Wallsten	5,674,277	A	10/1997	Freitag
4,662,885	A	5/1987	DiPisa, Jr.	5,695,498	A	12/1997	Tower
4,665,906	A	5/1987	Jervis	5,702,368	A	12/1997	Stevens et al.
4,681,908	A	7/1987	Broderick et al.	5,713,953	A	2/1998	Vallana et al.
4,710,192	A	12/1987	Liotta et al.	5,716,417	A *	2/1998	Girard et al. 623/2.38
4,733,665	A	3/1988	Palmaz	5,746,709	A	5/1998	Rom et al.
4,777,951	A	10/1988	Cribier et al.	5,749,890	A	5/1998	Shaknovich
4,787,899	A	11/1988	Lazarus	5,766,151	A	6/1998	Valley et al.
4,796,629	A	1/1989	Grayzel	5,782,809	A	7/1998	Umeno et al.
4,797,901	A	1/1989	Baykut	5,800,456	A	9/1998	Maeda et al.
4,819,751	A	4/1989	Shimada et al.	5,800,508	A	9/1998	Goicoechea et al.
4,834,755	A	5/1989	Silvestrini et al.	5,817,126	A	10/1998	Imran
4,851,000	A *	7/1989	Gupta 623/2.18	5,824,041	A	10/1998	Lenker
4,856,516	A	8/1989	Hillstead	5,824,043	A	10/1998	Cottone, Jr.
4,872,874	A	10/1989	Taheri	5,824,053	A	10/1998	Khosravi et al.
4,878,495	A	11/1989	Grayzel	5,824,056	A	10/1998	Rosenberg
4,878,906	A	11/1989	Lindemann et al.	5,824,061	A	10/1998	Quijano et al.
4,883,458	A	11/1989	Shiber	5,824,064	A	10/1998	Taheri
4,909,252	A	3/1990	Goldberger	5,840,081	A	11/1998	Andersen et al.
4,917,102	A	4/1990	Miller et al.	5,843,158	A	12/1998	Lenker et al.
4,922,905	A	5/1990	Strecker	5,851,232	A	12/1998	Lois
4,954,126	A	9/1990	Wallsten	5,855,597	A	1/1999	Jayaraman
4,966,604	A	10/1990	Reiss	5,855,601	A	1/1999	Bessler et al.
4,979,939	A	12/1990	Shiber	5,860,996	A	1/1999	Tower
4,986,830	A	1/1991	Owens et al.	5,861,028	A	1/1999	Angell
4,994,077	A	2/1991	Dobben	5,868,783	A	2/1999	Tower
5,002,559	A	3/1991	Tower	5,876,448	A	3/1999	Thompson et al.
5,007,896	A	4/1991	Shiber	5,888,201	A	3/1999	Stinson et al.
5,026,366	A	6/1991	Leckrone	5,891,191	A	4/1999	Stinson
5,032,128	A	7/1991	Alonso	5,906,619	A	5/1999	Olson et al.
5,037,434	A	8/1991	Lane	5,907,893	A	6/1999	Zadno-Azizi et al.
5,047,041	A	9/1991	Samuels	5,913,842	A	6/1999	Boyd et al.
5,059,177	A	10/1991	Towne et al.	5,925,063	A	7/1999	Khosravi
5,061,273	A	10/1991	Yock	5,944,738	A	8/1999	Amplatz et al.
5,085,635	A	2/1992	Cragg	5,951,288	A *	9/1999	Sawa 433/173
5,089,015	A	2/1992	Ross	5,954,766	A	9/1999	Zadno-Azizi et al.
				5,957,949	A *	9/1999	Leonhardt et al. 623/1.24
				5,968,068	A	10/1999	Dehdashti et al.

US 7,892,281 B2

Page 3

5,984,957 A	11/1999	Laptewicz, Jr. et al.	6,663,663 B2	12/2003	Kim et al.
5,997,573 A	12/1999	Quijano et al.	6,669,724 B2	12/2003	Park et al.
6,022,370 A	2/2000	Tower	6,673,089 B1	1/2004	Yassour et al.
6,027,525 A	2/2000	Suh et al.	6,673,109 B2	1/2004	Cox
6,029,671 A	2/2000	Stevens et al.	6,676,698 B2	1/2004	McGuckin, Jr. et al.
6,042,589 A	3/2000	Marianne	6,682,558 B2	1/2004	Tu et al.
6,042,598 A	3/2000	Tsugita et al.	6,682,559 B2	1/2004	Myers et al.
6,042,607 A	3/2000	Williamson, IV	6,685,739 B2	2/2004	DiMatteo et al.
6,051,014 A	4/2000	Jang	6,689,144 B2	2/2004	Gerberding
6,059,809 A	5/2000	Amor et al.	6,689,164 B1	2/2004	Seguin
6,110,201 A	8/2000	Quijano et al.	6,692,512 B2	2/2004	Jang
6,146,366 A	11/2000	Schachar	6,692,513 B2	2/2004	Streeter et al.
6,159,239 A	12/2000	Greenhalgh	6,695,878 B2	2/2004	McGuckin, Jr. et al.
6,162,208 A	12/2000	Hipps	6,702,851 B1	3/2004	Chinn et al.
6,162,245 A	12/2000	Jayaraman	6,719,789 B2	4/2004	Cox
6,168,614 B1	1/2001	Andersen et al.	6,730,118 B2	5/2004	Spenser et al.
6,171,335 B1	1/2001	Wheatley et al.	6,730,377 B2	5/2004	Wang
6,200,336 B1	3/2001	Pavcnik et al.	6,371,970 B1	4/2002	Khosravi et al.
6,203,550 B1	3/2001	Olson	6,733,525 B2	5/2004	Yang et al.
6,210,408 B1	4/2001	Chandrasekaran et al.	6,736,846 B2	5/2004	Cox
6,218,662 B1	4/2001	Tchakarov et al.	6,752,828 B2	6/2004	Thornton
6,221,006 B1	4/2001	Dubrul et al.	6,758,855 B2	7/2004	Fulton, III et al.
6,221,091 B1	4/2001	Khosravi	6,769,434 B2	8/2004	Liddicoat et al.
6,241,757 B1	6/2001	An et al.	6,786,925 B1	9/2004	Schoon
6,245,102 B1	6/2001	Jayaraman	6,790,229 B1	9/2004	Berrekouw
6,248,116 B1	6/2001	Chevillon	6,792,979 B2	9/2004	Konya et al.
6,258,114 B1	7/2001	Konya et al.	6,797,002 B2	9/2004	Spence
6,258,115 B1	7/2001	Dubrul	6,821,297 B2	11/2004	Snyders
6,258,120 B1	7/2001	McKenzie et al.	6,830,575 B2	12/2004	Stenzel et al.
6,277,555 B1	8/2001	Duran et al.	6,830,584 B1	12/2004	Seguin
6,299,637 B1	10/2001	Shaolia et al.	6,830,585 B1	12/2004	Artof
6,302,906 B1	10/2001	Goicoechea et al.	6,846,325 B2	1/2005	Liddicoat
6,309,382 B1	10/2001	Garrison et al.	6,866,650 B2	3/2005	Stevens
6,309,417 B1	10/2001	Spence et al.	6,872,223 B2	3/2005	Roberts
6,327,772 B1	12/2001	Zadno-Azizi et al.	6,875,231 B2	4/2005	Anduiza et al.
6,338,735 B1	1/2002	Stevens	6,883,522 B2	4/2005	Spence et al.
6,348,063 B1	2/2002	Yassour et al.	6,887,266 B2	5/2005	Williams et al.
6,350,277 B1	2/2002	Kocur	6,890,330 B2	5/2005	Streeter et al.
6,352,708 B1	3/2002	Duran et al.	6,893,460 B2	5/2005	Spenser et al.
6,371,983 B1	4/2002	Lane	6,896,690 B1	5/2005	Lambrecht et al.
6,379,383 B1	4/2002	Palmaz et al.	6,908,481 B2	6/2005	Cribier
6,380,457 B1	4/2002	Yurek et al.	6,913,600 B2	7/2005	Valley et al.
6,398,807 B1	6/2002	Chouinard et al.	6,929,653 B2	8/2005	Streeter
6,409,750 B1	6/2002	Hyodoh et al.	6,936,066 B2	8/2005	Palmaz et al.
6,425,916 B1	7/2002	Garrison et al.	6,939,365 B1	9/2005	Fogarty et al.
6,440,164 B1	8/2002	DiMatteo et al.	6,951,571 B1	10/2005	Srivastava
6,454,799 B1	9/2002	Schreck	6,986,742 B2	1/2006	Hart et al.
6,458,153 B1	10/2002	Bailey et al.	6,989,027 B2	1/2006	Allen et al.
6,461,382 B1	10/2002	Cao	6,989,028 B2	1/2006	Lashinski et al.
6,468,303 B1	10/2002	Amplatz et al.	6,991,649 B2	1/2006	Sievers
6,475,239 B1	11/2002	Campbell et al.	7,018,401 B1	3/2006	Hyodoh et al.
6,482,228 B1	11/2002	Norred	7,018,406 B2 *	3/2006	Seguin et al. 623/2.1
6,488,704 B1	12/2002	Connelly et al.	7,041,128 B2	5/2006	McGuckin, Jr. et al.
6,494,909 B2	12/2002	Greenhalgh	7,044,966 B2	5/2006	Svanidze et al.
6,503,272 B2	1/2003	Duerig et al.	7,048,014 B2	5/2006	Hyodoh et al.
6,508,833 B2	1/2003	Pavcnik et al.	7,097,659 B2	8/2006	Woolfson et al.
6,527,800 B1	3/2003	McGuckin, Jr. et al.	7,101,396 B2	9/2006	Artof et al.
6,530,949 B2	3/2003	Konya et al.	7,105,016 B2	9/2006	Shui et al.
6,530,952 B2	3/2003	Vesely	7,115,141 B2	10/2006	Menz et al.
6,562,031 B2	5/2003	Chandrasekaran et al.	7,147,663 B1	12/2006	Berg et al.
6,562,058 B2	5/2003	Seguin et al.	7,153,324 B2	12/2006	Case et al.
6,569,191 B1 *	5/2003	Hogan 623/1.11	7,160,319 B2	1/2007	Chouinard et al.
6,569,196 B1	5/2003	Vesely	7,175,656 B2	2/2007	Khairkahan
6,585,758 B1	7/2003	Chouinard et al.	7,186,265 B2	3/2007	Sharkawy et al.
6,592,546 B1	7/2003	Barbut et al.	7,195,641 B2	3/2007	Palmaz et al.
6,605,112 B1	8/2003	Moll et al.	7,198,646 B2	4/2007	Figulla et al.
6,613,077 B2	9/2003	Gilligan et al.	7,201,761 B2	4/2007	Woolfson et al.
6,622,604 B1	9/2003	Chouinard et al.	7,201,772 B2	4/2007	Schwammenthal et al.
6,632,243 B1	10/2003	Zadno-Azizi et al.	7,252,682 B2	8/2007	Seguin
6,635,068 B1	10/2003	Dubrul et al.	7,300,457 B2	11/2007	Palmaz
6,652,571 B1	11/2003	White et al.	7,300,463 B2	11/2007	Liddicoat
6,652,578 B2	11/2003	Bailey et al.	7,316,706 B2	1/2008	Bloom et al.
6,656,213 B2	12/2003	Solem	7,329,278 B2	2/2008	Seguin

US 7,892,281 B2

Page 4

7,335,218 B2	2/2008	Wilson et al.	2003/0199971 A1	10/2003	Tower et al.
7,338,520 B2	3/2008	Bailey et al.	2003/0199972 A1	10/2003	Zadno-Azizi et al.
7,374,571 B2	5/2008	Pease et al.	2003/0212410 A1	11/2003	Stenzel et al.
7,381,218 B2	6/2008	Shreck	2003/0212452 A1	11/2003	Zadno-Azizi et al.
7,384,411 B1	6/2008	Condado	2003/0212454 A1	11/2003	Scott et al.
7,429,269 B2	9/2008	Schwammenthal et al.	2004/0034411 A1	2/2004	Quijano et al.
7,442,204 B2	10/2008	Schwammenthal et al.	2004/0039436 A1	2/2004	Spenser et al.
7,462,191 B2	12/2008	Spenser et al.	2004/0049224 A1	3/2004	Buehlmann et al.
7,470,284 B2	12/2008	Lambrecht et al.	2004/0049262 A1	3/2004	Obermiller et al.
7,481,838 B2	1/2009	Carpentier et al.	2004/0049266 A1	3/2004	Anduiza et al.
7,544,206 B2	6/2009	Cohn et al.	2004/0082904 A1	4/2004	Houde et al.
7,556,646 B2	7/2009	Yang et al.	2004/0088045 A1	5/2004	Cox
7,682,390 B2	3/2010	Seguin	2004/0093005 A1	5/2004	Durcan
7,780,726 B2	8/2010	Seguin	2004/0093060 A1	5/2004	Seguin et al.
7,806,919 B2	10/2010	Bloom et al.	2004/0097788 A1	5/2004	Mourlas et al.
2001/0001314 A1	5/2001	Davison et al.	2004/0098112 A1	5/2004	DiMatteo et al.
2001/0002445 A1	5/2001	Vesely	2004/0106976 A1	6/2004	Bailey et al.
2001/0007956 A1	7/2001	Letac et al.	2004/0106990 A1	6/2004	Spence et al.
2001/0010017 A1	7/2001	Letac et al.	2004/0111096 A1	6/2004	Tu et al.
2001/0011189 A1	8/2001	Drasler et al.	2004/0116951 A1	6/2004	Rosengart
2001/0021872 A1	9/2001	Bailey et al.	2004/0117004 A1	6/2004	Osborne et al.
2001/0025196 A1	9/2001	Chinn et al.	2004/0122468 A1	6/2004	Yodfat et al.
2001/0032013 A1	10/2001	Marton	2004/0122516 A1	6/2004	Fogarty
2001/0039450 A1	11/2001	Pavcnik et al.	2004/0127979 A1	7/2004	Wilson
2001/0041928 A1	11/2001	Pavcnik et al.	2004/0138742 A1	7/2004	Myers et al.
2001/0044647 A1	11/2001	Pinchuk et al.	2004/0138743 A1	7/2004	Myers et al.
2002/0010508 A1	1/2002	Chobotov	2004/0153146 A1	8/2004	Lashinski et al.
2002/0029014 A1	3/2002	Jayaraman	2004/0167573 A1	8/2004	Williamson
2002/0032480 A1	3/2002	Spence et al.	2004/0167620 A1	8/2004	Ortiz
2002/0032481 A1	3/2002	Gabbay	2004/0186563 A1	9/2004	Iobbi
2002/0035396 A1	3/2002	Heath	2004/0193261 A1	9/2004	Berrekouw
2002/0042650 A1	4/2002	Vardi et al.	2004/0210240 A1	10/2004	Saint
2002/0052651 A1	5/2002	Myers et al.	2004/0210304 A1	10/2004	Seguin et al.
2002/0058995 A1	5/2002	Stevens	2004/0210307 A1	10/2004	Khairkahan
2002/0072789 A1	6/2002	Hackett et al.	2004/0215333 A1	10/2004	Duran
2002/0077696 A1	6/2002	Zadno-Azizi et al.	2004/0215339 A1	10/2004	Drasler et al.
2002/0095209 A1	7/2002	Zadno-Azizi et al.	2004/0225353 A1	11/2004	McGuckin, Jr.
2002/0099439 A1	7/2002	Schwartz et al.	2004/0225354 A1	11/2004	Allen
2002/0103533 A1	8/2002	Langberg et al.	2004/0254636 A1	12/2004	Flagle et al.
2002/0107565 A1	8/2002	Greenhalgh	2004/0260394 A1	12/2004	Douk et al.
2002/0111674 A1	8/2002	Chouinard et al.	2004/0267357 A1	12/2004	Allen et al.
2002/0123802 A1	9/2002	Snyders	2005/0010246 A1	1/2005	Streeter
2002/0133183 A1	9/2002	Lentz et al.	2005/0010285 A1	1/2005	Lambrecht et al.
2002/0138138 A1	9/2002	Yang	2005/0010287 A1	1/2005	Macoviak
2002/0151970 A1	10/2002	Garrison et al.	2005/0015112 A1	1/2005	Cohn et al.
2002/0161392 A1	10/2002	Dubrul	2005/0027348 A1	2/2005	Case et al.
2002/0161394 A1	10/2002	Macoviak et al.	2005/0033398 A1	2/2005	Seguin
2002/0193871 A1	12/2002	Beyersdorf et al.	2005/0043790 A1	2/2005	Seguin
2003/0014104 A1	1/2003	Cribier	2005/0049692 A1	3/2005	Numamoto
2003/0023300 A1	1/2003	Bailey et al.	2005/0049696 A1	3/2005	Siess
2003/0023303 A1	1/2003	Palmar et al.	2005/0055088 A1	3/2005	Liddicoat et al.
2003/0028247 A1	2/2003	Cali	2005/0060029 A1	3/2005	Le
2003/0036791 A1	2/2003	Bonhoeffer et al.	2005/0060030 A1	3/2005	Lashinski et al.
2003/0040771 A1	2/2003	Hyodoh et al.	2005/0075584 A1	4/2005	Cali
2003/0040772 A1	2/2003	Hyodoh et al.	2005/0075712 A1	4/2005	Biancucci
2003/0040792 A1	2/2003	Gabbay	2005/0075717 A1	4/2005	Nguyen
2003/0050694 A1	3/2003	Yang et al.	2005/0075719 A1	4/2005	Bergheim
2003/0055495 A1	3/2003	Pease et al.	2005/0075724 A1	4/2005	Svanidze
2003/0065386 A1	4/2003	Weadock	2005/0075727 A1	4/2005	Wheatley
2003/0069492 A1	4/2003	Abrams et al.	2005/0075730 A1	4/2005	Myers
2003/0109924 A1	6/2003	Cribier	2005/0075731 A1	4/2005	Artof
2003/0125795 A1	7/2003	Pavcnik et al.	2005/0085841 A1	4/2005	Eversull et al.
2003/0130726 A1	7/2003	Thorpe et al.	2005/0085842 A1	4/2005	Eversull et al.
2003/0130729 A1	7/2003	Paniagua et al.	2005/0085843 A1	4/2005	Opolski et al.
2003/0139804 A1	7/2003	Hankh et al.	2005/0085890 A1	4/2005	Rasmussen et al.
2003/0149475 A1	8/2003	Hyodoh et al.	2005/0085900 A1	4/2005	Case et al.
2003/0149476 A1	8/2003	Damm et al.	2005/0096568 A1	5/2005	Kato
2003/0149478 A1	8/2003	Figulla et al.	2005/0096692 A1	5/2005	Linder et al.
2003/0153974 A1	8/2003	Spenser et al.	2005/0096724 A1	5/2005	Stenzel et al.
2003/0181850 A1	9/2003	Diamond et al.	2005/0096734 A1	5/2005	Majercak et al.
2003/0191519 A1	10/2003	Lombardi et al.	2005/0096735 A1	5/2005	Hojeibane et al.
2003/0199913 A1	10/2003	Dubrul et al.	2005/0096736 A1	5/2005	Osse et al.
2003/0199963 A1	10/2003	Tower et al.	2005/0096738 A1	5/2005	Cali et al.

US 7,892,281 B2

Page 5

2005/0107871	A1	5/2005	Realyvasquez et al.	2007/0239254	A1	10/2007	Marchand et al.
2005/0113910	A1	5/2005	Paniagua	2007/0239265	A1	10/2007	Birdsall
2005/0119688	A1	6/2005	Berheim	2007/0239266	A1	10/2007	Birdsall
2005/0131438	A1	6/2005	Cohn	2007/0239269	A1	10/2007	Dolan et al.
2005/0137686	A1	6/2005	Salahieh	2007/0239271	A1	10/2007	Nguyen
2005/0137688	A1	6/2005	Salahieh et al.	2007/0239273	A1	10/2007	Allen
2005/0137692	A1	6/2005	Haug	2007/0244544	A1	10/2007	Birdsall et al.
2005/0137695	A1	6/2005	Salahieh	2007/0244545	A1	10/2007	Birdsall et al.
2005/0137701	A1	6/2005	Salahieh	2007/0244546	A1	10/2007	Francis
2005/0143809	A1	6/2005	Salahieh	2007/0244553	A1	10/2007	Rafiee et al.
2005/0148997	A1	7/2005	Valley et al.	2007/0244554	A1	10/2007	Rafiee et al.
2005/0165477	A1	7/2005	Anduiza et al.	2007/0244555	A1	10/2007	Rafiee et al.
2005/0187616	A1	8/2005	Realyvasquez	2007/0244556	A1	10/2007	Rafiee et al.
2005/0203549	A1	9/2005	Realyvasquez	2007/0244557	A1	10/2007	Rafiee et al.
2005/0203605	A1	9/2005	Dolan	2007/0250160	A1	10/2007	Rafiee
2005/0203618	A1	9/2005	Sharkawy	2007/0255394	A1	11/2007	Ryan
2005/0222674	A1	10/2005	Paine	2007/0255396	A1	11/2007	Douk et al.
2005/0228495	A1	10/2005	Macoviak	2007/0288000	A1	12/2007	Bonan
2005/0234546	A1	10/2005	Nugent	2008/0004696	A1	1/2008	Vesely
2005/0240200	A1	10/2005	Bergheim	2008/0009940	A1	1/2008	Cribier
2005/0240263	A1	10/2005	Fogarty et al.	2008/0015671	A1	1/2008	Bonhoeffer
2005/0261759	A1	11/2005	Lambrecht et al.	2008/0021552	A1	1/2008	Gabbay
2005/0283962	A1	12/2005	Boudjemline	2008/0048656	A1	2/2008	Tan
2006/0004439	A1	1/2006	Spenser et al.	2008/0065001	A1	3/2008	Marchand et al.
2006/0009841	A1	1/2006	McGuckin et al.	2008/0065206	A1	3/2008	Liddicoat
2006/0052867	A1	3/2006	Revuelta et al.	2008/0071361	A1	3/2008	Tuval et al.
2006/0058775	A1	3/2006	Stevens et al.	2008/0071362	A1	3/2008	Tuval et al.
2006/0089711	A1	4/2006	Dolan	2008/0071363	A1	3/2008	Tuval et al.
2006/0100685	A1	5/2006	Seguin et al.	2008/0071366	A1	3/2008	Tuval et al.
2006/0116757	A1	6/2006	Lashinski et al.	2008/0071368	A1	3/2008	Tuval et al.
2006/0135964	A1	6/2006	Vesely	2008/0077234	A1	3/2008	Styrc
2006/0142848	A1	6/2006	Gabbay	2008/0082165	A1	4/2008	Wilson et al.
2006/0167474	A1	7/2006	Bloom et al.	2008/0082166	A1	4/2008	Styrc et al.
2006/0178740	A1	8/2006	Stacchino et al.	2008/0133003	A1	6/2008	Seguin et al.
2006/0195134	A1	8/2006	Crittenden	2008/0140189	A1	6/2008	Nguyen et al.
2006/0206192	A1	9/2006	Tower et al.	2008/0147105	A1	6/2008	Wilson et al.
2006/0206202	A1	9/2006	Bonhoefer et al.	2008/0147180	A1	6/2008	Ghione et al.
2006/0247763	A1	11/2006	Slater	2008/0147181	A1	6/2008	Ghione et al.
2006/0259134	A1	11/2006	Schwammenthal et al.	2008/0147182	A1	6/2008	Righini et al.
2006/0259136	A1	11/2006	Nguyen et al.	2008/0154356	A1	6/2008	Obermiller et al.
2006/0259137	A1	11/2006	Artof et al.	2008/0161910	A1	7/2008	Revuelta et al.
2006/0265056	A1	11/2006	Nguyen et al.	2008/0161911	A1	7/2008	Revuelta et al.
2006/0271166	A1	11/2006	Thill et al.	2008/0183273	A1	7/2008	Mesana et al.
2006/0271175	A1	11/2006	Woolfson et al.	2008/0188928	A1	8/2008	Salahieh et al.
2006/0276874	A1	12/2006	Wilson et al.	2008/0215143	A1	9/2008	Seguin et al.
2006/0282161	A1	12/2006	Huynh et al.	2008/0215144	A1	9/2008	Ryan et al.
2007/0005129	A1	1/2007	Damm et al.	2008/0228254	A1	9/2008	Ryan
2007/0005131	A1	1/2007	Taylor	2008/0228263	A1	9/2008	Ryan
2007/0010878	A1	1/2007	Raffiee et al.	2008/0234797	A1	9/2008	Styrc
2007/0016286	A1	1/2007	Case et al.	2008/0243246	A1	10/2008	Ryan et al.
2007/0027518	A1	2/2007	Herrmann et al.	2008/0255651	A1	10/2008	Dwork
2007/0027533	A1	2/2007	Douk	2008/0255660	A1	10/2008	Guyenot et al.
2007/0043435	A1	2/2007	Seguin et al.	2008/0255661	A1	10/2008	Straubinger et al.
2007/0051377	A1	3/2007	Douk et al.	2008/0262593	A1	10/2008	Ryan et al.
2007/0073392	A1	3/2007	Heyninck-Janitz	2009/0005863	A1	1/2009	Goetz et al.
2007/0078509	A1	4/2007	Lotfy et al.	2009/0012600	A1	1/2009	Styrc et al.
2007/0078510	A1	4/2007	Ryan	2009/0048656	A1	2/2009	Wen
2007/0088431	A1	4/2007	Bourang et al.	2009/0054976	A1	2/2009	Tuval et al.
2007/0093869	A1	4/2007	Bloom et al.	2009/0069886	A1	3/2009	Suri et al.
2007/0100439	A1	5/2007	Cangialosi	2009/0069887	A1	3/2009	Righini et al.
2007/0100440	A1	5/2007	Figulla	2009/0069889	A1	3/2009	Suri et al.
2007/0100449	A1	5/2007	O'Neil et al.	2009/0138079	A1	5/2009	Tuval et al.
2007/0112415	A1	5/2007	Bartlett	2009/0164004	A1	6/2009	Cohn
2007/0162102	A1	7/2007	Ryan et al.	2009/0164006	A1	6/2009	Seguin et al.
2007/0162113	A1	7/2007	Sharkawy et al.	2009/0171447	A1	7/2009	VonSeggesser
2007/0185513	A1	8/2007	Woolfson et al.	2009/0192585	A1	7/2009	Bloom et al.
2007/0203391	A1	8/2007	Bloom et al.	2009/0192586	A1	7/2009	Tabor et al.
2007/0225681	A1	9/2007	House	2009/0192591	A1	7/2009	Ryan et al.
2007/0232898	A1	10/2007	Huynh et al.	2009/0198316	A1	8/2009	Laske et al.
2007/0233228	A1	10/2007	Eberhardt et al.	2009/0216310	A1	8/2009	Straubinger et al.
2007/0233237	A1	10/2007	Krivoruchko	2009/0216312	A1	8/2009	Straubinger et al.
2007/0233238	A1	10/2007	Huynh et al.	2009/0216313	A1	8/2009	Straubinger et al.
2007/0238979	A1	10/2007	Huynh et al.	2009/0240264	A1	9/2009	Tuval et al.

US 7,892,281 B2

Page 6

2009/0240320 A1 9/2009 Tuval
2009/0281619 A1 11/2009 Le et al.
2010/0004740 A1 1/2010 Seguin et al.
2010/0030328 A1 2/2010 Seguin et al.
2010/0036485 A1 2/2010 Seguin
2010/0069852 A1 3/2010 Kelley
2010/0094411 A1 4/2010 Tuval et al.
2010/0100167 A1 4/2010 Bortlein et al.
2010/0131054 A1 5/2010 Tuval et al.
2010/0137979 A1 6/2010 Tuval et al.
2010/0145439 A1 6/2010 Seguin et al.
2010/0152840 A1 6/2010 Seguin et al.
2010/0198346 A1 8/2010 Keogh et al.
2010/0234940 A1 9/2010 Dolan
2010/0256723 A1 10/2010 Murray

FOREIGN PATENT DOCUMENTS

DE 195 46 692 C2 6/1997
DE 195 46692 A1 6/1997
DE 198 57 887 A1 7/2000
DE 199 07 646 8/2000
DE 100 48 814 9/2000
DE 10010074 10/2001
DE 100 49 812 4/2002
DE 100 49 813 4/2002
DE 100 49 815 4/2002
EP 0103546 3/1984
EP 0597967 12/1994
EP 0850607 7/1998
EP 1057459 A1 6/2000
EP 1057460 A1 6/2000
EP 1088529 4/2001
EP 1255510 11/2002
EP 0937439 B1 9/2003
EP 1340473 9/2003
EP 0819013 6/2004
FR 2 800 984 11/1999
FR 2788217 12/1999
FR 2 815 844 10/2000
GB 2056023 3/1981
GB 2433700 12/2007
SU 1271508 11/1986
WO 91/017720 11/1991
WO 93/001768 2/1993
WO 95/29640 11/1995
WO 98/14137 4/1998
WO 98/29057 7/1998
WO 99/33414 7/1999
WO 00/41652 7/2000
WO 00/44313 8/2000
WO 00/47136 8/2000
WO 00/47139 8/2000
WO 01/35870 5/2001
WO 01/49213 7/2001
WO 01/54625 8/2001
WO 01/62189 8/2001
WO 01/64137 9/2001
WO 01/76510 10/2001
WO 02/22054 3/2002
WO 02/36048 5/2002
WO 02/41789 5/2002
WO 02/43620 6/2002
WO 02/47575 6/2002
WO 02/49540 6/2002
WO 03/003943 1/2003
WO 03/003949 1/2003
WO 03/011195 2/2003
WO 03/030776 4/2003
WO 2004/019811 3/2004
WO 2004/019825 3/2004
WO 2004/023980 3/2004
WO 2004/041126 5/2004

WO 2004/058106 7/2004
WO 2004/089250 10/2004
WO 2005/004753 1/2005
WO 2005/027790 3/2005
WO 2005/046528 5/2005
WO 2008/047354 4/2008
WO 2008/100599 8/2008
WO 2008/150529 12/2008
WO 2009/002548 12/2008
WO 2009/045338 4/2009
WO 2009/061389 5/2009
WO 2009/091509 7/2009

OTHER PUBLICATIONS

U.S. Appl. No. 61/192,199, filed Sep. 15, 2008.
U.S. Appl. No. 12/253,858, filed Oct. 17, 2008.
U.S. Appl. No. 12/596,343, filed Apr. 14, 2008.
U.S. Appl. No. 61/129,170, filed Jun. 9, 2008.
Andersen, H.R. et al, "Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs." Euro. Heart J. (1992) 13:704-708.
Babaliaros, et al., "State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair," Cardiology 2007; 107:87-96.
Bailey, "Percutaneous Expandable Prosthetic Valves," in: Topol EJ, ed. Textbook of Interventional Cardiology. vol. II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276.
Block, et al., "Percutaneous Approaches to Valvular Heart Disease," Current Cardiology Reports, vol. 7 (2005) pp. 108-113.
Bonhoeffer, et al, "Percutaneous Insertion of the Pulmonary Valve," Journal of the American College of Cardiology (United States), May 15, 2002, pp. 1664-1669.
Bonhoeffer, et al, "Percutaneous Mitral Valve Dilatation with the Multi-Track System," Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Oct. 1999, pp. 178-183.
Bonhoeffer, et al, "Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction," Lancet (England), Oct. 21, 2000, pp. 1403-1405.
Bonhoeffer, et al, "Technique and Results of Percutaneous Mitral Valvuloplasty With the Multi-Track System," Journal of Interventional Cardiology (United States), 200, pp. 263-268.
Bonhoeffer, et al, "Transcatheter Implantation of a Bovine Valve in Pulmonary Position: a Lamb Study," Circulation (United States), Aug. 15, 2000, pp. 813-816.
Boudjemline, et al, "Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals," Circulation (United States), Mar. 16, 2004, 109, p. e161.
Boudjemline, et al, "Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?" Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-BR66.
Boudjemline, et al, "Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: a Hybrid Approach," Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 1037-1041.

US 7,892,281 B2

Page 7

- Boudjemline, et al, "Percutaneous Aortic Valve Replacement: Will We Get There?" Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706.
- Boudjemline, et al, "Percutaneous Closure of a Paravalvular Mitral Regurgitation with Amplatzer and Coil Prostheses," Archives des Maladies du Coeur Et Des Vaisseaux (France), May 2002, pp. 483-486.
- Boudjemline, et al, "Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—a Sheep Study," Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116.
- Boudjemline, et al, "Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study," European Heart Journal 22, Sep. 2001, p. 630.
- Boudjemline, et al, "Percutaneous Implantation of a Valve in the Descending Aorta in Lambs," European Heart Journal (England), Jul. 2002, pp. 1045-1049.
- Boudjemline, et al, "Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: an Experimental Study," Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087.
- Boudjemline, et al, "Percutaneous Valve Insertion: a New Approach," Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742.
- Boudjemline, et al, "Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits," European Heart Journal 22, Sep. 2001, p. 355.
- Boudjemline, et al, "Steps Toward Percutaneous Aortic Valve Replacement," Circulation (United States), Feb. 12, 2002, pp. 775-778.
- Boudjemline, et al, "The Percutaneous Implantable Heart Valve," Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93.
- Boudjemline, et al, "Transcatheter Reconstruction of the Right Heart," Cardiology in the Young (England), Jun. 2003, pp. 308-311.
- Coats, et al, "The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention," European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543.
- Cribier, A. et al, "Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description," Circulation (2002) 3006-3008.
- Davidson et al., "Percutaneous therapies for valvular heart disease," Cardiovascular Pathology 15 (2006) 123-129.
- Hanzel, et al., "Complications of percutaneous aortic valve replacement: experience with the Cribier-Edwards™ percutaneous heart valve," EuroIntervention Supplements (2006), I (Supplement A) A3-A8.
- Huber, et al., "Do Valved Stents Compromise Coronary Flow?" Eur. J. Cardiothorac. Surg. 2004;25:754-759.
- Khambadkone, "Nonsurgical Pulmonary Valve Replacement: Why, When, and How?" Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
- Khambadkone, et al, "Percutaneous Implantation of Pulmonary Valves," Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548.
- Khambadkone, et al, "Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results," Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375.
- Khambadkone, et al, "Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection," Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-IV-643.
- Lutter, et al, "Percutaneous Aortic Valve Replacement: an Experimental Study. I. Studies on Implantation," The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776.
- Lutter, et al, "Percutaneous Valve Replacement: Current State and Future Prospects," Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206.
- Medtech Insight, "New Frontiers in Heart Valve Disease," vol. 7, No. 8 (2005).
- Palacios, "Percutaneous Valve Replacement and Repair, Fiction or Reality?" Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663.
- Ruiz, "Transcatheter Aortic Valve Implantation and Mitral Valve Repair: State of the Art," Pediatric Cardiology, vol. 26, No. 3 (2005).
- Saliba, et al, "Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents," Archives des Maladies du Coeur et des Vaisseaux (France), 1999, pp. 591-596.
- Webb, et al., "Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery," Circulation (2006), 113;842-850.
- Yonga, et al, "Effect of Percutaneous Balloon Mitral Valvotomy on Pulmonary Venous Flow in Severe Mitral Stenosis," East African Medical Journal (Kenya), Jan. 1999, pp. 28-30.
- Yonga, et al, "Percutaneous Balloon Mitral Valvotomy: Initial Experience in Nairobi Using a New Multi-Track Catheter System," East African Medical Journal (Kenya), Feb. 1999, pp. 71-74.
- Yonga, et al, "Percutaneous Transluminal Balloon Valvuloplasty for Pulmonary Valve Stenosis: Report on Six Cases," East African Medical Journal (Kenya), Apr. 1994, pp. 232-235.
- Yonga, et al, "Percutaneous Transvenous Mitral Commissurotomy in Juvenile Mitral Stenosis," East African Medical Journal (Kenya), Apr. 2003, pp. 172-174.
- Commeau et al, "Percutaneous balloon dilatation of calcific aortic valve stenosis: anatomical and haemodynamic evaluation," 1988, British Heart Journal, 59:227-238.
- Stassano et al., "Mid-term results of the valve-on-valve technique for bioprosthetic failure," Eur. J. Cardiothorac. Surg. 2000; 18:453-457.
- Expert report of Dr. Nigel Buller, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (83 pages).
- Expert report of Dr. Nigel Buller, non-confidential annex—infringement, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (12 pages).
- Expert report of Dr. Rodolfo Quijano, dated Jan. 9, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (18 pages).
- First Expert report of Prof. David Williams, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (41 pages).
- First Expert report of Prof. Martin Rothman, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (64 pages).

Exhibit L, Page 15

Exhibit 1 Page 13

US 7,892,281 B2

Page 8

Fourth Expert report of Prof. Martin Rothman, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (10 pages).

Second Expert report of Dr. Nigel Buller, dated Feb. 25, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (24 pages).

Second Expert report of Dr. Rodolfo Quijano, dated Feb. 26, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages).

Second Expert report of Prof. David Williams, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (15 pages).

Second Expert report of Prof. Martin Rothman, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (11 pages).

Third Expert report of Dr. Nigel Buller, dated Apr. 21, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages).

Third Expert report of Dr. Rudolfo Quijano, dated Apr. 27, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (3 pages).

Third Expert report of Prof. David Williams, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (9 pages).

Pavcnik et al., "Aortic and venous valve for percutaneous insertion," Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292.

First Expert report of Dr. Nigel Person Buller (30 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Second Expert report of Dr. Nigel Person Buller (5 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Drawing by Dr. Buller (Edwards Expert) of his interpretation of the "higher stent" referred to at col. 8, lines 13-222 of Andersen EP 592410B1 (1 page), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Drawing by Dr. Buller (Edwards Expert) of "higher stent" on the schematic representation of the aortic valve area set out in Figure 2 of Rothman's first expert report (1 page), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

First Expert report of Professor John R.4 Pepper (20 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Second Expert report of Professor John R. Pepper (3 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery

Division Patents Court, United Kingdom, Case No. HC-07-C01243.

First Expert report of Dr. Anthony C. Lunn (7 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

First Witness statement of Stanton Rowe (9 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Second Witness statement of Stanton Rowe (3 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

PVT slides naming Alain Cribier, Martin Leon, Stan Rabinovich and Stanton Rowe (16 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

First Expert report of Professor Martin Terry Rothman (75 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Reply Expert report of Professor Martin Terry Rothman (9 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

First Expert report of Richard A. Hillstead (41 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Reply Expert report of Richard A. Hillstead (9 pages), *Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc.*, High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243.

Pelton et al, Medical Uses of Nitinol, Materials Science Forum vols. 327-328 pp. 63-70. (2000)

Trial Transcripts, *Edwards Lifesciences AG and Edwards Lifesciences, LLC v. Medtronic Core Valve LLC*, United States District Court for the District of Delaware, Civil Action No. 1:08-CV-00091-GMSM, Mar. 23, 2010-Apr. 1, 2010.

Affidavit of Michael D. Gadeberg, Jul. 8, 2010-Apr. 1, 2010.

Slide Deck for Plaintiff's Closing Arguments in *Edwards Lifesciences AG and Edwards Lifesciences, LLC v. Medtronic Core Valve LLC*, United States District Court for the District of Delaware, Civil Actoin No. 1:08-CV-00091-GMS, Apr. 1, 2010 (107 pages).

Response to Restriction Requirement, U.S. Appl. No. 12/823,428, dated Nov. 15, 2010 (9 pages).

* cited by examiner

U.S. Patent

Feb. 22, 2011

Sheet 1 of 25

US 7,892,281 B2




FIG 3





FIG 2



U.S. Patent

Feb. 22, 2011

Sheet 2 of 25

US 7,892,281 B2




FIG 9




FIG 10





FIG 4



U.S. Patent

Feb. 22, 2011

Sheet 4 of 25

US 7,892,281 B2

FIG 11




FIG 12






FIG. 13




FIG. 14

U.S. Patent

Feb. 22, 2011

Sheet 6 of 25

US 7,892,281 B2




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20

U.S. Patent

Feb. 22, 2011

Sheet 9 of 25

US 7,892,281 B2

